

**ZOBAIR M. YOUNOSSI MD, MPH, FACP, FACG, AGAF**

**3300 Gallows Road  
Falls Church, Virginia 22042  
703-776-2540**

**PERSONAL INFORMATION**

- Date of Birth: November 5, 1959  
Citizenship: United States

**EDUCATION**

- **Doctor of Medicine, Alpha Omega Alpha** 1985-1989  
University of Rochester School of Medicine & Dentistry,  
Rochester, New York
- **Master of Public Health in Health Services Administration** 1992-1995  
San Diego State University School of Public Health,  
San Diego, California
- **Bachelor of Science in Biology** 1981-1984  
George Mason University, Fairfax, Virginia

**POST GRADUATE TRAINING**

- **Fellowship in Gastroenterology and Hepatology** 1992-1995  
Scripps Clinic & Research Foundation  
La Jolla, California
- **Internal Medicine Residency Program (categorical)** 1989-1992  
Scripps Clinic & Research Foundation  
La Jolla, California

**PROFESSIONAL EXPERIENCE**

- **Vice President for Research** 2010-Present  
Inova Health System, Falls Church, Virginia
- **Executive Director of Research** 2006-2010  
Inova Health System, Falls Church, Virginia
- **Executive Director, Center for Liver Diseases** 2000-Present  
Inova Fairfax Hospital, Falls Church, Virginia
- **Medical Director, Inova Research Center** 2005-2006  
Inova Health System, Falls Church, Virginia
- **Medical Director, Liver Transplant Program** 2000-2006  
Inova Fairfax Hospital, Falls Church, Virginia
- **Professor of Medicine, Virginia Commonwealth University** 2005-Present  
Inova Health System Campus, Falls Church, Virginia
- **Director, Translational Research Institute** 2005-2006  
Inova Fairfax Hospital, Falls Church, Virginia
- **Affiliate Professor of Biomedical Sciences, George Mason University** 2002-Present  
George Mason University, Fairfax, Virginia
- **Co-Director, Center for the Study of Genomics in Liver Diseases** 2002-Present  
George Mason University, Fairfax, Virginia
- **Staff Hepatologist, Department of Gastroenterology** 1995-2000  
The Cleveland Clinic Foundation, Cleveland, OH

- **Senior Researcher, I.H. Page Center for Outcomes Research** 1998-2001  
The Cleveland Clinic Foundation, Cleveland, OH
- **Associate Director, Gastroenterology Fellowship** 1998-2000  
The Cleveland Clinic Foundation, Cleveland, OH
- **Researcher, Molecular Cardiology Lab** Summer 1987  
NHLBI, National Institutes of Health, Bethesda, MD
- **Researcher, Molecular Biology Institute** Summer 1986  
University of California at Los Angeles, Los Angeles, CA
- **Staff Researcher, Mellon Institute** 1984-1985  
Carnegie - Mellon University, Pittsburgh, PA

### **ACADEMIC PRODUCTIVITY:**

- Scopus H-Index of 41 December 2010

### **CERTIFICATIONS**

- American Board of Internal Medicine, Internal Medicine 1992
- UNOS Qualified Transplant Physician 1995
- American Board of Internal Medicine, Gastroenterology 1995
- American Board of Internal Medicine, Gastroenterology (recertified 2005)
- American Board of Internal Medicine, Transplant Hepatology 2006

### **LICENSURE**

- Virginia License (Active, Exp. 11/30/10)
- California License (Inactive)
- Ohio License (Inactive)

### **HONORS AND AWARDS**

- Best Doctors in Virginia and Washington DC, Virginia Living Magazine 2011
- Alumni of the Year, College of Science, George Mason University 2008
- America's Top Physicians 2008
- George Mason University, COS, Outstanding Alumnus of the Year 2008
- Cambridge Who's Who 2007
- Best Doctors 2002
- Who's Who In Health Care 2002
- Top Doctors, Cleveland Magazine 1998
- Hanlon Award, San Diego State University 1995
- Outstanding Student Award, School of Public Health 1995  
San Diego State University
- Alpha Omega Alpha Honor Society, University of Rochester 1989
- Scholarship (High School) to Study in Villefranch de Roergue, France 1975

### **BOARD MEMBERSHIPS**

- Inova Health System Foundation Board, Member 2011
- Virginia Tobacco & Health Research Repository (VTHRR), Board of Directors 2010
- Virginia Biotechnology Research Partnership Authority, 2008  
Board of Directors (Appointed by Governor Tim Kaine of Virginia)

## JOURNAL REVIEWER AND EDITORIAL BOARD

- Journal of Clinical and Experimental Hepatology, **Editorial Board Member** 2010-Present
- World Journal of Hepatology, **Editorial Board Member** 2009-Present
- Annals of Gastroenterology & Hepatology, **Editorial Board Member** 2009-Present
- Annals of Gastroenterology and Hepatology, **Editorial Board Member** 2009-Present
- Annals of Hepatology, **Editorial Board Member** 2008-Present
- The Open Obesity Journal, **Editorial Board Member** 2008-Present
- The Open Hepatology Journal, **Editorial Board Member** 2008-Present
- The Open Gastroenterology Journal, **Editorial Board Member** 2007-Present
- “FACULTY OF 1000”, **Contributing member** 2009-2010
- Evidence Based Gastroenterology, **Associate Editor** 2000-2009
- Liver International, **Associate Editor** 2002-2005
- Hepatology, **Editorial Board Member** 2001-2004
- World Journal of Gastroenterology, **Editorial Board Member** 2006-Present
- Hepatology, **Journal Reviewer** 1996-Present
- Liver International, **Journal Reviewer** 2002-Present
- Archive of Internal Medicine, **Journal Reviewer** 2006-Present
- Swiss Medical Weekly, **Journal Reviewer** 2002-2003
- Liver, **Journal Reviewer** 2000-Present
- Journal of Viral Hepatitis, **Journal Reviewer** 2000-2001
- Liver Transplantation, **Journal Reviewer** 2000-Present
- Journal of Hepatology, **Journal Reviewer** 2000-Present
- New England Journal of Med Weekly Briefings, **Medical Advisor** 2000-2001
- Annals of Internal Medicine, **Journal Reviewer** 2004-Present
- Journal of American Medical Association, **Journal Reviewer** 2004-Present
- Quality of Life Research, **Journal Reviewer** 1999-Present
- Gastroenterology, **Journal Reviewer** 1999-Present
- The American Journal of Medicine, **Journal Reviewer** 1999-2001
- Clinical Journal of Gastroenterology, **Journal Reviewer** 2000-Present
- American Journal of Gastroenterology, **Journal Reviewer** 1998-Present
- Cleveland Clinic Journal of Medicine, **Journal Reviewer** 1997-Present
- Mayo Clinic Proceedings, **Journal Reviewer** 1997-1998
- Gut, **Journal Reviewer** 2007-Present
- Annals of Medicine, **Journal Reviewer** 2007-Present
- Obesity Surgery, **Journal Reviewer** 2008-Present

## PROFESSIONAL SOCIETIES

- The European Association for the Study of the Liver 2007-Present
- American College of Gastroenterology, Fellow (1999) 1995-Present
- American College of Physicians, Fellow (1997) 1994-Present
- American Society for Gastrointestinal Endoscopy 1995-Present
- American Gastroenterological Association, Fellow (2010) 1995-Present
- American Association for the Study of Liver Disease 1995-Present
- Alpha Omega Alpha Society 1988-Present

## PUBLIC SERVICE

- Virginia Biotechnology Research Park Authority, Member of Board of Directors (Appointed by Governor of Virginia) 2008-Present
- National Anemia Action Council, Member of Board of Directors 2007-2008
- American Liver Foundation, the National Capital Area Chapter. Medical Advisory Board, Chairman 2001-2009
- American Liver Foundation, the National Capital Area Chapter. Member of Board of Directors 2001-2009
- American Liver Foundation Ohio Chapter, MAC Member 1996-2000
- Expert Advisor to American Liver Foundation and the Cleveland Health Museum to Develop Program for School Children 1997
- Expert Hepatologist for HCV Coalition to the State of Ohio 1999
- National Viral Hepatitis Roundtable, Washington D.C. Representing AASLD 2003

### **NIH GRANT REVIEW COMMITTEES**

- NIAAA: Hepatitis C Cooperative Centers, U-19 2000
- NIAID: Hepatitis C Cooperative Research Center, University of Tennessee CRC Committee 2001
- NIDDK: Esophageal Varices Grant Review Committee (ZDK, GRB-7) 2003

### **NATIONAL/INTERNATIONAL SOCIETIES' COMMITTEE MEMBERSHIP**

- American Association for the Study of Liver Diseases *Development Committee, Member* 2007-Present
- REALIZE Publication Committee, Member 2010-Present
- Personalized Medicine Coalition, Member 2008-Present
- American College of Gastroenterology, American Association for the Study of Liver Disease and American Gastrointestinal Association *Collaborative Practice Guideline Group on Nonalcoholic Fatty Liver disease* 2009- Present
- American Association for the Study of Liver Diseases *Clinical Research Committee Member* 2007-Present
- American Association for the Study of Liver Diseases *International Relations Advisory Committee Member* 2007-Present
- National Anemia Action Council *Board of Directors, Member* 2007-2008
- American Association for the Study of Liver Diseases *Fatty Liver Abstract Committee Member* 2006-2008
- American Association for the Study of Liver Diseases, *Practice Guidelines Committee Member* 2002-2006
- American Liver Foundation, the National Capital Area Chapter *Medical Advisory Board, Chairman* 2001-2009
- American College of Gastroenterology *Research Committee Member* 2001-2003
- American Association for the Study of Liver Diseases, *Education Committee Member* 1999-2001

### **LOCAL COMMITTEE MEMBERSHIP**

- Inova Institutional Review Board Executive Committee (Chair) 2003-Present
- Inova's Research Oversight Committee (Chair) 2009-Present
- Inova's Technology Assessment Committee (Member) 2008-Present

- Inova Academic Advisory Council (Member) 2009-Present
- Joint Operating Advisory Committee of Inova Fairfax Hospital 2010-Present
- Chair of the Committee for Department Obstetrics and Gynecology  
Chairman Search 2010-2011
- Inova Research Advisory Committee (Chair) 2008-2010
- Inova Fairfax Hospital's Blueprint for Action Committee (Member) 2008-2009
- Inova Liver Transplant Steering Committee (Member) 2000-2006
- Inova Fairfax Hospital, Regional Referral Task Force (Member) 2005-2010
- VCU-Inova Partnership Committee on Research (Co-chair) 2006-2007
- Personalized Medicine Committee (Co-chair) 2007-2008
- Inova's Academic Advisory Committee (Member) 2005-2006
- Inova Transplant Section (Member) 2005-2006
- Inova Fairfax Hospital (IFH) Transplant Task Force (Member) 2006-2006
- Inova Institute of Research Steering Committee (Member) 2003-2005
- Virginia Commonwealth University's Committee on Translational Research 2005-2005
- Inova Transplant Center, Liver Transplant Selection Committee 2000-2006
- Inova Institute of Research, Physician Advisory Committee 2001-2003

### **MEDIA EXPOSURE**

- NBC's Today's Show. Story on Primary Sclerosing Cholangitis, 1996
- Cleveland Plain Dealer. Story on Liver Transplant and Liver Failure from Mushrooms 1997
- Local TV Channels in Cleveland. Stories on Mushroom-related Liver Failure 1997
- Local TV Channels in Cleveland. Stories on Hepatitis C 1997
- Local TV Channels in Northern Virginia. Story on Hepatitis C 2001
- Local TV Channels in Washington DC. Story on Hepatitis C, 2002
- National Public Broadcasting, Diane Rehm's Show. Story on Hepatitis C, 2002
- M.D. News Cover Feature 2003
- Cable News Network (CNN) Story on Hepatitis C, 2007
- Washington Post Story on Inova and Research. October 2007
- MedPage Today Story on Gene Expression of Hepatitis C. October 2007
- Newsweek, Times and Money Magazines, Translational Research with GMU, December 2007
- Voice of America Radio News Interview, December 2007
- Voice of America Television: Hepatitis and Africa Program, June 2008
- MedPage Today Interview: New Strategies in Liver Cancer and Hepatitis B, November 2008
- MedPage Today Interview: Hepatitis C Treatments Highlight AASLD Meeting. November 2008
- Washington Business Magazine: Inova-GMU Collaboration, January 2009
- ABC-TV Channel 8: Let's Talk Program on Brown Fat, April 2009
- MedPage Today. Metabolic Syndrome Hikes Mortality in Hepatitis C, April 2009
- Associated Press. Vitamin E and Non-alcoholic Fatty Liver Diseases. April 2010
- The Wall Street Journal, "Curing Hepatitis C Will Take More Than New Treatments". Nov 2010

### **TEACHING ACTIVITIES**

- Associate Program Director, Gastroenterology Fellowship, Cleveland Clinic Foundation 1998-2000
- Teaching Attending for Gastroenterology Fellows and Hepatology Advanced Fellows. Cleveland Clinic Foundation 1995-2000
- Teaching Staff, Internal Medicine Residents (Green Team) 1995-2000

- Cleveland Clinic Foundation  
Medical Students Teaching Staff 1995-2000  
Cleveland Clinic Foundation
- Outpatient Hepatology Rotation for Internal Medicine Residents, 1995-2000  
Cleveland Clinic Foundation
- Teaching Staff Hepatology Rotation, Gastroenterology Fellows 2001-2005  
Walter Reed Medical Center
- Teaching Staff for Medical Students and Residents. 2001-Present  
Inova Fairfax Hospital
- Teaching Staff for Gastroenterology Fellows, 2005-Present  
George Washington University
- Research Fellowship Mentor for Silvia Bondini, MD 2005-2006  
(University of Bologna)
- Teaching Faculty, Virginia Commonwealth University 2005-Present  
School of Medicine, Inova Campus
- Doctoral Thesis Committee, Michael Estep, PhD Candidate, 2003-Present  
George Mason University
- Doctoral Thesis Committee, Mohammed H.Jarrar, PhD Candidate, 2006-Present  
George Mason University
- Research Mentor to Students, Residents, and Fellows, 2005-Present  
Inova Health System
- Advanced Hepatology Fellowship Mentor for Janus P. Ong, MD 2001-2003
- Hepatology Clinical and Research Fellowship Mentor for Poonam Mishra, MD 2006-2007
- Hepatology Clinical and Research Fellowship Mentor for Nila Rafiq, MD 2007-2009

## **CLINICAL, TRANSLATIONAL AND OUTCOMES RESEARCH**

### ***Investigator- initiated Research Projects***

1. Non-Alcoholic Fatty Liver Disease Multi-Step Approach to Pathologic Definition, Natural History, Pathophysiology and Therapy of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis. 1996-present
2. Hepatitis C: Multiple Projects Dealing with Outcomes Research in HCV, Health-Related Quality of Life, Cost-Effectiveness Analyses and Assessment of Interferon-Induced Depression. 1996-present.
3. Transplant Research: Projects Dealing with Viral Hepatitis and Non-alcoholic Fatty Liver Disease Post-Transplantation (Liver and Other Solid Organ Transplantation) and Health-Related Quality of Life. 1996-Present.
4. Health-Related Quality of Life (HRQL) Development and Validation of Disease-Specific HRQL Instrument for Chronic Liver Disease (CLDQ) and its Hepatitis C version (CLDQ-HCV). Application of These Instruments, as well as Generic Instruments (SF-36) and Utility Assessments (Health Utility Index) to a Large Cohort of Patients with Various Types of Liver Diseases. 1996-Present
5. Decision Analysis: Economic Analysis Using Decision Modeling for Various Liver- Related Issues (Noroxin for SBP, Interferon + Ribavirin for HCV, Screening for HCV, etc.) and Economic Impact of Non-Alcoholic Fatty Liver Disease. 1996-Present.
6. A Randomized, Double-Blind Controlled Trial Comparing Combination of Interferon and Ribavirin to Interferon and Amantadine for Treatment of Patients with Chronic Hepatitis C Viral Infection: Non- Responders to Previous Interferon Therapy. Coordinating PI for a Multi-Center Clinical Trial. 1997-1999.
7. A Randomized Controlled Trial Comparing Roferon Induction Therapy to Standard Therapy for Patients with HCV Viremia and Normal ALT. Coordinating PI for a Two-Center Study. 1998-2000.

8. Selective Strategy for Treatment of Patient with Hepatitis C (Interferon Naive) with Interferon and Ribavirin. Coordinating PI for a Two Center Study. 1997-1999.
9. Triple Combination Therapy (Intron A, Ribavirin, Amantadine) for Chronic Hepatitis C Non-Responder to Interferon Monotherapy and Combination Therapy. Coordinating PI of Two-Center Study. 1998-2000.
10. Clinical Trial of Pegylated Intron A, Ribavirin and Amantadine. Combination for Treatment of Chronic Hepatitis C: A Multi-Center Study. Data Management Site. 1999-2002.
11. Pegylated Interferon + Ribavirin + Amantadine for Treatment of Chronic Hepatitis C: A Multi-Centered Clinical Trial. 2000-2003.
12. Genomics (Gene Expression) of Adipose Tissue and Liver Tissue of Patients with the Spectrum of Non-Alcoholic Fatty Liver Disease and NAFLD Related Fibrosis. 2001-Present.
13. The Impact of Hepatitis C Diagnosis on Patient Health-Related Quality of Life: A Prospective Cohort Study. 2001-2002
14. Impact of Ethnicity on the Development of Hepatocellular Carcinoma (HCC).2001-2002
15. Role of Liver Biopsy in Non-Alcoholic Fatty Liver (NAFLD) Survey. 2001-2002
16. Quality of Life Outcomes in Individuals with Fulminant Hepatic Failure (FHF). 2001-2003
17. Genetic Epidemiology of Non-Alcoholic Fatty Liver Disease (NAFLD). 2001-2008.
18. Phase II Open Label Study to Evaluate the Safety and Efficacy of RU-8811 in Patients with Types 3 and 4 Non-Alcoholic Fatty Liver Disease. 2002-2004.
19. Management of Anemia and Neutropenia Associated with Pegylated Interferon + Ribavirin Treatment of Chronic Hepatitis C: An Open-Label Dose Titration Study of Darbepoetin Alfa and Filgrastim. 2002-2006.
20. Predictors of Aggressive Disease and Responsiveness to Pegylated Interferon + Ribavirin in the Treatment of Chronic Hepatitis C. 2002-2010
21. Epidemiology of Non-Alcoholic Fatty Liver Disease. Multi-Center Epidemiologic Study. 2002-2008.
22. A Genomic Study of Obesity. 2003-2008
23. Genomics of Fibrosis (Liver, Lung and Heart Explants).2003-2008
24. Using NHANES database and NHANES-NDI Linked Mortality File Study Insurability of HCV. 2003-2004.
25. Genomics (Gene Expression) and Proteomics of Obesity and Metabolic Syndrome. The Study of Advances in Genomic Analysis for Investigating Differences in Morbidly Obese Subjects. 2003-Present.
26. The Study Investigating Differences in Gene Expressions in Hepatic Stellate Cells Related to Fibrosis. 2003-2009.
27. Hepatitis B and Health-Related Quality of Life. 2004-Present.
28. The Impact of Anemia on Health-Related Quality of Life. 2004-Present
29. The Impact of Steatosis in Chronic Hepatitis B. 2005-2006
30. Translational Research in Chronic Diseases. 2005-2010
31. Open-label Clinical Trial of High Dose URSO with or without Vitamin E in Severely Obese Patients with Non-alcoholic Steatohepatitis. 2005 – Present.
32. Neuropsychiatric Effects of Pegylated Interferon in Treatment of Hepatitis C (NIPIC) study. 2006-Present.
33. Predictors of Aggressive Disease and Responsiveness to Pegylated Interferon + Ribavirin in the Treatment of Chronic Hepatitis C: Proteomic Profiling Protocol. 2002-Present
34. Independent Predictors of Fatigue, Health-related Quality of Life and Symptoms in Patients with Chronic Liver Disease. 2006-2007
35. The Impact of Host Factors in Hepatitis C. 2006-2008
36. Neuropsychiatric Impact of Pegylated Interferon in Hepatitis C. 2006-2008
37. Thiopurine Methyltransferase (TPMT) & Azathioprine Metabolites in Adult Autoimmune Hepatitis. 2006-2009

38. Clinical, Laboratory and Health-related Quality of Life of Liver Disease in Hepatitis B. 2006-2009
39. The Impact of anemia on health-related quality of life of patients with hepatitis C. 2006-2009
40. Fatigue and Health-related Quality of Life (HQRL) Assessment in Blood Donors. 2006-2010
41. Pilot Study to Assess Biologic, Physiologic, Performance Measures and Self-Reports of Fatigue and Health-related Quality of Life (HRQL) in Patients with Non-alcoholic Fatty Liver Disease (NAFLD). 2006-2010
42. Survey of Hepatitis B (HBV), Hepatitis C (HCV), and Non-Alcoholic Fatty Liver Disease (NAFLD) Screening Factors Community Practices Study: A Pilot. 2006-2010
43. Assessment of Adipokines, Cytokines, and Other Proteins in Metabolic Syndrome and Non-alcoholic Fatty Liver Disease. 2006-Present
44. Is the Presence of Metabolic Syndrome Associated with Progression of Underlying Liver Disease? 2006-Present
45. Nutritional Assessment in Patients with Chronic Liver Disease. 2006-Present
46. Validation of the SF-3D in Patients with Chronic Liver Disease. 2006-Present
47. Health-related Quality of Life in Patients with Non-alcoholic Fatty Liver Disease (NAFLD) 2006
48. Functional Status and Quality of Life in Blood Donors. 2006-Present.
49. Comparative Analysis for Levels of Adipokines and Cytokines in Non-alcoholic Fatty Liver Disease and HCV. 2006-Present.
50. Life Time Medical and Economic Impact of Patients with Non-alcoholic Fatty Liver Disease 2006-Present.
51. Sleep Apnea in Patients with Non-alcoholic Fatty Liver Disease. 2006-Present.
52. Survey of HBV, HCV, and Non-alcoholic Fatty Liver Disease Screening Factors. A Pilot Study. 2006-Present.
53. Phosphoproteomics of Non-alcoholic Fatty Liver Disease and Weight Loss Post Bariatric Surgery 2006-Present
54. Long Term Follow up of Patients with Non-alcoholic Fatty Liver Disease Post Bariatric Surgery 2006-Present
55. Validation of SF-6D and Health Utility Index (HUI for Patients with Chronic Liver Disease. 2006-Present.
56. Assessment of Melanogenesis in Metabolic Syndrome and Obesity. 2007
57. Visceral Adipose as a Source of Inflammatory Cytokines in NASH and Fibrosis. 2007-2009
58. A Retrospective Assessment of the Prevalence of Hepatitis B (HBV) and Hepatitis C (HCV) in the Asian Community of Northern Virginia. 2007-2009
59. Lipomics of the Spectrum of NAFLD. 2007-2009.
60. Socio-Demographic, Clinical, and Social Influences on Health-Related Quality of Life in Individuals with Hepatitis C. 2007-2009
61. Prevalence of Hepatitis B (HBV) and Hepatitis C (HCV) in the Asian Community of Northern Virginia. 2007-2009
62. Long Term Follow-up of Patients with Non-alcoholic Fatty Liver Disease (CCF-Inova Data). 2007-2010
63. Gene Expression Factors Associated with Steatosis, Fibrosis, Genotypes and Patients' Ethnicity in Hepatitis C. 2007-Present
64. Human Activity Profile in Patients with Chronic Liver Disease 2007-Present
65. Development of Non-invasive Biomarkers for Non-alcoholic Steatohepatitis (Non-alcoholic Steatohepatitis) 2007-Present
66. Mortality in a Cohort of Patients with Non-alcoholic Fatty Liver Disease Using NHANES-NDI data, 2007-Present
67. Long Term Follow-Up of Patients with Non-Alcoholic Fatty Liver Disease (AFIP Data). 2008-Present
68. Association of Non-Alcoholic Fatty Liver Disease (NAFLD) and Coronary Artery Disease (CAD). 2008-2010

69. The Impact of Age and Other Demographic Factors on the Quality of Life of Patients with Chronic Liver Disease. 2008-Present.
70. Profiling of miRNA in the Adipose Tissue of the Morbidly Obese Patients with NASH and Normal Liver Biopsies. 2008-Present
71. Proteomics Profiling of Patients with NASH. 2008-Present
72. The Impact of Age and Other Demographic Factors on the Quality of Life of Patients with Chronic Liver Disease. 2008-Present
73. Melanogenesis in Human Adipose Tissue as Possible Drug Target for the Secondary Complications of Obesity. 2008-Present
74. Activity and Nutritional Predictors of Response to Bariatric Surgery. 2008-Present
75. Markers of Excessive Alcohol Consumption in Morbidly Obese Patients Undergoing Bariatric Surgery. 2008-Present
76. Insulin Resistance and its Relationship to Hepatitis-C Viral Titer. 2009-Present
77. Profiling and Validation of Reference Genes for the Chronic Conditions Related to Obesity and Metabolic Syndrome. 2009-Present
78. Resolution of Type 2 Diabetes after Bariatric Surgery. 2009-Present
79. Predictive Modeling of Metabolic Syndrome Complications Using Aggregated Data. 2009-Present
80. Obesity Related Inflammation and the Gastric Peptides of Bariatric Surgery Patients. 2009-Present
81. Gene Expression Profiling of Inflammatory Cytokine Targets and Obesity Related mRNA in Gastric Tissue Type "A", "B" and "F". 2009-Present
82. High-throughput Profiling of Microbial Trace DNA in Gastric Mucosa Samples of Morbidly Obese Patients. 2009-Present
83. RT-PCR Profiling of Brown Adipose Tissue (BAT) specific genes in visceral adipose tissue of lean and obese patients. 2009-Present
84. Stratification and Prediction of Outcomes of Bariatric Surgery Patients Using the Relative Wellness Index (RWI). 2009-Present
85. Tekscan Grip and Gait Study. 2009-Present
86. Validation of the CLDQ-HCV in the Hepatitis C-bearing Population. 2009-Present
87. Depression in Patients with Chronic Liver Disease. 2009-Present
88. The Socio-geographic Determinants of Patients with Chronic Liver Disease. 2009-Present
89. Physioflow study of patients with NAFLD and HCV. 2007-Present
90. The Impact of Metabolic Syndrome on Chronic Liver Diseases Using NHANES-NDI database 2009-Present

### ***Non-Pharmaceutical Research Projects***

1. Development of a Disease-Specific Health-Related Quality of Life for Patients with Chronic Liver Disease. I.H. Page Center, The Clinical Effectiveness Office. 1997
2. Utility of Ultrasound by Hepatologists. American College of Gastroenterology. Clinical Research Award. 1997
3. Non-Alcoholic Steatohepatitis. American College of Gastroenterology. Clinical Research Award. 1998
4. Development and Prospective Testing of Chronic Liver Disease Questionnaire. American College of Gastroenterology. Career Development Award. 1997-1999
5. A DiBisceglio (PI). NDDK's Multi-Center Long Term Treatment of Chronic Hepatitis C: HALT-C Trial (Consultant). NIDDK, NIH. 1998 - Present
6. Assessment of Radiological Features Associated with Non-Alcoholic Fatty Liver Disease (NAFLD). CCF Hepatology Section Grant. 2000
7. Hepatitis C and Spontaneous Infection Clearance Study (HASICS). American College of Gastroenterology Grant. 2000
8. SCLRC HEPWEB HCV Registry. Information Gathering on Patients with Hepatitis C Used to Evaluate the Characteristics, Treatment, Patterns, and Outcomes of These Patients. 2001.

9. Hepatitis B Epidemiology: National Study. Epidemiology of HBV in the US. To Determine the Prevalence of HBV Genotypes, Core Promoter and Precore HBV Variants in the US. 2001.
10. A National Registry of Patients with Hepatocellular Carcinoma. 2002-2004.
11. TRAP-C: Transplant-Related Accelerated Progression of Hepatitis C. A Collaborative Study with NIH to Study Post Transplant HCV. 2006 - 2008.
12. Using GIS and Simulation for Analyzing Optimal Geographical Boundaries and Organ Allocation System NIH/NIDDK, Naoru Koizumi, PhD (PI). 2010-present.

***Invited Industry-Sponsored Clinical Trials***

1. A Phase 3 Study to Compare the Safety and Efficacy of Alferon N Injection to Intron A in Previously Untreated Patients with Chronic Hepatitis C Interferon. 1996-1998.
2. A Study of Extended Lamivudine Treatment of Hepatitis B Patients Previously Enrolled in Phase II or Phase III Lamivudine Trials (NUCA3017). 1996-2002
3. Hepatitis Resource Network (HRN). 1998-2000
4. A Study to Determine Whether Production of Mx Protein by Hepatitis C Patients Predicts Response to Therapy. 1998-2001.
5. IL-12 for Treatment of Chronic Hepatitis C, (Non-responder) Genetic Institute. 1999-2000.
6. Hepatitis Resource Network (HRN). 1999-2002
7. A Randomized, Open Label, Multi-center, Efficacy and Safety Study of Pegylated Roferon Plus Ribavirin and Other Combinations for Chronic Hepatitis C, Previously Non-Responder to Rebetrone. 1999-Present.
8. A Protocol to Develop A Registry and Evaluate the Characteristics, Treatment, Patterns, and Outcomes of Patients with Hepatitis C at 10 U.S. Sites. 2000-2001
9. Protocol Number GS-98-435: An Open Label Study of the Safety and Efficacy of Adefovir Dipivoxil for the Treatment of Liver Disease Due to Lamivudine Resistant Hepatitis B (HBV) in Liver Transplant Patients. 2000-2002
10. PEG-Interferon a-2b + Ribavirin for Treatment of Patients with Chronic Hepatitis C who Have Previously Failed to Achieve a Sustained Virologic Response Following Interferon alfa or Interferon a-2b + Ribavirin Therapy. 2000-2003.
11. Evaluate the Safety and Efficacy of PEG-Interferon A-2b + Ribavirin for the Treatment of Patients with Chronic Hepatitis C who Have Previously Failed to Achieve a Sustained Virologic Response Following Interferon Alfa or Interferon A-2b + Ribavirin Therapy. 2001-2003.
12. Evaluate the Safety and Efficacy of Extended Lamivudine Treatment for Hepatitis B Patients Previously Enrolled in Phase II or Phase III Lamivudine Trials. 2001-2005.
13. Saliva vs. Serum Testing Of Hepatitis C. A Comparison of A Rapid One-Step Immunoassay Applied to the Detection of Hepatitis C Virus Antibodies with a Standard Method of the Detection of Hepatitis C Virus Antibodies in the Salvia and Serum of the Same Patient Population. 2001-2002.
14. Hepatitis B Immunoglobulin and Lamivudine for Treatment of Hepatitis B. 2001-2003.
15. Evaluate the Safety and Efficacy of Adefovir Dipivoxil for the Treatment of Liver Disease Due to Lamivudine Resistant Hepatitis B in Pre and Post-Liver Transplant Patients. 2001-2003.
16. Evaluate the Safety and Efficacy of Pegasys Versus Pegasys + Ribavirin Versus a Twelve-Week Treatment Delay in Patients with Chronic Hepatitis C. 2001-2003.
17. A Prospective Randomized, Multicenter, Open-Label, Comparative Safety Study of Pegasys( vs Pegasys( Plus Ribavirin Treatment vs a 12-Week Treatment Delay in Patients with Chronic Hepatitis C. 2001-2002
18. An Open-Label, Phase I/II Study of the Effect of Ethnicity on the Pharmacokinetics, Safety, and Antiviral Activity of Adefovir Dipivoxil 10mg/day in Nucleo-side Treatment Naïve HBV Infected Patients. 2001-2002

19. A Double-Blind, Placebo-Controlled Evaluation of Emtricitabine Once-Daily for the Treatment of Chronic Hepatitis B Virus Infection (Protocol No. FTCB-301). 2001-2002
20. An Open-Label Phase 1-2 Study of the Pharmacokinetics, Safety, and Antiviral Activity of Adefovir Dipivoxil in Nucleoside Treatment-Naïve HBV-Infected Patients. 2001-2002.
21. A Phase II, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of the Safety and Anti-Viral Effects of a Mixture of Two Monoclonal Antibodies (HBV-Ab) in Combination with Lamivudine in the Treatment of Patients with Chronic Hepatitis B Virus Infection. 2001-2002
22. A Randomized, Double-Blind, Placebo-Controlled Study to Compare the Effect of Procrit(r) (Epoetin alfa) once a Week Versus Placebo in the Treatment of Anemia and Maintenance of Optimal Ribavirin Dose in Hepatitis C Virus Infected Patients Treated with Combination Ribavirin/Interferon or Ribavirin/Pegylated Interferon. 2001-2004
23. Phase II/III Randomized, Placebo-Controlled Study of Safety and Anti-Fibrotic Efficacy of Interferon Gamma-1B In Patients with Severe Fibrosis or Compensated Cirrhosis Due to Hepatitis C. 2002.
24. A Pilot Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of the Safety and Efficacy of A Human HCV-Antibody (HCV-Ab<sup>xll</sup> 68) for Prevention of Hepatitis C Disease Recurrence in Patients who Have Received Hepatic Allografts for Treatment of End-Stage Liver Disease Due to Hepatitis C Virus Infection. 2002.
25. A Phase II Open Label Study to Evaluate the Safety and efficacy of RU-8811, in Patients with Types 3 or 4 Non-alcoholic Fatty Liver Disease. 2002-2003
26. A Multicenter Double-Blinded Study in Patients with Compensated Cirrhosis Due to Chronic Hepatitis C who are Non-Responders to Piror Interferon Alfa or Intereron Alfa+Ribavirin Therapy, comparing Treatment with Thymosin Alpha 1+ Peginterferon Alfa-2a with Peginterferon Alfa-2a + Placebo. 2002-2003
27. Peg-intron as Maintenance Therapy vs. an Untreated Control Group in Adult Subjects with Compensated Cirrhosis (Metavir F4), Secondary to Chronic Hepatitis C, Who Have Failed to Respond to Therapy With Any Interferon Plus Ribavirin. 2002-2003
28. A Phase 3b, Open Label Program of Adefovir Dipivoxil in the Treatment of Patients with Lamivudine-Resistant Chronic Hepatitis B Who Have Limited Treatment Options. 2002-2003
29. Peg-Intron Maintenance Therapy vs. an Untreated Control Group for Prevention of Progression of Fibrosis in Adults Subjects With Chronic Hepatitis C with Hepatic Fibrosis (Metavir Firbrosis Score of F2 or F3), Who Failed Therapy with Peg-Introl Plus Rebetrol. 2002-2003
30. A National Registry of Patients with Hepatocellular Carinoma-Epidemiology of Heptaocellular Carinoma Local Study dated April 15, 2002. 2002-2004
31. PEG-Intron Plus REBETOL for the Treatment of Subjects with Chronic Hepatitis C Who Failed to Respond to Previous Combination Therapy (Any Interferon Treatment in Combination with Ribavirin). 2002-2004
32. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel Study o Determine the Efficacy and Safety of Pravastatin 80 mg Administered Once Daily to Hypercholesterolemic Subjects with Chronic, well Compensated Liver Disease, October 7, 2002. 2003-2004
33. Randomized, Multicenter, Open Label, Phase IV Study Evaluating the Efficacy and Safety of 16-Week Versus 24-Week Treatment with PEGASYS® in Combination with Copegus® in Interferon-naïve Patients with Chronic Hepatitis C Genotype 2 or 3 Virus Infection NV17317B. 2003-2004
34. A Phase II, Multicenter, Open-Label, Follow-On Study of the Safety and Efficacy of a Human HCV Antibody (HCV-Abxll68) for Prevention of Hepatitis C Disease Recurrence in Patients Who Have Received Hepatic Allografts for Treatment f End-Stage Liver Disease Due to Hepatitis C Virus Infection and Who Have Demonstrated an Anti-Viral Response in Protocol XTL #2002-09. 2003-2004
35. Safety And Efficacy Of 16 Weeks Versus 24 Weeks Of Pegylated Interferon Alpha 2a And Ribavirin For Treatment Of Chronic Hepatitis C, Genotypes 2 and 3. 2004.
36. Randomized, Double-Blind Multicenter Study to Compare the Safety and Efficacy of Viramidine to Ribavirin in Treatment-Naïve Patients with Chronic Hepatitis C RNA003142-302. 2004-2005

37. A Phase 2 Study of VX-950 in Combination with Peginterferon Alfa-2a with Ribavirin in Subjects with Genotype 1 Hepatitis C who Have Not Received Prior Treatment. 2006.
38. A Randomized, Double-Blind, Controlled Evaluation of Tenofovir DF versus Adefovir Dipivoxil for the treatment of HBeAg Positive Chronic Hepatitis B. 2006-2007
39. A Partially Blinded, Randomized, Parallel Group Study to Evaluate the Potential Pharmacokinetic and Pharmacodynamic Interactions between Valopicitabine and Ribavirin when Administered in Combination with Pegylated Interferon Alfa-2a in Treatment of Naïve Patients with Chronic Hepatitis C. 2006-2008
40. An extension protocol to evaluate the long-term effects of treatment with peginterferon alfa-2a (PEG-IFN) or interferon (IFN) based therapies for patients with chronic hepatitis C. 2006-2009
41. A Randomized, Double-Blind, Controlled Evaluation of Tenofovir DF Versus Adefovir Dipivoxil for Treatment of Presumed Pre-core Mutant Chronic Hepatitis B. 2006-2009
42. A Phase 2 Double-Blind Multicenter Randomized Study Comparing Tenofovir Disoproxil Fumarate Emtricitabine Plus Tenofovir Disoproxil Fumarate and Entecavir in the Treatment of Chronic Hepatitis B Subjects with Decompensated Liver Disease and in the Prevention of Hepatitis B Recurrence Post-transplant. 2006-2009
43. A Phase 2 Study of VX-950 in Combination with Peginterferon Alfa-2a (Pegasyl) with or without Ribavirin (Copegus) in Subjects with Hepatitis C. 2006-2009
44. Randomized, Multicenter, Double-Blinded, Phase IV Study Evaluating The Efficacy (As Measured By Sustained Virological Response) And Safety Of 360 µg Induction Dosing Of Pegasys® In Combination With Higher Copegus® Doses In Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1 Virus Infection Of High Viral Titer And Baseline Body Weight Greater Than Or Equal To 85 Kg. 2007.
45. A Prospective, randomized, trial to investigate the effect of continued Adefovir versus combination regimens of Telbivudine plus Adefovir, and Telbivudine plus Tenofovir in patient with chronic hepatitis B and suboptimal viral suppression. 2007-2008
46. A Phase IB, Multicenter, Randomized, Double- Blinded and Placebo-Controlled Study of the Antiviral Activity, Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of VCH-916 in Treatment Naïve Subjects with Chronic Hepatitis C Infection. 2007-2009
47. Randomized, Multicenter, Double-Blinded, Phase IV study evaluating the efficacy and safety of induction dosing of Pegasys in combination with higher copegus doses in treatment naïve pts with chronic hepatitis. 2007-2009
48. A phase 3, randomized, multi-center study to evaluate the efficacy and safety of albumin interferon alfa-2b (alb-IFN) in combination with ribavirin compared with peginterferon alfa-2a (PEGASYS or PEG-IFNa2a) in combination with ribavirin in interferon alfa naïve subjects with chronic hepatitis C. 2007-2009
49. A phase 2 study of Telaprevir (VX-950) in combination with Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in subjects with genotype 1 Hepatitis C who have not achieved sustained viral response with a prior course of Interferon-based therapy. 2007-2009
50. A Rollover protocol of Telaprevir (VX-950) in combination with Peginterferon Alfa-2a (Pegasys), and Ribavirin (Copegus) in subjects enrolled in the control group (Group A) of study VX06-950-106 who did not achieve or maintain an undetectable HCV RNA level through sustained viral response. 2007-2010
51. An Open-Label, 3-Panel ,Dose-Escalation Study To Assess The Safety And Tolerability, Pharmacokinetics, And Viral Kinetics Of Two Doses Of Locteron™ (Polyactive™ – Interferon Alpha 2b) Given Every 2 Weeks For 4-12 Weeks In Comparison With PEG-Intron Given Weekly For 4-12 Weeks In Patients With Chronic Hepatitis C. 2008
52. An Open-Label, 3-Panel, Dose-Escalation Study to Assess the Safety and Tolerability, Pharmacokinetics, and Viral Kinetics of Two Doses of Locteron (PolyActive-Interferon Alpha 2b) given every 2 weeks for 4-12 weeks in comparison with PEG-Intron given week weekly for 4-12 weeks in patients with chronic hepatitis C. 2008-2009

53. Pivotal Study to Evaluate the Efficacy and Safety of the BreathID® System for Detection of Cirrhosis Using the 13C-Methacetin Breath Test (MBT). 2008-2009
54. A Phase 2, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Activity of GS-9450 in Adults with Non-Alcoholic Steatohepatitis (NASH). 2008-2009
55. Identification of Genetic Signatures Associated With Response Of HCV-Positive Patients To Treatment with Interferon-Alpha and Ribavirin. 2008-2009
56. A Phase 3, Safety and Efficacy Study of Boceprevir in Previously Untreated Subjects with Chronic Hepatitis C Genotype 1. 2008-2009
57. A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Comparing 24 or 48 Weeks of GS-9190, in Combination with Peginterferon Alfa 2a and Ribavirin, to 48 Weeks of Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic Hepatitis C Virus (HCV) Infection. 2008-2009
58. A Randomized Study of Stopping Treatment at 24 Weeks or Continuing Treatment to 48 Weeks in Treatment-Naïve Subjects with Genotype 1 Chronic Hepatitis C who Achieve an Extended Rapid Viral Response (ERVR) while Receiving Telaprevir, Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus). 2008-2009
59. An Open-Label, 3-Panel, Dose-Escalation Study To Assess The Safety And Tolerability, Pharmacokinetics, And Viral Kinetics of Two Doses Of Locteron™ (Polyactive™-Interferon Alpha 2b) Given Every 2 Weeks for 4-12 Weeks in Comparison With PEG-Intron Given Weekly for 4-12 Weeks in Patients With Chronic Hepatitis C. 2008-2009
60. A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of 2 Regimens of Telaprevir (With And Without Delayed Start) Combined With Pegylated Interferon Alfa-2a (Pegasys®) And Ribavirin (Copegus®) in subjects with chronic genotype 1 hepatitis C in Subjects with Chronic Genotype 1 Hepatitis C Infection who failed prior pegylated interferon plus ribavirin treatment. 2008-2010
61. A Randomized Study of Stopping Treatment at 24 Weeks or Continuing Treatment to 48 Weeks in Treatment-Naïve Subjects with Genotype 1 Chronic Hepatitis C who Achieve an Extended Rapid Viral Response (eRVR) While Receiving Telaprevir, Peginterferon Alfa2a (Pegasys) and Ribavirin (Copegus). 2008-2010
62. A multi-center research study of genetic signatures associated with response of HCV-positive patients to treatment with interferon-alpha and ribavirin. 2008-2010
63. A Phase 3 Study of 2 Dose Regimens of Telaprevir in Combination with Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Treatment-Naive Subjects with Genotype I Chronic Hepatitis C. 2008-2010
64. Phase 2B, Partially Blinded, Randomized Study in Treatment Naïve Subjects with HCV Genotype 1 to Compare the Efficacy, Safety, and Tolerability of Three Doses of Locteron Plus Ribavirin Given Bi-weekly In Comparison With PEG-Intron Plus Ribavirin given Weekly. 2009-2010
65. A Phase 2b, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of GS-9450 in Adults with Chronic Hepatitis C Virus Infection. 2009-2010
66. A 3-Year, Virology Follow up Study in Subjects Previously Treated with Telaprevir in Select Clinical Studies. 2009-2010
67. A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluation the Safety and Efficacy of Filibuvir Plus Pegylated Interferon Alpha-2A and Ribavirin in Treatment Naïve, HCV Genotype 1 Infected Subjects. 2009
68. Development of a Hepatitis C Patient Assessment Questionnaire (HEPA) for Hepatitis C Virus (HCV) infected patients with Antiviral Treatment. 2009.
69. A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple Dose Trial of the Safety, Efficacy, and Pharmacokinetics of ANA598 Administered with Pegylated Interferon and Ribavirin in Treatment-Naïve Genotype 1 Patients with Chronic Hepatitis C Infection. 2009-Present
70. Protocol GS-US-196-0123, "A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 12 and 24 Weeks of Response Guided Therapy With GS-9190, GS-9256, Ribavirin

(Copegus<sup>®</sup>) and Peginterferon Alfa 2a (Pegasys<sup>®</sup>) in Treatment Naïve Subjects with Chronic Genotype 1 Hepatitis C Virus Infection, Gilead Sciences 2010-Present.

71. A phase IIa, randomized, double-blind (subject and investigator blind, sponsor open) placebo-controlled trial to evaluate the safety, tolerability and antiviral activity of oral ACH-0141625 in combination with pegylated interferon alfa-2a and ribavirin in two segments, after 28 days of dosing and, subsequently, after 12 weeks of dosing in subjects with chronic hepatitis C virus genotype 1. Achillion 2010-Present
72. Phase III triple combination of pegylate Interferon, Ribavirin, Telaprevir for HCV genotype 1 Patients. Tibotec, 2010 Present

## PATENTS:

1. **U.S. Patent Application No. 12/155,562**  
**Title:** “Prognostic Chronic Hepatitis C Biomarkers”  
**Inventor:** **Zobair M. Younossi**
2. **U.S. Patent Application No. 61/265,449**  
**Title:** Protein Pathway Biomarker Signature Associated with Superimposed Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis in Patients with Chronic Hepatitis C”  
**Inventors:** **Zobair Younossi**, Dolores Limongi, Mariaelena Pierobon and Emanuel Petricoin.
3. **U.S. Patent Application No. 61/265,446**  
**Title:** “Protein Pathway Biomarkers Predicting Sustained Virologic Response (SVR) to Pegylated Interferon (PEG-IFN) and Ribavirin (RBV) in Patients with Chronic Hepatitis C (CH-C)”  
**Inventors:** **Zobair Younossi**, Dolores Limongi, Mariaelena Pierobon and Emanuel Petricoin.
4. **U.S. Patent Application No. 60/939,208**  
**Title:** “Utility of Signal Pathway and Drug Target Analysis from Fat Tissue for Metabolic Syndrome and Weight Loss Prognosis”  
**Inventors:** **Zobair Younossi**; Lance Liotta; Emmanuel Petricoin; Valerie Calvert.
5. **U.S. Patent Application No. 60/916,533**  
**Title:** “Liver Disease Diagnostic Using AKT/mTOR Pathway Activation State in Fat Cells  
**Inventors:** **Zobair Younossi**, Lance Liotta, and Emmanuel Petricoin
6. **U.S. Patent Application No. 12/139,173**  
**Title:** A Combination Of Non-Invasive Assays For Apoptosis, Necrosis And Adipocytokines As Diagnostic Predictor Of Nonalcoholic Steatohepatitis (NASH)  
**Inventors:** **Zobair Younossi**, Anna Baranova, Mohammed Jarrar, Vikas Chandhoke

## PUBLICATIONS

### *Books*

1. Z Younossi, J Ong, R O’Shea. *Contemporary Diagnosis and Management of Hepatitis C*. Handbooks in Health Care (First edition), 2003.
2. Z Younossi. *Practical Management of Liver Diseases*. (Textbook Editor), Cambridge Press, 1<sup>st</sup> edition, 2008.
3. M Jarrar, Z Younossi, A Baranova. Pathogenesis of Non Alcoholic Fatty Liver Disease and Circulatory Levels of Adipocytokines. VDM Verlag Publishing, Germany 2008

### *Journal Supplements*

1. Z Younossi (Guest Editor). Viral Hepatitis: A Guide to Practicing Clinician. *Cleveland Clinic Journal of Medicine (Supplement)*; October 2000.
2. Z Younossi (Guest Editor). Optimizing Adherence to Therapy in Chronic Hepatitis C: Challenges and Emerging Strategies. *Cleveland Clinic Journal of Medicine (Supplement)*, 3 (Vol. 71); 2004.

3. Z Younossi. Non-alcoholic Steatohepatitis and Non-alcoholic Fatty Liver Disease, *Clinics in Liver Disease (Guest Editor)*, 11(xiii-xiv); 2007
4. Z Younossi, J Capeau (Co-Editors). Metabolic Complications from Hepatitis C. *Liver International (Supplement): Volume 29, Supplement 2*; 2009

### **Book Chapters**

1. E Beutler, D Carson, J Sipe, J Romine, R McMillan, Z Younossi, V Rodgers, J Koziol. *Clinical Development of 2-Cholorodeoxyadenosine. Nucleosides in Cancer Therapy*. Beutler E (ed). Marcel Mekker. 1996.
2. Z Younossi. Acute Upper Gastrointestinal Bleeding. *Saunders Manual of Medical Practice*, 1st edition. 1999.
3. Z Younossi. Acute Upper Gastrointestinal Bleeding. *Saunders Manual of Medical Practice*, 2nd edition. 2000.
4. Z Younossi. Health-related Quality of Life Measurement in Patients with Chronic Liver Disease. *Advances in Hepatic Encephalopathy & Metabolism in Liver Disease*. Yurdaydin C, Bozkaya H (Editors). Ankara University Press. 2000.
5. S Herten, J Stoller, Z Younossi. Alpha-1 Antitrypsin Deficiency. (Book Chapter). *Hepatology: A Practical Approach* (First Edition). Elsevier Sciences. 2005.
6. G Grant, V Chandhoke, Z Younossi. Specific Disorders Associated with Non-Alcoholic Fatty Liver Disease. (Book Chapter). *Fatty Liver Diseases: Non-Alcoholic Steatohepatitis and Related Disorders*. Blackwell Publishers, 1<sup>st</sup> edition. 2004.
7. A Baranova, Z Younossi. Adipokines in Non-alcoholic Fatty Liver Diseases. *Adipose Tissue and Adipokines in Health and Disease* (First Edition). The Humana Press. 2006.
8. J Ong, Z Younossi. Epidemiology and Natural History of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis. *Clinics in Liver Disease* 2007; 11(1):1-16.
9. P Mishra, N Rafiq, Z Younossi. Non-Alcoholic Fatty Liver Disease. *Practical Management of Liver Diseases*. (Younossi Z, Editor), Cambridge Press. 2008.
10. A Baranova, L Liotta, E Petricoin. New Technologies in the Study of Liver Diseases. *Clinician's Guide to Common Liver Diseases*. (Younossi Z, Editor), Cambridge Press. 2008.
11. A Dan, Z Younossi. Depressive Symptoms and Health-Related Quality Of Life. *Handbook of Disease Burdens and Quality of Life Measures*. (Victor Preedy and Ronald Ross Watson, Editors). Springer Press. 2008
12. A Baranova, A Biredinc, M Estep, ZM Younossi. Pathogenesis of obesity-related chronic liver diseases as the study case for the systems biology. *Textbook of Systems Biology for Signaling Networks* (Sangdun Choi, Editor). 2010
13. Z Younossi. Epidemiology and Clinical Presentation of Non Alcoholic Fatty Liver Disease. *Proceeding of 8<sup>th</sup> International Meeting on Therapy in Liver Disease* 2011 (In Press).
14. J Kallman, Z Younossi. Quality of Life After Liver Transplantation for Hepatitis C. *Hepatitis C And Liver Transplantation Textbook* (Sandeep Mukherjee, MBBCh, Editor), 2010 (In press)
15. N Rafiq, Z M. Younossi. Hepatic Changes of Obesity and the Effects of Weight Loss. *Handbook of Obesity Surgery*. Current Concepts and Therapy of Morbid Obesity and Related Diseases. Editors: Mervyn Deitel, Michel Gagner, John B. Dixon, Atul K. Madan, Jacques Himpens (In Press 2011)
16. J Kallman, ZM Younossi. Health-related Quality of Life in Patients with Hepatic Encephalopathy., *Hepatic Encephalopathy Textbook*. Mullen & Dr. Prakash Editors. Springer Science (In Press 2011)

### **Journal Articles**

#### **Articles Related to Non-Alcoholic Fatty Liver Disease and Obesity:**

1. Z Younossi, T Gramlich, Y Liu, C Matteoni, M Pettrelli, J Goldblum, L Rybicki, AC McCullough. Non- Alcoholic Fatty Liver: Assessment of Variability in the Pathologic Interpretations. *Modern Pathology*, Vol. 11, (6):560-565; 1998.

2. Z Younossi. Non-Alcoholic Fatty Liver Disease: A Review. *Current Gastroenterology Reports*, Vol. 1 (No.1); 1999.
3. C Matteoni, Z Younossi, T Gramlich, N Boparai, Y Liu, A McCullough. A Non-Alcoholic Fatty Liver Disease: A Spectrum of Clinical and Pathologic Severity. *Gastroenterology*, 116-1413-1419; 1999.
4. S Saadeh, Z Younossi. Non-Alcoholic Fatty Liver Disease: A Spectrum from Steatosis to Non-Alcoholic Steatohepatitis. *Cleveland Clinic Journal of Medicine*, Vol. 67 (No.2):96-104; 2000.
5. J Ong, Z Younossi, V Reddy, T Gramlich, L Price, N Boparai. Cryptogenic Cirrhosis and Post-Transplant Non-Alcoholic Fatty Liver Disease. *Liver Transplantation*. Vol. 7 (No.9):797-801, 2001.
6. J Ong, Z Younossi, C Speer, N Boparai, T Gramlich. Chronic Hepatitis C and Superimposed Non-Alcoholic Fatty Liver Disease. *Liver*, 21:206-271, 2001.
7. S Saadeh, ZM Younossi, EM Remer, T Gramlich, JP Ong, M Hurley, KD Mullen, JN Cooper, MJ Sheridan. The Utility of Radiological Imaging in Non-Alcoholic Fatty Liver Disease. *Gastroenterology*, Vol. 123(No.3):745-50, 2002.
8. B Mulhall, J Ong, Z Younossi. Non-Alcoholic Fatty Liver Disease: An Overview. *Journal of Gastroenterology and Hepatology*, Vol. 17 (No.11):123-147, 2002.
9. ZM Younossi, AM Diehl, JP Ong. Non-Alcoholic Fatty Liver Disease: An Agenda for Clinical Research. *Hepatology*, Vol. 35(No.4):746-52, 2002.
10. J Ong, Z Younossi. Is Hepatocellular Carcinoma Part of the Natural History of Non-Alcoholic Steatohepatitis? *Gastroenterology*, Vol. 123(No.1):375-378, 2002.
11. J Ong, Z Younossi. Non-Alcoholic Fatty Liver Disease – Two Decades Later: Are We Smarter About Its Natural History? *American Journal of Gastroenterology*, Vol. 98(No. 9), 2003.
12. T Gramlich, D Kleiner, A McCullough, C Matteoni, N Boparai, Z Younossi. Pathologic Features Associated with Fibrosis in Non-Alcoholic Fatty Liver Disease. *Human Pathology*, Vol. 35 (No.2):196-199; 2004.
13. Z Younossi, T Gramlich, C Matteoni, N Boparai, A McCullough. Non-Alcoholic Fatty Liver Disease in Patients with Type II Diabetes. *Clinical Gastroenterology and Hepatology*, Vol. 2(No.3):262-265; 2004.
14. R Collantes, Z Younossi. Hepatitis C and Non-Alcoholic Fatty Liver Disease. *Hepatitis Index and Reviews*, Vol. Ii, No 1:5-6; 2004.
15. R Collantes, J Ong, Z Younossi. Non-Alcoholic Fatty Liver and the Epidemic of Obesity. *Cleveland Clinic Journal of Medicine*, Vol. 71(No.8):657-664; 2004.
16. B Mullhall, Z Younossi. Non-Alcoholic Steatohepatitis. *Current Treatment Options in Gastroenterology*, 7:423-430, 2004.
17. Z Younossi. Interactions between Nonalcoholic Fatty Liver Disease and Hepatitis C Viral Infection. *Journal of Gastroenterology and Hepatology* 19, S253-S257; 2004.
18. T Taddei, Z Younossi. The Efficacy of Weight Reduction in Nonalcoholic Fatty Liver Disease. *Evidence-Based Gastroenterology*. 5(3):96-97, August 2004.
19. J Ong, H Elariny, R Collantes, A Younoszai, V Chandhoke, HD Reines, Z Goodman, ZM Younossi. Predictors of Nonalcoholic Steatohepatitis and Advanced Fibrosis in Obese Patients Obesity Surgery 15(3):310-15, 2005.
20. Z Younossi, F Gorreta, J Ong M, K Schlauch, L Del Giacco, H Elariny, A Younoszai, Z Goodman, A Christensen, V Chandhoke, G Grant. Hepatic Gene Expression in Patients with Non-alcoholic Steatohepatitis. *Liver Int*. 25(4):760-71, 2005.
21. A Baranova, R Collantes, SJ. Gowder, H Elariny, K Schlauch, A Younoszai, S King, M Randhawa, S Pusulury, T Alsheddi, JP. Ong, LM. Martin, V Chandhoke, ZM. Younossi, MD. Obesity-related Differential Gene Expression in the Visceral Adipose Tissue. *Obes Surg*. 15(6):758-65, 2005.
22. S Srivastava, Z Younossi. Morbid Obesity, Non-Alcoholic Fatty Liver Disease, and Weight Loss Surgery. *Hepatology* 42(2):490-92, 2005.

23. R Collantes, Z Younossi. Nonalcoholic Fatty Liver Disease and Diabetes. *Panminerva Medica*, 2005.
24. J Ong, Z Younossi. Approaches to the Diagnosis and Therapy of Non-alcoholic Fatty Liver Disease. *Clinics in Liver Disease*, 9(4):617-634, 2005.
25. A Baranova, K Schlauch, S Gowder, R Collantes, V Chandhoke, Z Younossi. Microarray Gene Expression Studies of Obesity-Related Non-Alcoholic Fatty Liver Disease. *Liver International*; 25 (6):1091-1096, 2005.
26. Z Younossi, A Baranova, K Ziegler, L Del Giacco, K Schlauch, T Born, H Elariny, F Gorreta, A VanMeter, A Younoszai, J Ong, Z Goodman, V Chandhoke. A Genomic and Proteomic of Study of the Spectrum of Non-Alcoholic Fatty Liver Disease. *Hepatology* 41(3):665-674. 2005.
27. RS Collantes, JP Ong, ZM Younossi. The Metabolic Syndrome and Nonalcoholic Fatty Liver Disease. *Panminerva Med.*, 48(1):41-8, 2006.
28. M Mendoza, Z Younossi. Diabetic Hepatosclerosis: A Novel Entity or a Rare Form of Non-Alcoholic Fatty Liver Disease. *Hepatology*, 44(5):1362-3, 2006.
29. A Baranova, R Collantes, K Schlauch, H Elariny, Z Younossi. A Comparison of Serum Levels and Gene Expression of Leptin, Resistin and Adiponectin in the Adipose Tissue of Obese Patients with Non-Alcoholic Fatty Liver Disease and Insulin Resistance. *Obesity Surgery*, 16(9):1118-25, 2006.
30. A Baranova, R Collantes, K Schlauch, H Elariny, Z Younossi. A Comparison of Serum Levels and Gene Expression of Leptin, Resistin and Adiponectin in the Adipose Tissue of Obese Patients with Non-Alcoholic Fatty Liver Disease and Insulin Resistance. *Obesity Surgery*, 16(9):1118-25, 2006.
31. S Bondini, J Kallman, A Wheeler, S Prakash, T Gramlich, D Jondle, ZM. Younossi. The Impact of Non-Alcoholic Fatty Liver Disease on Chronic Hepatitis B. *Liver International*, 27(5):607-11, 2007
32. Z Younossi, A McCullough, J Ong, D Barnes, A Post, A Tavill, D Bringman, L Martin, J Assmann, T Gramlich, K Mullen, R O'Shea, W Carey, R Ferguson. Obesity and Non-Alcoholic Fatty Liver Disease in Chronic Hepatitis C. *Journal of Clinical Gastroenterology*, Vol. 38:705-709, 2004.
33. Z Younossi: Non-alcoholic Fatty Liver Disease: Detection & Treatment: *World Gastroenterology News*: Vol. 12: 14-15, 2007.
34. A Baranova, M Randhawa, M Jarrar, ZM Younossi. Adipokines and Melanocortins in the Hepatic Manifestation of Metabolic Syndrome: Non-Alcoholic Fatty Liver Disease. *Expert Review of Molecular Diagnostics* 7 (2): 195-205, 2007.
35. S Bondini, DE Kleiner, ZD Goodman, T Gramlich, ZM. Younossi. Pathologic Assessment of Non-alcoholic Fatty Liver Disease. *Clinics in Liver Disease* 11:17-23, 2007.
36. JP Ong, ZM Younossi. Epidemiology and Natural History of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis. *Clinics in Liver Disease* 11:1-16, 2007.
37. A Baranova, L Liotta, E Petricoin, ZM Younossi. The Role of Genomics and Proteomics Technologies in Studying Non-Alcoholic Fatty Liver Disease. *Clinics in Liver Disease* 11:209-220, 2007.
39. ZM Younossi, Preface. Non-alcoholic Fatty Liver Diseases and Non-alcoholic Steatohepatitis. *Clinics in Liver Disease* 11 (2007) xxii-xiv.
40. P Mishra, ZM Younossi. Current Treatment Strategies for Non-alcoholic Fatty Liver Disease. *Current Drug Discovery Technologies*. 4:133-140, 2007
41. C Nugent, ZM Younossi. Evaluation and Management of Obesity-related Non-alcoholic Fatty Liver Disease. *Nature Clinical Practice Gastroenterology & Hepatology* 14 (No. 8):432-441, 2007.
42. VS Calvert, R Collantes, H Elariny, Arian Afendy, A Baranova, M Mendoza, Z Goodman, L Liotta, EF Petricoin, ZM. Younossi. A Systems Biology Approach to Non Alcoholic Fatty Liver Disease Pathogenesis Using Multiplexed Cell Signaling Analysis. *Hepatology* 46 (1):166-172, 2007
43. Z Younossi: Non-alcoholic Fatty Liver Disease: Detection & Treatment: *World Gastroenterology News*: Vol. 12: 14-15, 2007.
44. A Baranova, M Randhawa, M Jarrar, ZM. Younossi. Adipokines and Melanocortins in the Hepatic Manifestation of Metabolic Syndrome: Non-Alcoholic Fatty Liver Disease. *Expert Review of Molecular Diagnostics* 7 (2): 195-205, 2007.

45. S Bondini, DE Kleiner, ZD Goodman, T Gramlich, ZM. Younossi. Pathologic Assessment of Non-alcoholic Fatty Liver Disease. *Clinics in Liver Disease* 11:17-23, 2007.
46. JP Ong, ZM Younossi. Epidemiology and Natural History of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis. *Clinics in Liver Disease* 11:1-16, 2007.
47. A Baranova, L Liotta, E Petricoin, ZM. Younossi. The Role of Genomics and Proteomics Technologies in Studying Non-Alcoholic Fatty Liver Disease. *Clinics in Liver Disease* 11:209-220, 2007.
48. ZM Younossi, Preface. *Clinics in Liver Disease* 11 (2007) xxii-xiv.
49. P Mishra, ZM Younossi. Current Treatment Strategies for Non-alcoholic Fatty Liver Disease. *Current Drug Discovery Technologies*. 4:133-140, 2007.
50. A Baranova, K Schlauch, H Elariny, M Jarrar, C Bennett, C Nugent, S Crowder, R Collantes, ZM Younossi. Gene Expression Patterns in the Hepatic Tissue and in the Visceral Adipose Tissue of Patients with Non-Alcoholic Fatty Liver Disease. *Obesity Surgery*. 17(8):1111-8, 2007.
51. A Dan, J Kallman, A Wheeler, Z Younoszai, R Collantes, S Bondini, L Gerber, Z Younossi. Health-related Quality of Life in Patients with Non-Alcoholic Fatty Liver Disease. *Alimentary Pharmacology & Therapeutics* 26(6):815-820, 2007
52. P Mishra, ZM. Younossi. Abdominal Ultrasound for Diagnosis of Non-Alcoholic Fatty Liver Disease. *Am J of Gastro*. 102(12):2716-7, 2007
53. Petricoin, ZM Younossi. Reply to the letter to the Editor: Bioinformatics as a Tool to Identify Gene/Protein-Pathways Associated with Non-Alcoholic Fatty Liver Disease/Non-alcoholic Steatohepatitis. *Hepatology* 46(4):1306-1307, 2007
54. A Baranova, Z Younossi. The Future Is Around the Corner: Non-Invasive Diagnosis of the Progressive Nonalcoholic Steatohepatitis. *Hepatology*. 2008; 47(2):373-5
55. M Jarrar, A Baranova, R Collantes, B Ranard, M Stepanova, C Bennett, Y Fang, H Elariny, Z Goodman, V. Chandhoke, ZM. Younossi. Adipokines and Cytokines in Non-Alcoholic Fatty Liver Disease. *Alimentary Pharmacology & Therapeutics* 2008; 1;27(5):412-21.
56. Z Younossi. Current Management of Non-alcoholic Fatty Liver Disease. *Aliment Pharmacol Ther*. 2008 Jul; 28(1):2-12.
57. C Nugent, CH Bai, H Elariny, P Gopalakrishnan, C Quigley, M Garone Jr., M Afendy, O Chan, A Wheeler, A Afendy , ZM Younossi. Improvement of Metabolic Syndrome after Laparoscopic Bariatric Surgery. *Obes Surg*. 2008; 18(10):1278-86.
58. A Baranova, Z Younossi. Reply to the Letter to the Editor: "A "Biomarker Biopsy" for the Diagnosis of NASH: Promises from CK-18 Fragments" by Yusuf Yilmaz, Engin Ulukaya, Enver Dolar. *Obes Surg*. 2008; 18(11):1509-10.
59. Z Younossi, M Jarrar, C Nugent, M Afendy, C Quigley, M Stepanova, H Elariny, Z Goodman, V Chandhoke. A Novel Diagnostic Biomarker Panel for Obesity Related Non-Alcoholic Steatohepatitis. *Obesity Surg* 2008; 18(11):1430-7.
60. CH Kim, ZM Younossi. Non-Alcoholic Fatty Liver Disease. *Cleveland Clinic J of Medicine* 2008; 75 (9):673-680
61. A. Baranova, Z. Younossi. Adipokines and Cytokines in Non-alcoholic Fatty Liver Disease: Authors' Reply. *Alimentary Pharmacology & Therapeutics*. 2008; 28(2) 267-68.
62. N. Rafiq, Z. Younossi. The Impact of Non-alcoholic Fatty Liver Disease on Chronic Hepatitis B and C. *Practical Gastroenterology*. 2008; 32 (7):14-28.
63. N. Rafiq, Z. Younossi. Interaction of Metabolic Syndrome, Non-alcoholic Fatty Liver Disease and Chronic Hepatitis C. *Expert Review of Gastroenterology and Hepatology*. 2008 2(2): 207-15.
64. C H Kim, J Kallman, CH Bai, L Pawloski, C Gewa, A Arsalla, ME Sabatella, ZM. Younossi Nutritional Assessments of Patients with Non-Alcoholic Fatty Liver Disease. *Obesity Surgery* 2010 Feb;20(2):154-60
65. JP. Ong, A Pitts, ZM. Younossi. Increased Mortality and Liver-Related Mortality in Patients with Nonalcoholic Fatty Liver Disease. *J of Hepatology* 2008; 49:608-612

66. P Mishra, C Nugent, A Afendy, C Bai, P Bhatia, M Afendy, Y Fang, H Elariny, Z Goodman, ZM Younossi. Apneic-Hypopneic Episodes during Obstructive Sleep Apnea are Associated with Histologic Nonalcoholic Steatohepatitis (Non-alcoholic Steatohepatitis). *Liver International* 2008 28(8):1080-6.
67. W Dunn, R Xu, D Wingard, C Rogers, P Angulo, ZM Younossi, JB Schwimmer, Suspected Nonalcoholic Fatty Liver Disease and Mortality Risk in a Population-based Cohort Study. *Am J of Gastroenterology* 2008; 103(9):2263-71
68. N Rafiq, Z Younossi. Weight Loss and Its Impact on Non-Alcoholic Fatty Liver Disease. *Seminars in Liver Disease* 2008; 28 (4):427-33
69. N Rafiq, ZM Younossi. Can we Use Clinical Parameters to Predict Non-Alcoholic Steatohepatitis in Morbidly Obese Patients? *Evidence-Based Gastroenterology* 2008; 9 (No 3):69-70
70. M Randhawa, T Huff, JC Valencia, ZM Younossi, V Chandhoke, VJ. Hearing, A Baranova. Evidence for the Ectopic Synthesis of Melanin in Human Adipose Tissue. *FASEB J.* 2009 Mar; 23(3):835-43.
71. N Rafiq, CH Bai, Y Fang, M Srishord, A McCullough, T Gramlich, ZM Younossi. Long-Term Follow-Up of Patients with Non-Alcoholic Fatty Liver. *Clinical Gastro and Hepatology* 2009; 7(2):234-8
72. Z Younossi, A McCullough. Metabolic Syndrome, Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus: Impact on Disease Progression and Treatment Response. *Liver Int.* 2009 Mar; 29 Suppl. 2:3-12.
73. B Lam, Z Younossi. Treatment of Non-Alcoholic Fatty Liver Disease. *Annals of Hepatology* 2009; 8 (1): Supplement: S51-S59
74. JB Kallman, A Arsalla, V Park, S Dhungel, P Bhatia, D Haddad, A Wheeler, ZM Younossi. Screening for Non-alcoholic Fatty Liver Disease (NAFLD), Hepatitis B (HBV) and Hepatitis C (HCV): A Survey of Community-based Physicians. *Aliment Pharmacol Ther.* 2009 May 1; 29(9):1019-24.
75. N Rafiq, Z Younossi. Evaluation and Management of Non-Alcoholic Fatty Liver Disease. *Clinics in Liver Disease* 2009; 13:249–266
76. JM Estep, A Baranova, N Hossain, H Elariny, K Ankrah, A Afendy, V Chandhoke, ZM. Younossi. Expression of Cytokine Signaling Genes in Non-Alcoholic Steatohepatitis and Hepatic Fibrosis. *Obes Surg.* 2009 May;19 (5):617-24.
77. N Hossain, A Afendy, M Stepanova, F Nader, M Srishord, Z Goodman, Z Younossi. Independent Predictors of Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease. *Clin Gastroenterol Hepatol.* Nov 2009;7(11):1224-9
78. ZM Younossi, A Afendy, M Stepanova, N Hossain, I Younossi, K Ankrah, T Gramlich, A Baranova. Gene Expression Profile Associated with Superimposed Non-Alcoholic Fatty Liver Disease in Patients with Chronic Hepatitis C. *Liver Int.* 2009 Volume 29, Issue 9:1403-1412
79. J Ong, M Stepanova, ZM Younossi. Outcomes of patients with Non-Alcoholic Fatty Liver Disease. *J of Hepatology* 2009
80. JP Ong, ZM Younossi. Non-Alcoholic Fatty Liver Disease after Liver Transplantation: A Case of Nurture and Nature. *Am J of Gastroenterology* 2010, Vol. 105, Issue 3:621-623
81. B Lam, ZM Younossi. Treatment options for Non-Alcoholic Fatty Liver Disease. *Therap Adv Gastroenterol.* 2010 Mar;3 (2):121-37.
82. M Stepanova, N Hossain, A Afendy, ZD. Goodman, A Baranova, ZM Younossi. Hepatic Gene Expression of Caucasian and African-American Patients with Non-Alcoholic Fatty Liver Disease. *Obes Surg.* 2010 May; 20(5):640-50.
83. M Stepanova, R Aquino, A Alsheddi, R Gupta, Y Fang, ZM Younossi. Clinical Predictors of Fibrosis in Patients with Chronic Liver Disease. *Aliment Pharmacol Ther* 2010, ;31(10):1085-94
84. Z Younossi, A Baranova, M Stepanova, V Calvert, A Afendy, Z Goodman, L Liotta, E Petricoin. Phosphoproteomic Biomarkers Predicting Histologic Nonalcoholic Steatohepatitis and Fibrosis. *J Proteome Res.* *J Proteome Res.* 2010, 4;9(6):3218-24.

85. J Kallman, A Wheeler, HK Alathari, Y Fang, M Stepanova, H Elariny, ZM Younossi. Association of Components of Metabolic Syndrome with Depression and Anxiety in Patients Undergoing Weight Reduction Surgery. *Open Obesity Journal* 2010, 2:125-131
86. M Estep, D Armistead, N Hossain, Elariny, Z Goodman, A Baranova, ZM Younossi. Differential Expression of miRNAs in the Visceral Adipose of Patients with Non-Alcoholic Fatty Liver Disease. *Aliment Pharmacol Ther* 2010;32(3):487-97.
87. R Mehta, A Birerdinc, N Hossain, A Afendy, V Chandhoke, ZM Younossi, A Baranova. Validation of endogenous reference genes for qRT-PCR analysis of human visceral adipose samples. *BMC Molecular Biology* 2010, 11:39.
88. J Estep, A Birerdinc, ZM Younossi. Non-invasive diagnostic tests for non-alcoholic fatty liver disease. *Current Molecular Medicine*. 2010; Volume 10, Issue 2:166-172
89. ZM. Younossi, S Page, N Rafiq, A Birerdinc, M Stepanova, N Hossain, A Afendy, Z Younoszai, Z Goodman, A Baranova. A Biomarker Panel for Non-alcoholic Steatohepatitis (NASH) and NASH-Related Fibrosis. *Obes Surg*. 2010 Jun 8. [Epub ahead of print]
90. M Stepanova, N Rafiq, ZM. Younossi. Components of Metabolic Syndrome as Independent Predictors of Mortality In Chronic Liver Disease: A Population-Based Study. *Gut*. 2010; 59 (10):1410-5.
91. A Weinstein, J Kallman, M Stepanova L Poms, Y Fang, J Moon, F Nader, ZM. Younossi. Depression in Patients with Nonalcoholic Fatty Liver Disease and Chronic Viral Hepatitis B and C. *PSYCHOSOMATIC* 2011 (In Press).
92. N Hossain, M Stepanova, A Afendy, F Nader, N Rafiq, Y Younossi, Z Goodman, ZM. Younossi. Non-Alcoholic Steatohepatitis (NASH) in Patients with Polycystic Ovarian Syndrome. *Scand J Gastroenterol*. 2010 Nov 30. [Epub ahead of print]
93. B Lam, Z Younossi. Novel treatment strategies for patients with non-alcoholic fatty liver disease. *Clinical Investigation* February 2011, Vol. 1, No. 2, Pages 229-239
94. A Baranova, T Tran, A Birerdinc, ZM Younossi. Systematic Review: Association of Polycystic Ovary Syndrome (PCOS) with Metabolic Syndrome and Non-alcoholic Fatty Liver Disease (NAFLD). *Aliment Pharmacol Ther*. 2011 Jan 20. doi: 10.1111/j.1365-2036.2011.04579.x. [Epub ahead of print].
95. ZM. Younossi, M Stepanova, M Afendy, Y Fang, Y Younossi, H Mir, M Srishord. The Changing Face of Chronic Liver Diseases in the United States in the Past Two Decades. Submitted 2011.
96. M Stepanova, N Rafiq, H Makhlof, R Agrawal, I Kaur, Z Younoszai, Z Goodman, ZM. Younossi. Long-Term Mortality Outcomes for Patients with the Spectrum of Non-alcoholic Fatty Liver Disease (NAFLD). Submitted 2011
97. Z Younossi, M Stepanova, N Rafiq, H Makhlof, I Kaur, Z Younoszai, R Agrawal, Z Goodman. Pathologic Criteria for Non-alcoholic Steatohepatitis (NASH): Inter-protocol Agreement and Ability to Predict Liver-Related Mortality. Submitted 2011
98. G Vernon, ZM. Younossi. Epidemiology and Natural History of Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH) in the Adult Population. Submitted 2011
99. L Pawloski, T Leslie, J Kallman Price, N Hossain, Y Fang, ZM. Younossi, The Socio-geographic Determinants of Patients with Chronic Liver Disease. Submitted 2011

**Articles Related to Quality of Life Research:**

100. Z Younossi. Quality of Life Assessment and Chronic Liver Disease. *American Journal of Gastroenterology*, Vol. 93 (7):1037-1041; 1998.
101. Z Younossi. Economic and Quality of Life Outcomes in Viral Hepatitis. *Viral Hepatitis Reviews*, Vol. 5 (No. 6):220-230, 1999.
102. Z Younossi, G Guyatt, M Kiwi, D King, N Boparai. Development of a Disease-Specific Health-Related Quality of Life Index for Chronic Liver Disease. *Gut*, 44:1-6; 1999.

103. Z Younossi, M Kiwi, N. Boparai, G Guyatt. An In-Depth Assessment of Quality of Life in Chronic Cholestatic Liver Disorders. *American Journal of Gastroenterology*, Vol. 95 (No.2):497-502; 2000.
104. Z Younossi, M McCormick, N Boparai, L Farquhar, JM Henderson, G Guyatt. The Impact of Liver Transplantation on Health-Related Quality of Life. *Liver Transplantation*, Vol. 6:779-783; 2000.
105. Z Younossi, N Boparai, M McCormick, G Guyatt. Assessment of Utilities and Health-Related Quality of Life in Chronic Liver Diseases. *American Journal of Gastroenterology*, Vol. 96 (No.2): 579-583; 2001.
106. Z Younossi, N Boparai, M Kiwi, L Price, M Kiwi, G Guyatt. Health-Related Quality of Life Assessment in Chronic Liver Disease: Impact of Type and Severity of Disease. *American Journal of Gastroenterology*, Vol. 96 (No.7):2199-2205, 2001.
107. Z Younossi, N Boparai, M McCormick, L Price, G Guyatt. Assessment of Utilities and Health-Related Quality of Life in Patients with Chronic Liver Disease. *American Journal of Gastroenterology*, Vol. 96, (No.2):579-583, 2001.
108. LM Martin, MJ Sheridan, ZM Younossi. The Impact of Liver Disease on Health-Related Quality of Life: A Review of the Literature. *Current Gastroenterology Reports*, Vol. 4(No.1):79-83, 2002.
109. L Martin, K Irwin, Z Younossi. Health-Related Quality of Life and Chronic Liver Disease: Conceptual Challenges and Clinical Applications. *Clinical Perspective in Gastro*, 60-63, 2002.
110. P Pockros, M Shiffman, E Schiff, M. Sulkowski, ZM Younossi, DT. Dieterich, T Wright, SH. Mody, K Tang, BL. Goon, PJ. Bowers, G Leitz, N Afdhal and the PROACTIVE Study Group. Epoetin Alfa Improves Quality of Life in Anemic HCV-infected Patients Receiving Combination Therapy. *Hepatology* 40(6):1450-8, 2004.
111. S Saab, A Ibrahim, A Shpaner, Z Younossi, C Lee, F Durazo, S Han, K Esrason, V Wu, D Farmer, M Ghobrial, C Holt, Pharm, H Yersiz, L Goldstein, M Tong M, R Busuttil. MELD Fails to Measure Quality of Life in Liver Transplant Candidates. *Liver Transplantation & Surgery* 11(2):218-23, 2005.
112. B Spiegel, ZM. Younossi, RD Hayes, D Revicki, S Robbins, F Kanwal. The Impact of Hepatitis C on Health Related Quality of Life: A Systematic Review and Quantitative Assessment. *Hepatology*; 41 (4):790-800, 2005.
113. L Martin, Z Younossi. Health-Related Quality of Life (HRQL) in Chronic Liver Disease. *Digestive and Liver Disease* 37 (11):819-820, 2005.
114. L Martin, A Dunn, Z Younossi. Measurement of Health-Related Quality of Life in Patients with Chronic Liver Disease. *Liver Transplantation*, 12 (1):22-23, 2006.
115. A Dunn, L Martin, D Farmer, C Crone, J Ong, T Wise, S Robbins, ZM. Younossi. Depression, anemia and health-related quality of life in chronic hepatitis C. *J Hepatology*, 27:122-129, 2006
116. Z Younossi, J Kallman, J Kincaid. The Effects of HCV Infection and Management on Health-Related Quality of Life. *Hepatology* 45 (3): 806-816, 2007
117. J Kallman, MM O'Neill, B Larive, N Boparai, L Calabrese, ZM. Younossi. Fatigue and Health-related Quality of Life (HRQL) in Chronic Hepatitis C Virus Infection. *Dig Dis and Sciences*. 52(10):2531-9, 2007.
118. A Dan, L Martin, C Crone, J Ong, T Wise, L Ramsey, MS Sjogren ZM. Younossi. Anger Experiences among Hepatitis-C Patients: Relationship to Depressive Symptoms and Health-Related Quality of Life. *Psychosomatics*. 48(3):223-9, 2007.
119. B Spiegel, R Bolus, S Han, M Tong, E Esrailian, J Talley, T Tran, J Smith, J Karsan, F Durazo, B Bacon, P Martin, Z Younossi, S Hwa-Ong, F Kanwal. Development and Validation of a Disease-Targeted Health-Related Quality Of Life Instrument In Chronic Hepatitis B Infection: The HBQOL.1 V1.0. *Hepatology*, 46 (1):113-121 2007
120. S Bondini, J Kallman, A Dan, Z Younoszai, L Ramsey, F Nader, ZM. Younossi Health-Related Quality Of Life in Patients With Chronic Hepatitis B. *Liver International*. 27 (8):1119-1125, 2007
121. A Dan, J Kallman, R Srivastava, Z Younoszai, A Kim, Z Younossi. Health Utilizing assessment using SF-6D as Health Utility Index in patient with Chronic Liver Disease. *Liver Transplantation* 2008; 14(3):321-6.

122. KH Schulz, S Kroencke, H Ewers, H Schulz, ZM Younossi. The Factorial Structure of the Chronic Liver Disease Questionnaire (CLDQ). *Qual Life Res.* 2008; 17(4):575-84.
123. A. Dan, Z. Younossi. Long-term improvement in health-related quality of life after orthotopic liver transplantation. *Liver Transplantation* 2008; 14(10):1404-1405.
124. R Two, A Verjee-Lorenz, D Clayson, M Dalal, ZM Younossi. A Methodology for Successfully Producing Global Translations of Patient-Reported Outcome Measures for Use in Multiple Countries. *Value Health.* 2010 Jan;13(1):128-31.
125. A Afendy, J Kallman, M Stepanova, Z Younoszai, R Aquino, G Bianchi, G Marchesini, ZM Younossi. Predictors of Health-Related Quality Of Life (HRQL) In Patients with Chronic Liver Disease. *Aliment Pharmacol Ther* 2009;30(5):469-76
126. R. Two, A. Verjee-Lorenz, D Clayson, M. Dalal, K Grotzinger, ZM Younossi. Response to the letter from Ms. Tamzin Furtado. *Value in Health.* Volume 13, Issue 4, June 2010, Page 508
127. JP Ong, C Krüger-Jansen, G Oehler, J Lambert-Baumann, ZM. Younossi. The Impact of Oral L-Ornithine-L-Aspartate For The Treatment Of Hepatic Encephalopathy On Health-Related Quality Of Life. *Clin Drug Investig.* 2011 Jan 5. doi: 10.2165/11586700-000000000-00000. [Epub ahead of print]
128. S Saab, V Ng, C Landaverde, S Lee, WS Comulada, J Arevalo, F Durazo, S Huy Han, ZM Younossi, R W Busuttill. Development and validation of a disease specific questionnaire to measure health related quality of life in liver transplant recipients. *Liver Transplantation* 2011 (In Press)
129. S Saab, H Bownik, N Ayoub, ZM Younossi, F Durazo, S Han, J Hong, D Farmer, RW Busuttill. Differences in Health Related Quality of Life Scores after Orthotopic Liver Transplant with Respect to Selected Socioeconomic Factors. Submitted 2011
130. A Sanyal, ZM Younossi, R Brown, R Vemuru, M Jamal, S Huang, K Merchant, E Bortey, W Forbes. Rifaximin Improves Quality of Life in Cirrhotic Patients with Recurrent Hepatic Encephalopathy: A Randomized, Controlled Trial. Submitted 2011

**Articles Related to Outcomes and Health Services Research:**

131. Z Younossi, G Guyatt. Evidence-Based Medicine: A Method for Solving Clinical Problems in Hepatology. *Hepatology*, Vol. 30 (No. 4);829-832; 1999.
132. A Aggarwal, J Ong, Z Younossi, D Nelson, J Schafle, L Hoffman Hogg, A Arroliga. Predictors of Morality and Resource Utilization for Patients with Chronic Liver Disease Admitted to the Medical Intensive Care Unit. *Chest*, 119:1489-1493, 2001.
133. A Aggarwal, JP Ong, M Goormastic, DR Nelson, AC Arroliga, L Farquhar, J Mayes, ZM Younossi. Survival and Resource Utilization in Liver Transplant Recipients: The Impact of Admission to the Intensive Care Unit. *Transplant Proc.*, Vol. 35(No.8): 2998-3002, 2003.
134. T Gildea, WC Cook, DR Nelson, A Aggarwal, W Carey, ZM Younossi, AC Arroliga. Predictors of Long-term Mortality in Patients With Cirrhosis of the Liver Admitted to a Medical ICU. *Chest* 126(5):1598-603; 2004.
135. A Dunn, ZM. Younossi Outcome and Quality of Life in Patients with Polycystic Liver Disease after Liver or Combined Liver-Kidney Transplantation. *Liver Transplantation*, 12(8):1184-5, 2006.
136. CH Kim, ZM. Younossi. New Agents for Treatment of Chronic Hepatitis B: Are they Cost-Effective? *Evidence-Based Gastroenterology.* 8(1):25-26, February 2007.

**Articles Related to Hepatitis C:**

137. Z Younossi, J McHutchison. Serologic Tests for HCV Infection. *Viral Hepatitis Reviews*, Vol.2, (No.3): 161- 173; 1996.
138. Z Younossi. Hepatitis C: A Clinical Overview. *Cleveland Clinic Journal of Medicine*, Vol. 64:259-268; 1997.
139. K Sheathe, Z Younossi. Diagnostic Assays for Viral Hepatitis B and C. *Practical Gastroenterology*, Vol. XXII (5):39- 48; 1998.

140. Z Younossi, P Canuto. Hepatitis C update: Implication of Blood Transfusion Look Back. *Cleveland Clinic Journal of Medicine*, Vol. 65 (No. 8), 1998.
141. Z Younossi, P Canuto. Hepatitis C Update: Implication of Blood Transfusion Look back. *The Cleveland Clinic Journal of Medicine*, Vol. 65(No.8); 1998.
142. Z Younossi, W Braun, D Protiva, R Gifford, R Straffon. Chronic Viral Hepatitis in Renal Transplant Recipients with Allografts Functioning for More than Twenty Years. *Transplantation*, Vol. 67 (2):272-275; 1999.
143. C Matteoni, Z Younossi. Hepatitis C Testing: What Test for Which Patient. *Cleveland Clinic Journal of Medicine*, Vol. 66 (No.9):529- 530; 1999.
144. Z Younossi, T Gramlich, N Boparai, P George, J Mayes. Concordance in Pathologic Interpretation of Liver Biopsies in Post-Transplant Hepatitis C: Recurrence vs. Acute Cellular Rejection. *Archive of Pathology and Lab Medicine*, Vol. 123:143-145; 1999.
145. J Ong, D Barnes, Z Younossi, M Goormastic, T Gramlich, B Yen-Lieberman, K Hoersher, C Sheffield, J Young, R Starling, N Smedria, P MacCarthy. Outcomes of DeNovo Hepatitis C Virus Infection in Heart Transplant Recipients. *Hepatology*, Vol. 30 (No.5):1293-1298; 1999.
146. Z Younossi, M Singer, J McHutchison, K Shermock. Cost-Effectiveness of Interferon-Alpha 2b Combined with Ribavirin for the Treatment of Chronic Hepatitis C. *Hepatology*, Vol. 30 (No. 5):1328-1334; 1999.
147. Z Younossi, R Perillo. The Roles of Amantadine, Rimantadine, Ursodeoxycholic Acid and NSAIDS, Alone or in Combination with Alpha Interferon's in the Treatment of Chronic Hepatitis C. *Seminars in Liver Disease (Supplement)*, Vol. 19, 1:95-102; 1999.
148. D Zdilar, K Franco-Bronson, N Buchler, J Locala, Z Younossi. Hepatitis C, Interferon-Alpha and Depression. *Hepatology*. Vol. 31 (No.6): 1207-1211; 2000.
149. S Sarbah, Z Younossi. Hepatitis C: An Update on the Silent Epidemic. *Journal of Clinical Gastroenterology*, Vol. 30:125-143, 2000.
150. Z Younossi. Viral Hepatitis Guide to Practicing Physicians. *Cleveland Clinic Journal of Medicine*, 67, Supplement 1:SI6-45, 2000.
151. J McHutchison, Z Younossi. Treatment Strategies for Hepatitis C: Making the Best of Limited Options. *Cleveland Clinic Journal of Medicine*; 67:1-5, 2000.
152. Z Younossi. Chronic Hepatitis C in Young Healthy Individuals. *Evidence-Based Gastroenterology*, 1, 1:34-35, 2000.
153. J McHutchison, Z Younossi. Do Nonsteroidal Anti-Inflammatory Agents Improve Response to Interferon in Patients with Chronic Hepatitis C Virus Infection? *Evidence-Based Gastroenterology*,1:38-39, 2000.
154. S Saadeh, G Cammell, K Easley, Z Younossi, W Carey. Role of Liver Biopsy In Chronic Hepatitis C. *Hepatology*, Vol. 33(No.1):196-200; 2001.
155. J Ong, Z Younossi, T Gramlich, Z Goodman, J Mayes, S Sarbah, B Yen-Lieberman. Interferon alpha 2b And Ribavirin in Severe Recurrent Cholestatic HCV. *Transplantation*; 71 (10):1486-1488, 2001.
141. Z Younossi, K Mullen, W Zakko, S Hodnick, E Brandt, D Barnes, W Carey, A McCullough, K Easley. A Randomized, Double-Blind Controlled Trial of Interferon Alpha-2b and Ribavirin vs. Interferon Alpha-2b and Amantadine for Treatment of Chronic Hepatitis C, Non-Responders to Interferon. *Journal of Hepatology*, 34:128-133; 2001.
142. E Hadziyannis, A Hadziyannis, S Savas, I Rapti, M Kiwi, S Hodnick, F Spanou, C Starkey, B Yen-Liebeunan, Z Younossi. Hepatitis C Virus RNA Assays: Comparison of Superquant and Monitor. *Journal of Clinical Gastroenterology*, Vol. 33 (No.1):45-48, 2001.
143. M Singer, Z Younossi. Cost-Effectiveness of Screening for Hepatitis C Virus in Asymptomatic, Average Risk Adults: Has the Time Come? *American Journal of Medicine*, 111:614-621, 2001.
144. KM Shermock, ME Temple, Z Younossi. A Pharmacoeconomic Appraisal of Therapies for Hepatitis B and C. *Expert Opinion on Pharmacotherapy*, Vol. 2(No.2):205-211, 2001.
145. KM Shermock, ME Temple, Z Younossi. The Cost-Effectiveness of Treating Chronic Hepatitis C. *Drug Benefit Trends*, 14 (A):34-40, 2002.

146. K Sharieff, D Duncan D, Z Younossi. Advances in Treatment of Chronic Hepatitis C: Pegylated Interferons. *Cleveland Clinic Journal of Medicine*, Vol. 69(No.2):155-9, 2002.
147. B Mulhall, Z Younossi. Can Anti-Viral Therapy Improve Hepatitis C Related Fibrosis? *Evidence-Based Gastroenterology*, Vol. 3(No 2):67-68, 2002.
148. T Poynard, V Ratziu, J McHutchison, M Manns, Z Goodman, S Zeuzem, Z Younossi, J Albrecht. Effect of Treatment with Peginterferon or Interferon Alfa-2b and Ribavirin on Steatosis in Patients Infected with Hepatitis C. *Hepatology*, Vol. 38(No.1):75-85; 2003.
149. R Collantes, Z Younossi. Interferon Alfa-2b and Ribavirin Combination Is Effective In Patients with Hemophilia and Chronic Hepatitis C. *Evidence-Based Gastroenterology*. 4(1):26-28, February 2003.
150. M Duncan, Z. Younossi. Treatment Options for Nonresponders and Relapsers to Initial Therapy for Hepatitis C. *Cleveland Clinic Journal of Medicine*, 70 Supplement 4:S21-6, 2003.
151. Z Younossi, K Mullen, S Hodnick, D Barnes, W Carey, A McCullough, K Easley, T Gramlich, B Liebermann. Triple Combination of Interferon Alpha-2b, Ribavirin, and Amantadine for Treatment of Chronic Hepatitis C. *Journal Clinical Gastroenterology*, Vol. 36(No.5): 427-430; 2003.
152. A Di Bisceglie, A Lyra, M Schwartz, R Reddy, P Martin, G Gorges, A Lok, K Hussain, R Gish, D Van Thiel, Z Younossi et al. Hepatitis C-Related Hepatocellular Carcinoma: Influence of Ethnic Status. *American Journal of Gastroenterology*, Vol. 98 (No. 9): 2060-2063, 2003.
153. D Vassilopoulos, ZM Younossi, E Hadziyannis, N Boparai, B Yen-Lieberman, E Hsi, A Villa-Forte, E Ball, RP Kimberly, LH Calabrese. Study of Host and Virological Factors of Patients with Chronic HCV Infection and Associated Laboratory or Clinical Autoimmune Manifestations. *Clin Exp Rheumatol*. 21(6 Supplement 32):S101-11; 2003.
154. R Collantes, Z Younossi. Who is at Risk for Hepatitis C? *Cleveland Clinic Journal of Medicine*. Vol.71 (No.2):160-161; 2004.
155. J Ong, Z Younossi. Management of Anemia, Neutropenia, and Thrombocytopenia Associated with Antiviral Therapy for Chronic Hepatitis C. *Cleveland Clinic Journal of Medicine*, Supplement 3, Vol. 71:S17-S21; 2004.
156. J. Koff, Z Younossi. Hepatitis C with Normal Liver Enzymes: To Treat or Not to Treat. *American Journal of Gastroenterology*, Vol.9:6:972, 2004.
157. Z Younossi . Effective Hematologic Side Effect Management in Treatment of Chronic Hepatitis C. *Clinician's Companion VII*, 2004.
158. R Collantes, Z Younossi. Who is at Risk for Hepatitis C? *Cleveland Clinic Journal of Medicine*. Vol.71 (No.2):160-161; 2004.
159. J Ong, Z Younossi. Management of Anemia, Neutropenia, and Thrombocytopenia Associated with Antiviral Therapy for Chronic Hepatitis C. *Cleveland Clinic Journal of Medicine*, Supplement 3, Vol. 71:S17-S21; 2004.
160. NH Afdhal , DT Dieterich, PJ Pockros, ER Schiff, ML Shiffman, MS Sulkowski, T Wright T, ZM Younossi, BL Goon, KL Tang KL, PJ Bowers; Proactive Study Group. Epoetin Alfa Maintains Ribavirin Dose in HCV-Infected Patients: A Prospective, Double-Blind, Randomized Controlled Study. *Gastroenterology*, Vol.126; 5:1302-11, 2004.
161. J. Koff, Z Younossi. Hepatitis C with Normal Liver Enzymes: To Treat or Not to Treat. *American Journal of Gastroenterology*, Vol.9:6:972, 2004.
162. Z Younossi . Effective Hematologic Side Effect Management in Treatment of Chronic Hepatitis C. *Clinician's Companion VII*, 2004.
163. M Gupta, Z Younossi, Does Peginterferon Alfa-2a Have an Impact On Hepatitis C Recurrence After Orthotopic Liver Transplantation? *Evidence-Based Gastroenterology*. 6(2):61-62, May 2005.
164. B Mullhall, Z Younossi. The Impact of Adherence on Outcome of Antiviral Therapy of Chronic Hepatitis C. *Journal of Clinical Gastroenterology* 39:S23-S27, 2005.
165. B Spiegel, K Chen, M Broder, C Chiou, Z Younossi. Darbeoetin Alfa for the Management of Treatment-Induced Anemia in Hepatitis C: Clinical and Economic Consequences. *Clinical Gastroenterology and Hepatology* 3(10):1034-1042, 2005.

166. M Gupta, Z Younossi, Does Peginterferon Alfa-2a Have an Impact On Hepatitis C Recurrence After Orthotopic Liver Transplantation? Evidence-Based Gastroenterology. 6(2):61-62, May 2005.
167. B Mullhall, Z Younossi. The Impact of Adherence on Outcome of Antiviral Therapy of Chronic Hepatitis C. Journal of Clinical Gastroenterology 39:S23-S27, 2005.
168. R Collantes, Z Younossi. Management of Hematologic Side Effects of Peginterferon and Ribavirin with Growth Factors. Journal of Clinical Gastroenterology 39(1):S9-S13, 2005.
169. Z Younossi, A McCullough, D Barnes, A Post, J Ong , R O'Shea, L Martin, D Bringman, G Lavinthal, K Mullen, W Carey, T Tavill, R Ferguson, T Gramlich. Addition of Amantadine To Pegylated Interferon Alpha-2B And Ribavirin Does Not Improve The Efficacy of Anti-Viral Therapy For Chronic Hepatitis C. Dig Dis Sciences 50 (5):970-5, 2005
170. J Ong, R Collantes, A Pitts, L Martin, M Sheridan, Z Younossi. High Rates of Uninsured among Hepatitis C Positive Patients. Journal of Clinical Gastroenterology 39(9):826-830. 2005
171. C Entwisle, ZM Younossi. How Often Should Patients With Hepatitis C Be Screened For Esophageal Varices? Cleve Clin J Med. ;73(8):758-9, 2006.
172. TD Schiano, M Charlton, Z Younossi, E Galun, T Pruett, R Tur-Kaspa, R Eren, S Dagan, N Graham, PV Williams, J Andrews. Monoclonal Antibody HCV-Abxtl68 In Patients Undergoing Liver Transplantation For HCV: Results Of A Phase 2 Randomized Study. Liver Transplantation, 12(9):1381-9, 2006.
173. ZM Younossi. Specifically Targeted Antiviral Therapy (STAT-C) for Patients with Chronic Hepatitis C. Medscape Gastroenterology. P1-5. June 1, 2007.
174. N Rafiq, Z Younossi. The Impact of Steatosis on Viral Hepatitis B and C. Practical Gastroenterology 2007; XXXII (No.7):14-28
175. CH Kim, ZM. Younossi. Short Duration of Treatment for HCV Genotype 2 or 3 May Diminish Sustained Virologic Response. Evidence Based Gastroenterology 2007, Volume 8, Issue 4:75-77
176. H Gujral, ZM Younossi. Patients with Chronic Hepatitis C and No Health Insurance Coverage. Cleveland Clinic Foundation CME Page, 2007
177. Z Younossi, F Nader, C Bai, R Sjogren, JP. Ong, R Collantes, M Sjogren, L Ramsey, K Terra, H Gujral, C Gurung, M Srishord, Y Fang. A Phase II Dose Finding Study of Darbeoetin Alfa and Filgrastim in the Management of Anemia and Neutropenia in Chronic Hepatitis C. J Viral Hepatitis. 2008; 15(5):370-8.
178. ZM Younossi. New Directions in Hepatitis C Therapy: A Look at the Evolving Therapeutic Arsenal. Medscape Gastroenterology 2008 Medscape Gastroenterology. 2008, Posted 09/05/2008
179. I Bornman, ZM Younossi. Can the Dose of Ribavirin Be Reduced For Patients Infected With Hepatitis C, Genotypes 2 and 3? Evidence-Based Gastroenterology 2008; 9 (No 3):71-72
180. G Oeler, C Kruger-Jansen, ZM Younossi, Lambert-Baumann. L-Ornithin-L-Aspartat Verbessert Die Lebensqualität Von Patienten Mit Hepatischer Enzephalopathie. Med Welt 2008, 59:172-178.
181. H Mir, Z Younossi. Monoclonal and Polyclonal Antibodies to the HCV Envelope Protein. Clinics in Liver Disease 2009 Aug;13(3):477-86
182. A Birerdinc, A Afendy, M Stepanova, I Younossi, G Manyam, A Baranova, ZM. Younossi. Functional Pathway Analysis of Genes Associated with Response to Treatment for Chronic Hepatitis C. J Viral Hepat. 2010; 17:730-736.
183. Z Younossi. Mechanisms of Viral Eradication and Early Treatment in Hepatitis C: Implications for Therapy Clinical Update. AGA/Medscape Clinical Update; Published December 2009.
184. ZM. Younossi, A Baranova, A Afendy, R Collantes, A Bakshi, M Stepanova, G Manyam, C Santini, C Sigua, J Chan, A Iverson, SY Chang. Gene Expression Biomarkers Predicting Sustained Virologic Response in Patients with Chronic Hepatitis C Treated with Pegylated Interferon Alfa and Ribavirin. Hepatology. 2009 Mar; 49(3):763-74.
185. J Capeau, S Gharakhanian, Z Younossi. Metabolic Abnormalities in Chronic Hepatitis C. Introduction. Liver Int. 2009 Mar; 29 Suppl 2:1-2.

186. J Kallman, S Tran, A Arsalla, D Haddad, M Stepanova, Y Fang, VJ. Wrobel, M Srishord, ZM. Younossi. Vietnamese Community Screening for Hepatitis B (HBV) and Hepatitis C. *J Viral Hepat.* 2011 Jan;18(1):70-6.
187. ZM Younossi, M Stepanova. Hepatitis C Virus Infection, Age, and Hispanic Ethnicity Increase Mortality from Liver Cancer in the United States. *Clin Gastroenterol Hepatol.* 2010;8(8):718-23
188. A Baranova, M H. Jarrar, M Stepanova, A Johnson, N Rafiq, T Gramlich, V. Chandhoke, ZM. Younossi. Association of Serum Adipocytokines with Hepatic Steatosis and Fibrosis in Patients with Chronic Hepatitis C. *Digestion* 2011;83:32-40
189. A Birerdinc, Z Younossi. Emerging Therapies for Hepatitis C. *Expert Opin Emerg Drugs.* 2010 Dec;15(4):535-44.
190. M Estep, Z Younossi. Hepatitis C and Metabolic Syndrome. *Expert Review of Endocrinology and Metabolism* 2011 (In Press)
191. I Jacobson, P Cacoub, L Dal Maso, S Harrison, ZM Younossi. Chronic HCV infection II: Manifestations beyond the Liver. *Clin Gastroenterol Hepatol.* 2010 Dec;8(12):1017-29.
192. M Stepanova, F Kanwal, HB. El-Serag, ZM. Younossi. Insurance Status and Treatment Candidacy of Hepatitis C Patients: Analysis of Population-based Data from the United States. *Hepatology* 2011 Accepted manuscript online: 17 DEC 2010 03:44PM EST | DOI: 10.1002/hep.24131
193. Z Younossi, D Limongi, M Stepanova, M Pierobon, A Afendy, R Mehta, A Baranova, L Liotta, L Petricoin. Protein Pathway Activation Associated With Sustained Virologic Response In Patients With Chronic Hepatitis C Treated With Pegylated Interferon And Ribavirin. *J Proteome Res.* 2011 Jan 4. [Epub ahead of print]
194. J Moon, J Kallman, P Winter, M Srishord, Y Fang, L Pawloski, L Gerber, ZM Younossi. Nutritional and Activity Level Disparities Between Patients with Hepatitis C and Healthy Blood Donors. Submitted 2011
195. S Zeuzem, P Andreone, S Pol, E Lawitz, M Diago, S Roberts, R Focaccia, ZM Younossi, G Foster, A Horban, P Ferenci, F Nevens, B Müllhaupt, P Pockros, R Terg, D Shouval, B Hoek, O Weiland, R Van Heeswijk, S de Meyer, D Luo, G Boogaerts, R Polo, G Picchio, M Beumont, Telaprevir in Combination with Peginterferon and Ribavirin in Previously Treated Patients with Genotype 1 Chronic Hepatitis C. Submitted 2011

**Articles Related to Other Liver Diseases or Other Areas:**

196. L Miller, M Kalnoski, Z Younossi, J Bulinski, E Reisler. Antibodies Directed Against N Terminal Residues on Actin Do Not Block Acto-Myosin Binding. *Biochemistry.* 1985.
197. Z Younossi, P Foroozan. Crigler-Najjar Type II Treatment with Small-Dose Phenobarbital. *Digestive Diseases and Sciences, Vol. 40, No. 3:575, 1995.*
198. Z Younossi, P Pockros. Porphyria Cutanea Tarda and B-Immunoblastic Lymphoma: A case report. *American Journal of Hematology, Vol. 51 (No.3):252, 1996.*
199. Z Younossi, J McHutchison, T Ganiates. An Economic Analysis of Norfloxacin Prophylaxis against Spontaneous Bacterial Peritonitis. *Journal of Hepatology, 27:295-298; 1997.*
200. Z Younossi, W Strum, D Cloutier, P Teirstein, R Shatz. The Effect of Combined Anticoagulation and Low- Dose Aspirin on Upper Gastrointestinal Bleeding. *Digestive Diseases and Sciences, Vol. 41, No.2; 1997.*
201. Z Younossi, C Terran, T Ganiates, WD Carey. Ultrasound-Guided Liver Biopsy for Parenchymal Liver Disease: An Economic Analysis. *Digestive Diseases and Sciences, Vol. 43 (3):46-50; 1998.*
202. Z. Younossi, JG McHutchison, A Sedghi-Vaziri, CN Broussard. Transjugular Intrahepatic Porto-systemic Shunt and Changes in the Serum-Ascites Albumin Gradient. *Clinical Journal of Gastroenterology, 27 (2):149-151; 1998.*
203. J Ong, Z Younossi. Selective Bowel Decontamination and Its Use in Patients with Liver Disease: A Review. *Disease Management and Health Outcomes, Vol. 4 (No.1): 17-26; 1998.*

204. Z Younossi. Evaluating the Asymptomatic Individual Who has Mildly Elevated Liver Enzymes. The Cleveland Clinic Journal of Medicine, Vol. 65 (3):150-158; 1998.
205. Z Younossi. Epidemiology of Alcoholic Liver Disease. Clinics of Liver Disease, Vol. 2 (No.4):661-671; 1998.
206. B Parker, S Bhatia, Z Younossi, JM Henderson, J Tetzlaff. Autonomic Dysfunction of End-Stage Liver Disease Manifested as Defecation Syncope: Impact of Orthotopic Liver Transplantation. Liver Transplantation and Surgery, Vol. 5 (No. 6):497-501; 1999.
207. J Dumot, D Barnes, Z Younossi, J Henderson, W Carey. Immunogenicity of Hepatitis A Vaccine in Decompensated Liver Disease. American J of Gastroenterology, Vol. 94 (No.6):1601-1604; 1999.
208. J Ong, Z Younossi. Clinical Predictors of Large Esophageal Varices: How Accurate Are They: (Editorial) American Journal of Gastroenterology, Vol. 94 (No.11):3103-3105; 1999.
209. M Haug, M Ishitani, S Wimberley, W Carey, D Barnes, Z Younossi, J Mayes, M Henderson D Vogt. Hepatitis B immune globulin (HBIG) disposition after liver transplant (LT) in chronic hepatitis B (HBV). Clinical Pharmacology and Therapeutics. Volume 65, Issue 2, 1999, Page 128
210. A Duchini, Z Younossi, A Saven, G Bordin, H Knowles, P Pockros. An Open-Label Pilot Trial of Cladribine (2-CdA) in Patients with Primary Sclerosing Cholangitis. Journal of Clinical Gastroenterology, Vol. 31(No.4):292-296, 2000.
205. J Ong, M Sands, Z Younossi. Transjugular Intrahepatic Portosystemic Shunt: The Next Decade, Journal of Clinical Gastroenterology, Vol. 30: 14-28, 2000.
206. N Monserrate, JM Henderson, Z Younossi. Transjugular Intrahepatic Portosystemic Shunting and Ascites. Evidence-Based Gastroenterology, Vol. 1, (No.2) :78-79, 2000.
207. C Broussard, A Aggarwall, S Lacey, T Post, T Gramlich, M Henderson, Z Younossi. A Taste to Die for: Mushroom Poisoning- From Diarrhea to Liver Transplantation. American Journal of Gastroenterology, Vol. 96 (No.11):3195-3198, 2001.
208. BM Parker, SA Irefin, V Sabharwal, JE Tetzlaff, C Beven, Z Younossi, MT Karafa, DP Vogt, JM Henderson. Leukocyte Reduction during Orthotopic Liver Transplantation and Postoperative Outcome: A Pilot Study. Journal of Clin Anesth., 16:18-24; 2004.
209. S Srivastava, Z Younossi Can Lamivudine Prevent The Progression Of Liver Disease In Chronic Hepatitis B? Evidence-Based Gastroenterology. 6(1):26-27, March 2005.
210. S Elgawly, ZM. Younossi, Transjugular Intrahepatic Portosystemic (TIPS) Improves Transplant-Free Survival In Cirrhotic Patients With Refractory Ascites. Evidence Based Gastroenterology 2008; Volume 9, Issue 1:9-11
211. G Aragon, Z Younossi, Telbivudine: Another Option for Treatment of Patients with Chronic Hepatitis B. Evidence Based Gastroenterology 2008; Volume 9, Issue 2:19-22
212. G Aragon, Z Younossi. Evaluation of Asymptomatic Elevation of Liver Enzymes. Cleve Clin J Med. 2010 Mar;77(3):195-204.
213. M Estep, A Birerdinc, ZM Younossi. Biomarkers, the Pillars of Molecular Diagnostics and Personalized Medicine Revolution. Current Molecular Medicine 2009 (In Press)
214. JM Estep, G Grant, L O'Reilly, J Piper, J Jonsson, J Assmann, V Chandhoke, Z Younossi. Gene Expression Profile Associated with Hepatic Stellate Cells: Implications for Hepatic Fibrosis. Dig Dis Sci. 2010; 55:496-504
215. P Lal, A Birerdinc, A Baranova, ZM. Younossi. Non-Invasive Biomarkers for Hepatic Fibrosis. Submitted 2011
216. ZM. Younossi, M Stepanova. Changes in Hepatitis A and B Vaccination Rates in Patients with Chronic Liver Diseases and Type II Diabetes in the United States Population. Submitted 2011

***ABSTRACTS AND PRESENTATIONS TO INTERNATIONAL MEETINGS:***

***Presentations Related to Non-Alcoholic Fatty Liver Disease and Obesity:***

1. Z Younossi, T Gramlich, G Liu, M Pettrelli, J Goldblum, L Rybicki, C Matteoni, AJ McCullough. Assessment of Observer Variability on Pathologic Interpretation of Non-Alcoholic Steatohepatitis. American Association for Study of Liver Disease, Chicago 1997.
2. Z Younossi, C Matteoni, T Gramlich, G Liu, L Rybicki, AC McCullough. Clinico-Pathologic Outcomes in Non-Alcoholic Steatohepatitis. American Association for Study of Liver Disease. Chicago 1998.
3. C Matteoni, Z Younossi, T Gramlich, G Liu, L. Rybicki, AC McCullough. Non-Alcoholic Steatohepatitis: Risk Factors and Outcomes. Digestive Disease Week. New Orleans 1998
4. C Matteoni, Z Younossi, T Gramlich, G Liu, L. Rybicki, AC McCullough. Non-Alcoholic Steatohepatitis: Risk Factors and Outcomes. Digestive Disease Week. New Orleans 1998.
5. C Matteoni, Z Younossi, TG Gramlich, Y Liu, N Boparai, D Wohl, AJ McCullough. Histologic Iron is Not Increased in Non-Alcoholic Steatohepatitis. American Association for Study of Liver Disease. Chicago 1998.
6. Z Younossi, CA Matteoni, T Gramlich, Y Liu, N Boparai, D Wohl, AJ McCullough. Patient Characteristics Predicting Cirrhosis in Non-Alcoholic Steatohepatitis and Death in Non-Alcoholic Steatohepatitis. American Association for Study of Liver Disease. Chicago 1998
7. Z Younossi, CA Matteoni, TL Gramlich, N Boparai, L Price, AJ McCullough. Diabetes and Non-Alcoholic Fatty Liver Disease: A Worrisome Combination. Digestive Disease Week, Orlando, FL. Gastroenterology, Vol. 116 (No.4): 1292, 1999.
8. Z Younossi, TL Gramlich, BR Bacon, CA Matteoni, N Boparai, R O'Neill, AJ McCullough. Iron in Non- Alcoholic Fatty Liver Disease: Myth or Reality? Digestive Disease Week. Orlando, FL. Gastroenterology, Vol. 166 (No.4): 1293, 1999.
9. Z Younossi, DE Kleiner for the NIDDK's Non-alcoholic Steatohepatitis Pathology Working Group, T Gramlich, N Boparai. Application of NIDDK Non-alcoholic Steatohepatitis Pathologic Protocol to Patients with Non-Alcoholic Fatty Liver Disease. Digestive Disease Week. San Diego, CA. 2000
10. J Ong, V Reddy, T Gramlich, LL Price, N Boparai, Z Younossi. Cryptogenic Cirrhosis and Risk of Recurrent Non-Alcoholic Fatty Liver Disease Post-Liver Transplantation. Digestive Disease Week. San Diego, CA. 2000.
11. C Speer, J Ong, N Boparai, T Gramlich, Z Younossi. Chronic Hepatitis C: Association of Fat and Fibrosis. Oral Presentation. Digestive Disease Week. San Diego, CA. 2000.
12. S Saadeh, Z Younossi, E Remer, T Gramlich, K Mullen, J Cooper, M Sheridan. The Utility of Radiologic Assessments with CT, US and MRI in Establishing the Diagnosis of Non-Alcoholic Fatty Liver Disease. American Associate for the Study of Liver Diseases. Dallas, TX 2001. Hepatology, Vol.34 (No.4) Pt 2. 2001.
13. E Remer, S Saadeh, T Gramlich, J Ong, M Hurley, J Cooper, M Sheridan, Z Younossi. Variability of Radiologic Assessments in Non-Alcoholic Fatty Liver Disease (Non-alcoholic Fatty Liver). Poster with Distinction. Digestive Disease Week. San Francisco, CA. May 2002.
14. H Gujral, M Erario, G Anaya, J Ong, Z Younossi. Current Clinical Approaches to the Role of Liver Biopsy in Non-Alcoholic Fatty Liver Disease. Digestive Disease Week. (Oral Presentation). San Francisco, CA. May 2002.
15. J Ong, A Younoszai, H Elariny, Z Goodman, N Boparai, A Christensen, G Grant, V Chandhoke, J Cooper, Z Younossi. High Prevalence of Non-Alcoholic Steatohepatitis (Non-alcoholic Steatohepatitis) in Morbidly Obese Patients: Discordance between Elevated Liver Enzymes and Histology. Digestive Disease Week. San Francisco, CA. May 2002.
16. J Ong, H Elariny, A Younoszai, Z Goodman, G Grant, A Christensen, V Chandhoke, J Cooper, N Bopari, Z Younossi. Predictors of Non-Alcoholic Steatohepatitis and Fibrosis in Non-Alcoholic Fatty Liver Disease. American Association for Study of Liver Disease. Boston, MA. November 2002.
17. A Younoszai, J Ong, G Grant, L Del Giacco, F Gorreta, H Elariny, Z Goodman, A Christensen, C Jamison, V Chandhoke, Z Younossi. Genomics of the Spectrum of Non-Alcoholic Fatty Liver Disease. American Association for Study of Liver Disease. Boston, MA. November 2002.

18. G Grant, J Ong, F Gorreta, L Del Giacco, H Elariny, A Younoszai, Z Goodman, A Christensen, C Jamison, V Chandhoke, Z Younossi. Genetic Epidemiology of Non-Alcoholic Steatohepatitis. American Association for Study of Liver Disease. Boston, MA. 2002.
19. ZM Younossi, AJ McCullough, JP Ong, DS Barnes, A Post, KD Mullen, WD Carey, R O'Shea, G Levinthal, T Gramlich, L Martin, D Bringman, AS Tavill, DR Ferguson. Interaction of Steatosis and Non-Alcoholic Steatohepatitis (Non-alcoholic Steatohepatitis) with Chronic Hepatitis C. Digestive Disease Week. Orlando, FL. May 2003.
20. T Born, J Ong, K Schlauch, H Elariny, A Younoszai, Z Goodman, A Christensen, J Assmann, V Chandhoke, ZM Younossi. Insulin Resistance, Serum Leptin and Fibrosis in Non-Alcoholic Fatty Liver Disease (Non-alcoholic Fatty Liver). Digestive Disease Week. Orlando, FL. May 2003.
21. K Schlauch, J Ong, L del Giacco, F Goretta, G Grant, H Elariny, A Younoszai, Z Goodman, A Christensen, V Chandhoke, ZM Younossi. The Impact of Anti-Diabetic Medications on the Gene Expressions of Diabetics with Non-Alcoholic Fatty Liver Disease. Digestive Disease Week. Orlando, FL. May 2003.
22. J Ong, K Schlauch, L del Giacco, F Goretta, G Grant, H Elariny, A Younoszai, Z Goodman, A Christensen, V Chandhoke, ZM Younossi. The Impact of Insulin-Resistance on the Genomics of Non-Alcoholic Fatty Liver Diseases (Non-alcoholic Fatty Liver). Digestive Disease Week. Orlando, FL. May 2003.
23. K Schlauch, G Grant, J Ong, V Chandhoke, A Christensen, Z Younossi. A Genomic Study of Non-Alcoholic Fatty Liver Disease. Informatics, Microarray Data Analysis Conference. Zurich, Switzerland. February 2003.
24. K Miller, T Born, JP Ong, A Younoszai, H Elariny, K Schlauch, Z Goodman, Z Younossi. Proteomics of Non-Alcoholic Steatohepatitis (Non-alcoholic Steatohepatitis): Analysis of Protein Expression Profiles Using SELDI-TOF Mass Spectrometry. American Association for Study of Liver Disease. Boston, MA. October 2003.
25. A Mehrota, Z Goodman, H Elariny, A Younoszai, N Bopari, J Assmann, V Chandhoke, Z Younossi. The Utility of Immunostaining for Mallory Bodies in Non-Alcoholic Fatty Liver Disease. American Association for Study of Liver Disease. Boston, MA. October 2003.
26. F Gorreta, L Del Giacco, K Schlauch, A VanMeter, G Grant, A Christensen, V Chandhoke, Z Goodman, A Younoszai, H Elariny, JP Ong, Z Younossi. Gender Differences in Hepatic Gene Expression of Patients with Non-Alcoholic Steatohepatitis (Non-alcoholic Steatohepatitis). American Association for Study of Liver Disease. Boston, MA. October 2003.
27. K Schlauch, L O'Reilly, T Born, K Miller, J Ong, H Elariny, F Gorreta, L Del Giacco, A Younoszai, G Grant, V Chandhoke, Z Goodman, Z Younossi. A Genomic and Proteomic Study of Obesity-Related Non-Alcoholic Fatty Liver Disease. European Association for the Study of Liver Diseases. 2004.
28. S Nazarenko, A Baranova, H Elariny, K Schlauch, A Younoszai, S Gowder, T Alsheddi, F Goretta, O Court, D Reines, V Chandhoke, Z Younossi. Gene Expression Profiles Associated with Obesity. Digestive Disease Week. 2004.
29. V Chandhoke, A Baranova, S Nazarenko, H Elariny, K Schlauch, A Younoszai, S Gowder, T Alsheddi, S Pusulury, F Goretta, J Assmann, L Martin, Z Younossi. Gene Expression Profiles in Omental Adipose Tissue of Morbidly Obese Patients. Human Genome Meeting. 2004.
30. K Schlauch, J Ong, L Del Giacco, F Goretta, H Elariny, A Younoszai, A Christensen, V Chandhoke, Z Younossi. Hepatic Gene Expression Profile Related to the Metabolic Syndrome. Human Genome Meeting. 2004.
31. K Schlauch, F Gorreta, T Born, H Elariny, L Del Giacco, K Ziegler, A Van Meter, J. Ong, V Chandhoke, R Collantes, Z Goodman, Z Younossi. Hepatic Gene Expression and Serum Protein Profile of Patients with Metabolic Syndrome. Association for Study of Liver Disease. Boston, MA. October 2004.
32. Z Younossi, J Ong, H Elariny, F Gorreta, L Del Giacco, K Ziegler, T Born, K Schlauch, A Van Meter, R Collantes, A Baranova, G Grant, Z Goodman, V Chandhoke. Hepatic Gene Expression

- and Serum Protein Profile of Patients with Obesity-Related Non-Alcoholic Steatohepatitis (Non-alcoholic Steatohepatitis). North American Association for the Study of Obesity's Annual Scientific Meeting. Las Vegas, NV. November 2004.
33. J Ong, H Elariny, A Younoszai, R Collantes, Z Goodman, V Chandhoke, Z Younossi. Non-Alcoholic Steatohepatitis in Morbidly Obese Patients. Annual Scientific Meeting. North American Association for the Study of Obesity's. Las Vegas, NV. November 2004.
  34. G-H Wang, A Mehrotra, JP Ong, ZM Younossi, Z Goodman. P62 as a Reliable Marker for Mallory Bodies in Non-Alcoholic Steatohepatitis (Non-alcoholic Steatohepatitis). United States and Canadian Academy of Pathology Annual Meeting, Washington DC, 2005.
  35. A Baranova, R Collantes, K Schlauch, H Elariny, S Gowder, A Afendy, J Ong, Z Goodman, Vi Chandhoke, Z Younossi. Adiponectin Gene Expression in the Intra-Abdominal Adipose Tissue Of Patients With Non-Alcoholic Fatty Liver Disease: Diabetics Vs. Non-Diabetics. Digestive Disease Week 2005.
  36. S Gowder, K Schlauch, A Van Meter, R Collantes, V Chandhokw, ZM. Younossi, A Baranova. Melanin Biosynthesis Pathway Is Functional In Fat Tissue Collected From Morbidly Obese Patients. 19th International Pigment Cell Conference – “A Focus on Human Pigmentary Diseases” 2005.
  37. A Baranova, S Gowder, R Collantes, H Elariny, K Schlauch, A Afendy, JP Ong, Z Goodman, V Chandhoke, ZM Younossi. Serum Adipokines And The Associated Gene Expression In The Adipose Tissue Of Obese Patients With And Without Insulin Resistance Cytokine Meeting Toronto, CA, Digestive Disease And Sciences, Vol 50, Nr 10:1962, 2005
  38. R Collantes, A Baranova, H Elariny, S Gowder, L Del Giacco, K Schlauch, A VanMeter, Arian Afendy, JP Ong , Z Goodman, V Chandhoke, ZM Younossi. Gene Expression In Hepatic And White Adipose Tissues Of Patients With Obesity-Related Non-Alcoholic Steatohepatitis. European Association for the Study of Liver Disease Vienna, Austria. 2006.
  39. M Emblom-Callahan, SD Nathan, GM Grant, J Estep, S Ahmad, M Sulkowski, A Afendy, NB Burton, V Chandhoke, Z Younossi. Gene Expression Analysis of Myofibroblasts in End Stage Lung Disease: Implications for DNA Repair. American Thoracic Society Meeting (Oral Presentation) 2006.
  40. VS Calvert, R Collantes, H Elariny, A Baranova, A Afendy, Z Goodman, L Liotta, E Petricoin, and ZM. Younossi. Signal Pathway Proteomic Analysis of Human Adipose Tissue using Phosphoprotein Arrays: Insights into the Pathophysiology of Nonalcoholic Fatty Liver Disease and type 2 Diabetes. Digestive Disease Week Los Angeles, CA. 2006 (Oral Presentation)
  41. A Baranova, N. Ad, S. Gowder, H. Elariny, S Younossi, M. Jarrar, R. Collantes, V. Chandhoke, Z. Younossi. Serum Adiponectin and Resistin in Non-alcoholic Fatty Liver Diseases and Arteriosclerosis. Digestive Disease Week. Los Angeles, CA. 2006.
  42. VS. Calvert, R Collantes, H Elariny, A Baranova, A Afendy, Z Goodman, L Liotta, ZM. Younossi, E Petricoin. Signal Pathway Proteomic Analysis of Human Adipose Tissue using Phosphoprotein Arrays: Insights into the Pathophysiology of Nonalcoholic Fatty Liver Disease and type 2 Diabetes. HUPO Meeting 2006 (Oral Presentation)
  43. ZM Younossi, M Singer. Lifetime Medical and Economic Impact of Patients with Non-Alcoholic Fatty Liver Disease in the United States (US). Association for Study of Liver Disease. Boston, MA. 2006.
  44. V Calvert, R Collantes, H Elariny, A Afendy, A Baranova, M Mendoza, Z Goodman, L Liotta, E Petricoin, ZM Younossi. Distinguishing Progressive Fatty Liver Disease from the Non-Progressive Form Using Reverse Phase Phosphoproteomic Array Analysis of Intracellular Signaling Pathways. AASLD Meeting. Boston, MA.2006. (Oral Presentation).
  45. JP Ong, A Pitts, ZM Younossi. The Impact of Nonalcoholic Fatty Liver Disease on Mortality. A Population-based Cohort Study. Association for Study of Liver Disease, Boston, MA.2006.
  46. S Bondini, T Gramlich, L Ramsey, JP Ong, D Jondle, N Boparai, H Gujral, ZM Younossi. The Impact of Non-alcoholic Fatty Liver Disease on Chronic Hepatitis B. The Impact of

47. Z Younossi. Non-alcoholic Fatty Liver Disease on Chronic Hepatitis B. Association for Study of Liver Disease, Boston, MA. 2006.
48. V Calvert, R Collantes, H Elariny, A Afendy, A Baranova, M Mendoza, Z Goodman, L Liotta, E Petricoin, ZM Younossi. Insight into the Spectrum of Non-alcoholic Fatty Liver Disease Using Phosphoproteomic Array Analysis of Intracellular Signaling from Human Adipose Tissue. HUPO International Meeting 2006 (Oral Presentation).
49. M Jarrar, B Ranard, M Stepanova, C Nugent, H Elariny, C Bennett, R Collantes, Z Goodman, V Chandhoke, A Baranova, ZM Younossi. Hepatic Manifestation of Metabolic Syndrome: Non-alcoholic Fatty Liver Disease and Serum Adipokines. EASL, Barcelona. 2007.
50. A Baranova, M Jarrar, M Mendoza, H Elariny, R Collantes, B Ranard, K Schlauch, M Stepanova, Z Goodman, V Chandhoke, ZM Younossi, A Role Of The Pro-Inflammatory Background In The Development Of Non-Alcoholic Fatty Liver Disease. Keystone Conference. 2007.
51. V Calvert, R Collantes, H Elariny, A Afendy, A Baranova, C Nugent, Y Fang, J Deng, Z Goodman, L Liotta, E Petricoin, Z Younossi. Can Phosphoproteomic Analysis of White Adipose Tissue (WAT) Predict Presence of Insulin Resistance (IR) and Resolution of Diabetes Mellitus (DM) in Non-alcoholic Fatty Liver Disease? Digestive Disease Week, Washington DC, 2007
52. P Mishra, C Nugent, A Afendy, A Wheeler, CH Bai, P Bhatia, Y Fang, ZM Younossi Apneic-Hypopneic Episodes During Obstructive Sleep Apnea Can be Associated with Histologic Nonalcoholic Steatohepatitis (Non-alcoholic Steatohepatitis) Digestive Disease Week. Washington, D.C. 2007.
53. M Jarrar, H Elariny, R Collantes, C Nugent, Y Fang, M Stepanova, N Kopparti, Z Goodman, V Chandhoke, A Baranova, ZM Younossi Is Visfatin A Protective Adipoikine in Patients with Non-alcoholic Fatty Liver Disease Digestive Disease Week. Washington, D.C. 2007.
54. VS Calvert, C Nugent, R Collantes, H Elariny, A Afendy, A Baranova, Y Fang, J Deng, Z Goodman, L Liotta, E Petricoin, Z Younossi. Phosphoproteomic Biomarkers Predicting Weight Loss after Bariatric Surgery in Patients with Non-alcoholic Fatty Liver Disease. American Association for Study of Liver Disease, Boston, MA, 2007.
55. A Baranova, M Jarrar, C Nugent, A Afendy, C Quigley, M Stepanova, H Elariny, Z Goodman, V Chandhoke, Z Younossi. Non-invasive Diagnostic Biomarkers for Non-alcoholic Steatohepatitis (Non-alcoholic Steatohepatitis). American Association for Study of Liver Disease, Boston, MA, 2007.
56. CH. Kim, J.B. Kallman, R. Srivastava, R. Gupta, A. Murthy, M.E. Sabatella, L. Pawloski, Z.M. Younossi. Nutritional Assessment Of Patients With Non-Alcoholic Fatty Liver Disease And Chronic Viral Hepatitis. Association for Study of Liver Disease, Boston, MA, 2007.
57. CH Bai, C Nugent, M Garone, P Gopalakrishnan, C Quigley, Z Younoszai, M Afendy, R Collantes, M Srishord, H Elariny, ZM Younossi. Improvement of Metabolic Syndrome (MS) in Patients with Non-alcoholic Fatty Liver Disease After Bariatric Surgery. American College of Gastroenterology, Philadelphia, PA, 2007
58. Z Younossi, A Baranova, A Afendy, M Stepanova, N Hossain, I Younossi, K Ankrah, M Srishord, C Santini, J Chan, SY Chang. Gene Expression Associated with Hepatic Steatosis in Patients with Chronic Hepatitis C Genotype 1 (Poster with Distinction). Digestive Disease Week. San Diego, CA, 2008.
59. J Kallman, A Arsalla, A Wheeler, R Aquino, K Terra, R Euliano, ZM Younossi. The Impact of Hepatitis B (HBV), Hepatitis C and Non-Alcoholic Fatty Liver Disease Guidelines on Clinical Practices. Digestive Disease Week (Poster with Distinction). San Diego, CA, 2008.
60. N Rafiq, C Bai, Y Fang, M Srishord, A McCullough, ZM Younossi. Over Twenty Five Years of Follow up for A Non-alcoholic Fatty Liver Disease Cohort. (Oral Presentation). Digestive Disease Week. San Diego, CA, 2008.
61. W Dunn, R Xu, D Wingard, C Rogers, P Angulo, ZM. Younossi MD, JB. Schwimmer. Suspected Nonalcoholic Fatty Liver Disease and Mortality Risk in a Population-based Cohort Study. Digestive Disease Week. San Diego, CA, 2008.

62. Z Younossi, M Jarrar, C Nugent, M Randhawa , M Afendy, M Stepanova, A Afendy, N Rafiq, Z Goodman, V Chandhoke, A Baranova. Validation of A Diagnostic Biomarker Panel for Non-alcoholic Steatohepatitis (Non-alcoholic Steatohepatitis). (Oral Presentation). European Association for the Study of Liver, Milan, Italy 2008.
63. J Ong, A Pitts, Z Younossi. Non-Alcoholic Fatty Liver Disease Is Associated With Higher Overall Mortality And Liver Related Mortality. (Oral Presentation, Plenary Session). European Association for the Study of Liver, Milan, Italy 2008.
64. C Bai, C Nugent, H Elariny, P Gopalakrishnan, C Quigley, M Garone Jr., M Afendy, O Chan, A Wheeler, A Afendy , A Arsalla, ZM. Younossi. The Impact Of Laparoscopic Bariatric Surgery On Components Of Metabolic Syndrome. Annual Meeting of American Society for Metabolic & Bariatric Surgery. Washington DC. 2008
65. N Rafiq, R Gupta, R Aquino, JB. Kallman, M Garone, Y Fang, A Murthy, SAhmad, S Dhungel, S Kumar, C Quigley, N Hossain, A Alsheddi, CH Kim, ZM Younossi. Components of Metabolic Syndrome and Type 2 Diabetes are Associated with Advanced Liver Disease. (Poster Presentation). American College of Gastroenterology, Orlando, FL 2008.
66. M Stepanova, A Baranova, H Elariny, N Rafiq, A Afendy, V Chandhoke, ZM Younossi. American Association for Study Of Liver Disease. San Francisco, CA 2008
67. JM Estep, K Ankrah, H Elariny, Y Fang, V Chandhoke, A Baranova, ZM Younossi. Inflammatory Cytokine Gene Expression in the Visceral Adipose Tissue of NASH Patients with Type II Diabetes and/or Fibrosis. Mid-Atlantic Diabetes Symposium, National Institutes of Health, Bethesda, MD 2008
68. M Stepanova, A Baranova, H Elariny, N Rafiq, A Afendy, V Chandhoke, ZM Younossi, Differences In Hepatic Gene Expression Of Caucasians And African American Patients With Non-Alcoholic Fatty Liver Disease (NAFLD) American Association For Study Of Liver Disease. San Francisco, CA 2008
69. JM Estep, K Ankrah, H Elariny, I Kaur, Y Fang, V Chandhoke, A Baranova, ZM Younossi. Cytokine Signaling Gene Expression In The Adipose Tissue Is Associated With Fibrotic Changes In Patients With Non-Alcoholic Fatty Liver Disease (NAFLD) American Association For Study Of Liver Disease. San Francisco, CA 2008
70. N Rafiq, M Stepanova, B Lam, ZM. Younossi. Type 2 Diabetes, Obesity and Hypertension Are Associated With Mortality In Hepatitis C Patients. European Association for the Study of Liver, Copenhagen, Denmark 2009 (Oral Presentation)
71. ZM Younossi, A Baranova, M Stepanova, VS Calvert, A Afendy, Z Goodman, L Liotta, E Petricoin. Proteomics Biomarkers Predicting Histologic Non-Alcoholic Steatoheaptitis And Fibrosis. European Association for the Study of Liver, Copenhagen, Denmark 2009
72. A Baranova, N Rafiq, I Kaur, N Hossain, M Randhawa, V Chandhoke, ZM Younossi. Differences of Adipocytokine between Non-Alcoholic Fatty Liver Disease And Coronary Artery Disease. European Association for the Study of Liver, Copenhagen, Denmark 2009
73. M Stepanova, N Rafiq, H Mir, I Bornman, ZM Younossi. Mortality and Liver Related Mortality in Patients with Chronic Liver Disease: Association with Components of Metabolic Syndrome (MS) Digestive Disease Week, Chicago, Illinois, 2009 (Oral Presentation).
74. N Hossain, A Afendy, M Stepanova, N Rafiq, F Nader, M Srishord, Z Goodman, Z Younossi. Independent Predictors of Fibrosis in a Large Cohort of Patients with Non-Alcoholic Fatty Liver Disease. Digestive Disease Week, Chicago, Illinois, 2009.
75. M Estep, A Birerdinc, A Wheeler, S Page, M Stepanova, A Baranova, H Alathari, ZM Younossi. Carbohydrate-Deficient Transferrin in Patients with Fatty Liver Disease. Submitted to Obesity Meeting 2009.
76. M Garone, J Kallman, R Aquino, Y Fang, P Lee, H Elariny, ZM Younossi. Activity Level in Patients Undergoing Bariatric Surgery. Digestive Disease Week, Chicago, Illinois, 2009.

77. M Stepanova, A Wheeler, J Kallman, H Alathari, H Elariny, Y Fang, N Hossain, N Rafiq, Z Younossi . Psychiatric Disorders in Patients Undergoing Bariatric Surgery. The Obesity Society's Annual Scientific Meeting, Washington DC, Oct 2009
78. D Armistead, MJ Estep, M Stepanova, G Manyam, N Rafiq, H Elariny, A Baranova, ZD Goodman, ZM Younossi. Differential Expression of miRNA in Patients with Non-alcoholic Steatohepatitis. American Association For Study Of Liver Disease 2009, Boston MA
79. M Estep, A Birerdinc, A Wheeler, S Page, A Baranova, H Alathari, Z Younossi. Carbohydrate-Deficient Transferrin in Patients with Fatty Liver Disease Undergoing Bariatric Surgery. The Obesity Society's Annual Scientific Meeting, Washington DC, Oct 2009
80. ZM Younossi, N Rafiq, S Page, M Stepanova, N Hossain, A Birerdinc, ZD Goodman, A Baranova. A Novel Serum-based Biomarker Panel for Non-alcoholic Steatohepatitis (NASH) and NASH-related Fibrosis. American Association For Study Of Liver Disease 2009, Boston MA
81. N Hossain, M Stepanova, A Afendy, F Nader, N Rafiq, ZD Goodman, ZM Younossi. Non-alcoholic Steatohepatitis (NASH) in Patients with Polycystic Ovarian Syndrome (PCOS). American Association for Study of Liver Disease 2009, Boston MA.
82. S Page, N Rafiq, M Stepanova, A Afendy, A Birerdinc, ZD Goodman, A Baranova, ZM Younossi. Comparison of Different Biomarkers for Patients with Non-alcoholic Steatohepatitis. American Association for Study of Liver Disease 2009, Boston MA.
83. J M Estep, D Armistead, M Stepanova, N Hossain, H Elariny, A Baranova, Z Goodman, V Chandhoke, Z Younossi. Serum Cytokines and the Expression of miRNAs in the Visceral Adipose of Patients with Non-alcoholic Fatty Liver Disease. European Association for the Study of Liver Disease Meeting 2010. Oral Presentation
84. M Stepanova, D Limongi, A Afendy, M Pierobon, I Younossi, T Gramlich, L Liotta, E Petricoin, Z Younossi. Protein Pathway Biomarkers Signature Associated with Superimposed Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis in Patients with Chronic Hepatitis C. European Association for the Study of Liver Disease, 45<sup>th</sup> Annual Meeting 2010, Vienna, Austria.
85. R Mehta, A Birerdinc, N Hossain, A Moazzez, V Chandhoke, A Baranova, ZM Younossi. Profiling and Validation of Reference Genes in the Visceral Adipose Tissue (VAT). Digestive Disease Week, Annual Meeting 2010, New Orleans, Louisiana
86. A Birerdinc, R Mehta, N Hossain, B Yaqub, H Elariny, A Baranova, V Chandhoke, Z Younossi. Differential Gene Expression Profiling of Brown Adipose Tissue (BAT) Specific Genes in Visceral Adipose Tissue of Lean and Obese Individuals. Digestive Disease Week, Annual Meeting 2010, New Orleans, Louisiana
87. D Desai, M Estep, A Birerdinc, H Mir, A Baranova, V Chandhoke, Z Younossi. Markers of Insulin Resistance during HCV Treatment: A Relationship to Sustained Virologic Response (SVR). Digestive Disease Week, Annual Meeting 2010, New Orleans, Louisiana
88. M Estep, M Abawi, S Bolden, M Stepanova, N Hossain, Z Goodman, V Chandhoke, A Baranova, Z Younossi. Serum Obestatin Concentrations in Non-alcoholic Fatty Liver Disease (NAFLD) with Fibrosis. Digestive Disease Week, Annual Meeting 2010, New Orleans, Louisiana (Submitted).
89. M Stepanova, G Mayam, N Hossain, V Chandhoke, A Baranova, Z Goodman, Z Younossi. Functional Pathway Analysis of Gene Expression in Patients with Non-alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH). (Top 15% Poster Presentation) European Association for the Study of Liver Disease, 45<sup>th</sup> Annual Meeting 2010, Vienna, Austria.
90. S Page, N Rafiq, A Birerdinc, M Stepanova, N Hossain, A Afendy , Z Younoszai, Z Goodman, A Baranova, ZM Younossi. A Biomarker Panel for Non-alcoholic Steatohepatitis (NASH) and NASH-Related Fibrosis (Oral Presentation). Virginia Academy of Science 2010, Harrisonburg, Virginia.
91. M Abawi, A Zirzow, M Estep, N Hossain, H Elarainy, Z Goodman, V Chandhoke, Z. Younossi, A Baranova Alpha-Melanin Stimulating Hormone (αMSH) and Melanin Concentrating Hormone (MCH) Expression in Obesity and Obesity Related Disease (Oral Presentation). Virginia Academy of Science 2010, Harrisonburg, Virginia.

92. R Mehta, A Birerdinc, N Hossain, A Afendy, V Chandhoke, Z Younossi, A Baranova, Endogenous reference gene validation for qRT - PCR studies on human visceral adipose tissue (Oral Presentation). Virginia Academy of Science 2010, Harrisonburg, Virginia.
93. N Niranjana, A Baranova, Z Younossi, A Birerdinc. Role of Insulin Resistance in PCOS and Implications for Development of Metabolic syndrome and Hepatic Steatosis (Oral Presentation). Virginia Academy of Science 2010, Harrisonburg, Virginia.
94. A Zirzow, M Estep, N Hossain, H Elariny, Z Goodman, V Chandhoke, A. Baranova, Z Younossi. Expression of Cytokines and Cytokine Receptors in Morbidly Obese Patients with Non-alcoholic fatty liver disease (Oral Presentation). Virginia Academy of Science 2010, Harrisonburg, Virginia.
95. E Eom, A Birerdinc, A Baranova, ZM Younossi. Preservation of Serum and mRNA Samples For Downstream High Throughput Studies. Virginia Academy of Science 2010, Harrisonburg, Virginia.
96. M Stepanova, M Srishord, F Nader, ZM Younossi. Insulin Resistance (IR) and Type II Diabetes (DM) Are Independent Predictors of Overall and Liver-Related Mortality in Non-alcoholic Fatty Liver Disease (NAFLD) and Alcohol-related Liver Disease (ALD): A Population-Based Study. American Association for Study of Liver Disease 2010, Boston MA
97. N Rafiq, HR Makhlof, R Agrawal, I Kaur, Z Younoszai, M Stepanova, Z Goodman, ZM Younossi. Long Term Mortality Outcomes in Patients with Biopsy-Proven Non-alcoholic Fatty Liver Disease. American Association for Study of Liver Disease 2010, Boston, MA
98. N Hossain, M Stepanova, Y Younossi, Y Fang, B Raybuck, ZM Younossi. High Prevalence of Coronary Artery Disease (CAD) in Patients with Non-alcoholic Fatty Liver Disease (NAFLD). American College of Gastroenterology, Annual Meeting 2010, San Antonio, Texas
99. R Alhussain, R Mehta, A Birerdinc, N Hossain, Y Baraki, H Elariny, V Chandhoke, A Baranova, Ancha, ZM Younossi. Profiling and Validation of Reference Genes in the Gastric Tissue of Morbidly Obese Patients. American College of Gastroenterology, Annual Meeting 2010, San Antonio, Texas
100. M Estep, A Zirzow, M Stepanova, N Hossain, Y Barakai, H Elariny, A Moazzez, Z Goodman, V Chandhoke, A Baranova, Z Younossi. Baseline Serum Obestatin Correlates with Rate of Weight Loss after Bariatric Surgery. American College of Gastroenterology, Annual Meeting 2010, San Antonio, Texas
101. M Stepanova, N Rafiq, H Makhlof, Z. Younoszai, I Kaur, R Agrawal, Z Goodman, Z Younossi. P-NASH Scores Predicting Liver-Related Mortality in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) EASL Monothematic Conference on Evaluation of Disease Severity and Prognosis in Chronic Liver Disease 2011) Nice, France
102. R Mehta, A Birerdinc, L Wang, A Afendy, M Stepanova, H Elariny, Z Goodman, V Chandhoke, A Baranova, Zobair M. Younossi. Gastric Gene Expression of Inflammatory Cytokines in Non-alcoholic Fatty Liver Disease. Digestive Disease Week 2011, Chicago, IL (Submitted)
103. A Baranova, M Jarrar, M Abawi, L Wang, A Afendy M Stepanova, M Estep, A Moazzez, Z Goodman, V Chandhoke, ZMYounossi. Soluble Molecules Released from Visceral Adipose Tissue May Contribute To the Development of Advanced Non-Alcoholic Fatty Liver. Digestive Disease Week 2011, Chicago, IL (Submitted)
104. L Gerber, S Page, JK Price, A Baranova, P Winter, ZM Younossi. Association of Soluble Serum Molecules and Fatigue in Patients with Chronic Liver Disease. Digestive Disease Week 2011, Chicago, IL (Submitted)
105. Z Younossi, M Stepanova, B Lam, M Srishord. Components of Metabolic Syndrome and the Rising Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH) in the United States. Digestive Disease Week 2011, Chicago, IL (Submitted)
106. N Rafiq, M Stepanova, H Makhlof, R Agrawal, Z Younoszai, S Hallaji, Z Goodman. Z Younossi. Agreement Between Different Pathologic Criteria For Non-Alcoholic Steatohepatitis. The International Liver Congress 2011 - 46th annual meeting of the European Association for the Study of the Liver (EASL) 2011, Berlin, Germany

107. Z Younossi, M Stepanova, M Afendy, Y Fang, Y Younossi, H Mir, M Srishord. The Changing Face of Chronic Liver Disease In The United States: The Rising Epidemic Of Non-Alcoholic Fatty Liver Disease. The International Liver Congress 2011 - 46th annual meeting of the European Association for the Study of the Liver (EASL) 2011, Berlin, Germany, Oral Presentation
108. M Stepanova, N Rafiq, H Makhlof, Z Younoszai, I Kaur, R Agrawal, Z Goodman, Z Younossi. Features of Non-Alcoholic Steatohepatitis As Independent Predictors Of Liver-Related Mortality. The International Liver Congress 2011 - 46th annual meeting of the European Association for the Study of the Liver (EASL) 2011, Berlin, Germany, Oral Presentation
109. M Estep, G Vernon, L Wang, M Stepanova, A Younoszai, H Elariny, Z Goodman, V Chandhoke, A Baranova, Z Younossi. Serum Des-Acylghrelin Concentration Is Associated With Histologic Non-Alcoholic Steatohepatitis and Fibrosis In Patients With Nonalcoholic Fatty Liver Disease. The International Liver Congress 2011 - 46th annual meeting of the European Association for the Study of the Liver (EASL) 2011, Berlin, Germany
110. A Birerdinc, R Mehta, L Wang, A Afendy, M Stepanova, H Elariny, A Moazzez, Z Goodman, V Chandhoke, A Baranova, Z Younossi. Expression of Energy Metabolism Related Genes in the Gastric Tissue of Obese Patients. Digestive Disease Week 2011, Chicago, IL (Submitted)
111. M Estep, H Sharma, G Vernon, D Armistead, N Hossain, H Elariny, Z Goodman, V Chandhoke, A Baranova, Z Younossi. Expression level of IL20, MTOR, IL13RA1, and SEMA4C are increased in the visceral adipose tissue of patients with non-alcoholic steatohepatitis while there is a decrease in the expression levels of their regulatory miRNAs. Digestive Disease Week 2011, Chicago, IL (Submitted)
112. M Stepanova, M Afendy, G Vernon, F Nader, Z Younossi. Components of Metabolic Syndrome and the Rising Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH) in the United States. Digestive Disease Week 2011, Chicago, IL (Submitted)
113. H Sharma, M Estep, D Armistead, G Vernon, N Hossain, A Moazzez, Z Goodman, V Chandhoke, A Baranova, ZM Younossi. Expression level for miRNA processing enzymes DICER1, RNASEN, and DGCR8 are increased in the visceral adipose tissue of non-alcoholic steatohepatitis (NASH) patients. Digestive Disease Week 2011, Chicago, IL (Submitted)
114. R Mehta, A Birerdinc, L Wang, A Afendy, M Stepanova, H Elariny, Z Goodman, V Chandhoke, A Baranova, ZM Younossi. Gastric Gene Expression of Inflammatory Cytokines in Non-alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH). Digestive Disease Week 2011, Chicago, IL (Submitted)

**Presentations Related to Quality of Life Research:**

115. Z Younossi, M Kiwi, D King, G Guyatt. A Liver Disease-Specific Health Related Quality of Life Index: Chronic Liver Disease Questionnaire (CLDQ). American Association for Study of Liver Disease. Chicago 1997.
116. Z Younossi, M Kiwi, M Secic, G Guyatt. Health Related Quality of Life in Chronic Liver Disease. Digestive Disease Week. New Orleans 1998.
117. Z Younossi, M O'Neil, M Kiwi, M Secic, L Calabrese. Hepatitis C: Rheumatologic, Health Related Quality of Life, Virologic and Histologic Outcomes. Digestive Disease Week. New Orleans 1998.
118. Z Younossi, ML Kiwi, N Boparai. Reduction of Health-Related Quality of Life in Patients Infected with Hepatitis C. Oral presentation. International Society for Quality of Life Research. Baltimore, MD 1998.
119. Z Younossi, N Boparai, ML Kiwi, L Farquhar, M McCormick, G Guyatt. Can Quality of Life Predict Resource Utilization in Liver Transplant Candidates. American Association for Study of Liver Disease. Chicago 1998.
120. Z Younossi, N Boparai, ML Kiwi, M McCormick, G Guyatt. Extensive Evaluation of Quality of Life in a Large Cohort of Patients with a Variety of Chronic Liver Disease. American Association for Study of Liver Disease. Chicago 1998.

121. Z Younossi, ML Kiwi, M McCormick, N Boparai, G Guyatt. Performance of a New Disease-Specific Quality of Life Instrument in Cholestatic Liver Disease. American Association for Study of Liver Disease. Chicago 1998.
122. D Miller, Z Younossi, M Kiwi, N Boparai. Short Form 36 Performance with Worsening Severity of Disease: Chronic Liver Disease and Multiple Sclerosis. International Society for Quality of Life Research. Baltimore, MD 1998.
123. Z Younossi, M McCormick, N Boparai, L Price, G Guyatt. Health-Related Quality of Life Measured by Generic, Disease-Specific and Utility Instruments. American Association for Study of Liver Disease, 1999.
124. Z Younossi, M McCormick, N Boparai, L Price, G Guyatt. Impact of Chronic Liver Disease on Patients' Utilities. Digestive Disease Week, Orlando, FL. Gastroenterology, Vol. 116 (No.4): 1293, 1999.
125. Z Younossi, G Marchesini for the Italian Study Group for HRQL in Cirrhosis, N Boparai, L Price, M McCormick. Health-Related Quality of Life in Over 1000 Patients with Chronic Liver Disease: The Impact of Age, Gender, Culture, Severity and Type of Liver Disease. American Association for Study of Liver Disease. Dallas, TX. 1999.
126. Z Younossi, N Boparai, M McCormick. A Disease-Specific Health-Related Quality of Life Instrument for Chronic Hepatitis C: CLDQ-HCV. American Association for Study of Liver Disease. Dallas, TX. 2000.
127. L Martin, Z Younossi, L Price, A McCullough, J Ong, M Srishord, N Boparai. The Impact of Ribavirin-Induced Anemia on Health-Related Quality of Life. Martin L, et al. Hepatology.34: pt 2. Abstract 1711. 2001.
128. Z Younossi, L Martin, N Afdhal, A McCullough, M Sheridan. The Impact of Obesity, Gender and Age on Health-Related Quality of Life Using the HCV Specific HRQL Instrument. Hepatology, Vol. 34 (No.4) Pt 2. 2001.
129. Z Younossi, L Martin, M McCormick. Impact of Ascites on Health-Related Quality of Life European Association for the Study of Liver Diseases, Monothematic Conference. London, UK. June 2002.
130. L Martin, D Bringman, R Joseph, R Ghanta, JP Ong, C Crone, G Herman, A McCullough, Z Younossi. Depression, Interferon Alpha (IFN) and Health Related Quality of Life (HRQL) in Chronic Hepatitis C (CH-C). American Association for Study of Liver Disease. Boston, MA. October 2003.
131. N Afdhal, G Leitz, L Tang, Z Younossi. Hemoglobin Increase is Independently Associated with Increased Health-Related Quality of Life (HRQL) in Anemic Interferon/Ribavirin (IFN/RBV)-Treated Hepatitis C Virus (HCV)-Infected Patients Treated with Epoetin Alfa. American Association for Study of Liver Disease. Boston, MA. October 2003.
132. N Afdhal, G Leitz, S Mody, Z Younossi. Epoetin Alfa Improves and Maintains Health-Related Quality of Life in Anemic HCV-Infected Patients Receiving Interferon/Ribavirin (IFN/RBV): HRQL Results from the Proactive Study. American Association for Study of Liver Disease. Boston, MA. October 2003.
133. B Spiegel, ZM. Younossi, RD Hayes, D Revicki, S Robbins, F Kanwal. The Impact of Hepatitis C on Health Related Quality of Life: A Systematic Review and Quantitative Assessment. Digestive Disease Week 2005.
134. J Kallman, A Dan, A Wheeler, Z Younoszai, S Bondini, L Gerber, ZM Younossi. Health-related Quality of Life (HRQL) in Patients with Non-alcoholic Fatty Liver Disease. Association for Study of Liver Disease, Boston, MA. 2006.
135. B Spiegel, R Bolus, M Tong, E Esralian, J Talley, T Tran, J Smith, H Karsan, F Durazo, B Bacon, P Marin, Z Younossi, S Hwa, J Ong, F Kanwal. Development and Validation of a Disease-Targeted Health Related Quality of Life in Chronic Hepatitis B Infection: The HBQOL V1.0, Association for Study of Liver Disease, Boston, MA. 2006.

136. A Dan, J Kallman, R Srivastava, Z Younoszai, A Kim, ZM Younossi. Health Utility Assessment Using SF-6D and Health Utility Index (HUI) in Patients with Chronic Liver Disease. Digestive Disease Week, Washington DC, 2007
137. J Kallman, A Afendy, M Stepanova, Z Younoszai, R Aquino, G Bianchi, G Marchesini, ZM Younossi. Health-related Quality of Life (HRQL) in Patients with Chronic Liver Diseases. Digestive Disease Week, Chicago, Illinois, 2009.
138. A Weinstein, L Gerber, J Moon, J. Kallman, Y Fang, P Winter, D Moore, Z Younossi. Relationship between chronic sleep restriction and health-related quality of life. Psychosomatic Medicine, 72(3), A-123. American Psychosomatic Society 68th Annual Scientific Meeting, March 10 - 14, 2010, Portland, Oregon
139. J Moon, J Kallman, Z Younoszai, Zahra, P Winter, Y Fang, L Gerber, ZM Younossi. Validation of Chronic Liver Disease-HCV Version (CLDQ-HCV) with Fatigue Severity Scale. Digestive Disease Week, Annual Meeting 2010, New Orleans, Louisiana.
140. JB Kallman, PM Winter, J Moon, M Earley, L Gerber, ZM Younossi. Determination of Relationships between Objective and Self-Reports of Fatigue and Physical Performance in Subjects with Chronic Liver Disease. American Association for Study of Liver Disease 2010, Boston MA
141. A Weinstein, JB Kallman, M Stepanova, BP Lam, LW Poms, F Yun, C Bach, H Alathari, ZM Younossi. Prevalence and Independent Predictors of Psychiatric Conditions in Patients with Chronic Liver Disease (CLD). American Association for Study of Liver Disease 2010, Boston MA
142. Z Younossi, A Sanyal, R Brown, R Vemuru, M Jamal, S Huang, K Merchant, E Bortey, W Forbes, The Effect of Rifaximin on the Health Related Quality of Life (HRQL) in Patients with Cirrhosis and Recurrent Hepatic Encephalopathy. Digestive Disease Week 2011, Chicago, IL (Submitted)
143. J Kallman, J Moon, P Winter, F Nader, Y Fang, L Gerber, Z Younossi. Hemoglobin Level is Associated with the Physical Functioning, Activity, Energy, and Vitality Aspects of Health-related Quality of Life in Patients with Chronic Hepatitis C. Digestive Disease Week 2011, Chicago, IL (Submitted)
144. L Gerber, S Page, J Kallman Price, A Baranova, P Winter, Z Younossi. Association of Serum Biomarkers with Fatigue in Patients with Chronic Liver Disease. Digestive Disease Week 2011, Chicago, IL (Submitted)
145. M Soni, M Awad, ME Earley, J Kallman Price, Z Younossi. Longitudinal Study of Dietary Habits and Activity Level in Patients with Chronic Liver Disease (CLD). Digestive Disease Week 2011, Chicago, IL (Submitted).

**Presentations Related to Outcomes and Health Services Research:**

146. Z Younossi, J McHutchison. Is Norfloxacin for Spontaneous Bacterial Peritonitis Cost-Effective: An Economic Analysis. 46th Annual American Association for Study of Liver Disease Meeting. Chicago, IL. 1995. Hepatology, Vol. 22, Nov. 4, 166A, 1995.
147. C Teran, Z Younossi, W Carey. Cost-Effectiveness of Ultrasound-Guided Liver Biopsy for Diffuse Parenchymal Liver Disease. Digestive Disease Week Meeting. San Francisco, CA. Gastroenterology, Vol. 100 (No.4), A43, 1996.
148. A Aggarwal, J Ong, Z Younossi, A Arroliga, D Nelson, J Schafle, L Hoffman Hogg. Predictors of Survival and Resource Utilization in Patients with Liver Disease Admitted to Intensive Care Unit. American Association for Study of Liver Disease. Dallas, TX. 1999.
149. A Aggarwal, J Ong, D Nelson, J Schafle, L Hoffman Hogg, Z Younossi, A Arroliga. Prognostic Indicators in Patients with Chronic Liver Disease Admitted to the Medical Intensive Care Unit. American College of Chest Physicians. 1999.
150. S Bhatia, Z Younossi, N Boparai, J Henderson, B Parker. Factors Associated with Mortality in Acute Hepatic Failure. International Liver Transplantation Society. Berlin, Germany. June 2001.
151. Hepatology, Vol.34 (No.4) Pt 2. 2001.

152. J Ong, L Martin, M Sheridan, R Collantes, P Nadkarni, Z Younossi. Health Insurance Status of Hepatitis C Virus-Positive Adult Persons in the United States. The American Public Health Association Meeting. 2003.
153. JB Kallman, NLH. Gerber, Y Fang, CH Kim, R Gupta, ZM Younossi. Demographic, Diagnostic and Disease Characteristics in Patients with Chronic Liver Disease that Correlate with Level of Physical Activity. American Academy of Physical Medicine & Rehabilitation 2008.
154. NL Gerber, J Kallman, CH Kim, R Gupta, ZM Younossi. Demographic, Diagnostic and Disease Characteristics in Patients with Chronic Liver Disease that Correlate with Level of Physical Activity. The American Academy of Physical Medicine and Rehabilitation. San Diego, CA, November. 2008
155. NL Gerber, J Kallman, I Kaur, Y Fang, ZM Younossi. Demographic, diagnostic and disease characteristics of patients with chronic liver disease correlates with physical activity. ISPRM Istanbul, Turkey, 2009
156. N Rafiq, M Stepanova, H M. Mir, IM Bornman, B Lam, M Srishord, ZM. Younossi. Diabetes Related Mortality in Patients with Chronic Liver Disease. American Association for Study of Liver Disease 2009, Boston MA (Oral Presentation).
157. J Kallman, SV Tran, A Arsalla, D Haddad, M Stepanova, F Yun, V Wrobel, M Srishord, ZM Younossi. Screening for Hepatitis B (HBV) and Hepatitis C (HCV) in a Vietnamese Community of Northern Virginia. American Association for Study Of Liver Disease 2009, Boston MA.
158. C Gennings, R Agrawal, Y Fang, C Bach, B Lam, ZM Younossi. Stratification and Prediction of Outcomes of Bariatric Surgery Patients using the Relative Wellness Index (RWI). Digestive Disease Week, Annual Meeting 2010, New Orleans, Louisiana
159. M Stepanova, HM Mir, N Hossain, ZM Younossi. Diabetes Mellitus and Viral Hepatitis are Independent Predictors of Overall, Liver-Related and Hepatocellular Carcinoma-Related Mortalities in Hispanic Americans. AASLD 2010 Annual Meeting, Boston, MA
160. Z Younossi, M Stepanova, Y Younossi, M Srishord. Effectiveness of Recommendations for Hepatitis A (HAV) and Hepatitis B (HBV) Vaccinations for Patients with Chronic Liver Disease. Digestive Disease Week 2011, Chicago, IL (Submitted)
161. Z Younossi, M Stepanova, B Lam, I Younossi, H Mir. Low Vaccination Rates Against Hepatitis A (HAV) and Hepatitis B (HBV) in Patients with Chronic Liver Disease (CLD) and with Type 2 Diabetes (DM): A Study of the United States Population. Digestive Disease Week 2011, Chicago, IL (Submitted)

**Presentations Related to Hepatitis C:**

162. Z Younossi, D Bylund, L Wilkes, J McHutchison. Anti-LKM Antibody as a Predictor of Response to Alpha Interferon in Chronic Hepatitis C. #1280, Hepatology, 1994.
163. Z Younossi, I McHutchison. Interferon Treatment of Chronic Hepatitis C Infection: An Economic Analysis of Different Strategies. Digestive Disease Week Meeting. San Francisco, CA. 1996. Gastroenterology, Vol. 110 (No.4), A47, 1996.
164. G Cammell, K Easley, Z Younossi, W Carey. Predicting Cirrhosis without Liver Biopsy in Patients with Chronic Hepatitis C. Digestive Disease Week. Washington DC. Gastroenterology, Vol. 112(No.4), 1997.
165. G Cammell, Z Younossi, W Carey. The Utility of Liver Biopsy in Diagnosis of Hepatitis C. Digestive Disease Week. Washington, DC. Vol. 111(No.4), 1997.
166. Z Younossi, T Gramlich, M Goormastic, L Farquhar, M Westveer, P George, D Barnes, W Carey, J Mayes, D Vogt, JM Henderson. Hepatitis C (HCV) After Orthotopic Liver Transplantation. Recurrence vs. Rejection? Digestive Disease Week. Washington, DC. Vol. III,(No.4), 1997.
167. W Braun, Z Younossi. The Management of Hepatitis B and C in Twenty-Year Renal Transplant Recipients. Oral Presentation. American Society of Transplant Physicians. Chicago 1998.
168. Z Younossi, K Mullen, W Zakko, E Brandt, S Hodnick, M Kiwi, L Borzi, K Easley. Interferon 2b and Ribavirin vs. Interferon 2b and Amantadine for Chronic Hepatitis C (Nonresponder): A Multi-

- Center, Randomized, and Double-Blind Clinical Trial. American Association for Study of Liver Disease. Chicago 1998.
169. E Hadziyannis, Z Younossi, M Kiwi, S Hodnick C Starkey, B Yen-Lieberman. Comparison of Two PCR- Based Methods for Quantification of Hepatitis C RNA. American Association for Study of Liver Disease. Chicago 1998.
  170. M O'Neil, Z Younossi, K Lee, M Kiwi, B Larive, L Calabrese. Epidemiology of Rheumatic Symptomatology in Patients Infected with Hepatitis C Virus. American College of Rheum. San Diego, CA 1998.
  171. Z Younossi, M Singer, K Shermock, J McHutchison. The Role of Genotyping in Cost-Effectiveness of Interferon and Ribavirin for Chronic Hepatitis C. Digestive Disease Week, Orlando, FL. Gastroenterology, Vol. 166 (No.4): A1293, 1999.
  172. IT Mayes, DP Vogt, JM Henderson, Z Younossi, D Barnes, WD Carey. Early Experience with Deliberate Cyclosporine Conversion for Recurrent Hepatitis C After Liver Transplantation. American Hepato-Pancreato-Biliary Congress. 1999.
  173. J Ong, D Barnes, M Goormastic, B Yen-Lieberman, TL Gramlich, Z Younossi. Outcome of De Novo Hepatitis C in Heart Transplant Recipients of HCV-Antibody Positive Donors. Digestive Disease Week. Orlando, FL. Gastroenterology, Vol. 166 (No.4): A1259, 1999.
  174. T Gramlich, J Ong, DS Barnes, M Goormastic, B Yen-Lieberman, Z Younossi. Pathologic Features of Hepatitis C in Heart Transplant Recipients. Digestive Disease Week, Orlando, FL. Gastroenterology, Vol. 116 (No.4): 1217, 1999.
  175. Z Younossi, M Singer. Is Screening for Hepatitis C Cost-Effective? American Association for Study of Liver Disease. Dallas, TX. 1999.
  176. M Singer, Z Younossi. Screening for Hepatitis C: Is it Cost Effective? Oral Presentation. Society for Medical Decision Making. 1999.
  177. Z Younossi, K Mullen, W Zakko, E Brandt, S Hodnick D Barnes, W Carey, A McCullough, K Easley. Interferon 2b-Amantadine vs. Interferon Alpha-2b-Ribavirin Combination in Chronic Hepatitis C: Analysis of a Randomized Double-Blind Trial. American Association for Study of Liver Disease. Dallas, TX. 1999.
  178. Z Younossi, N Dawson, E Stoller, S Wolfe. Lay Perceptions of Hepatitis C and Variation by Ethnic Origin. Hepatology, 1999.
  179. D Vasillopoulos, Z Younossi, E Hadziyannis, N Boparai, T Gramlich, B Yen-Lieberman, E His, D Cook, E Ball, R Kimberly, L Calabrese. Patterns of Immune Activation in Hepatitis C Infection Associated With or Without Autoimmune Manifestations. American Association for Study of Liver Disease. Dallas, TX. 1999.
  180. J Ong, N Boparai, C Speer, T Gramlich, M Kiwi, Z Younossi. Anxiety and Depression in Chronic Hepatitis C. American Association for Study of Liver Disease. Dallas, TX. 1999.
  181. Z Younossi, K Mullen, S Hodnick M McCormick, D Bringman, D Barnes, WD Carey, AJ McCullough, K Easley. Triple Combination Therapy for Treatment of Chronic Hepatitis C. Digestive Disease Week. San Diego, CA. 2000.
  182. Z Younossi, A McCullough, N Buchler, K Mullen, W Carey, D Barnes, B Donofrio. Induction vs. Standard Interferon Monotherapy for Patients with HCV Viremia and Normal ALT. Digestive Disease Week. San Diego, CA. 2000.
  183. A DiBisceglie, S Schwartz, R Reddy, P Martin, G Gores, A Look, R Gash, D Van Thief, Z Younossi, M Tong, T Hassanein, L Balart, J Fleckenstein, A Blei. Hepatitis C and Hepatocellular Carcinoma in African Americans. Digestive Disease Week. San Diego, CA. 2000.
  184. D Vassilopoulos, Z Younossi, E Hadziyannis, N Boparai, T Gramlich, B Yen-Lieberman, E His, D Cook, E Ball, RP Kimberly. A Villa-Forte, LH Calabrese. Autoimmune Manifestations of Hepatitis C: Patterns of Immune Activation. American Journal of Rheumatology. 2000.
  185. S Sarbah, Z Younossi, T Gramlich, A DiBisceglie, J Mayes, A Younoszai, M Goornastic. Hepatocellular Carcinoma, Hepatitis C and Ethnicity. American Association for Study of Liver Disease. Dallas, TX. 2000.

186. Z Younossi, KD Mullen, S Hodnick, D Barnes, W Carey, AJ McCullough, K Easley. Triple Combination of Interferon cx2b, Ribavirin and Amantadine for Hepatitis C Treatment Failures. American Association for Study of Liver Disease. Dallas, TX. 2000.
187. J Ong, Z Younossi. The Impact of Leukocyte Filtration during Orthotopic Liver Transplantation on HCV RNA Levels. American Associate for the Study of Liver Diseases. Dallas, TX 2001. Hepatology, Vol.34 (No.4) Pt 2. 2001.
188. J McHutchison, B Yoffe, R Brown, E Schiff, M Shiffman, R Carithers, T Wright, M Fried, R Gish, Z Younossi, N Poulos. Preliminary Report of the Development of a Hepatitis C Web-Based Patient Registry at 11 U.S. Hepatology Units. American Associate for the Study of Liver Diseases 2001.
189. L Martin, K Irwin, Z Younossi. Development of a Hepatitis C-Specific Instrument for Monitoring Treatment Adherence. Digestive Disease Week 2002. San Francisco, CA. May 2002.
190. Z Younossi, A McCullough, D Barnes, A Post, J Ong, K Mullen, W Carey, R O'Shea, G Levinthal, T Gramlich, L Martin, D Bringman, A Tavill, D R Ferguson. Pegylated Interferon, Ribavirin and Amantadine for Treatment of Chronic Hepatitis C: A Multi-Center Clinical Trial. American Association for Study of Liver Disease. Boston, MA. 2002.
191. ZM Younossi, AJ McCullough, DS Barnes, A Post, JP Ong, KD Mullen, WD Carey, R O'Shea, G Levinthal, T Gramlich, L Martin, D Bringman, AS Tavill, DR Ferguson. Triple Combination of Pegylated Interferon Alpha 2b, Ribavirin and Amantadine for the Treatment of Chronic Hepatitis C. Digestive Disease Week. Orlando, FL. May 2003.
192. ZM Younossi, AJ McCullough, DS Barnes, A Post, JP Ong, KD Mullen, WD Carey, R O'Shea, G Levinthal, T Gramlich, L Martin, D Bringman, AS Tavill, DR Ferguson. Triple Combination of Pegylated Interferon Alpha 2b, Ribavirin and Amantadine for the Treatment of Chronic Hepatitis C. Schering Hepatitis Investigators' Network VII (SHINE). Huntington Beach, CA. February 2003.
193. Z Younossi, J Ong, R Collantes, J Assmann, R Sjogren, M Sjogren, D Farmer, L Martin. Darbepoetin Alfa (Da) for Ribavirin-Induced Anemia in Patients with Chronic Hepatitis C (CH-C) Treated with Pegylated Interferon and Ribavirin (PEG-IFN/RBV): A Preliminary Analysis. (Oral Presentation). Digestive Disease Week. New Orleans 2004.
194. Z Younossi, J Chan, K Schlauch, J Assmann, C Santini, J Ong, J Martin, T Gramlich, L McAllister S-Y Chang. Gene Expression Profiles of Patients with Chronic Hepatitis C (CH-C) Treated with Pegylated Interferon Alfa-2b and Ribavirin (PEG-IFN/RBV). Digestive Disease Week. 2004.
195. P Pockros, M Shiffman, E Schiff, N Afdhal, M Sulkowski, Z Younossi, T Wright, D Dieterich, J Jenkins, Gerhard J. Leitz, Peter J. Bowers. Long-Term Treatment with Epoetin Alfa Maintains Ribavirin Dose and Hemoglobin Levels in Anemic HCV-Infected Patients Receiving Interferon/Ribavirin (IFN/RBV) Therapy. Digestive Disease Week. 2004.
196. J Stamates, P Pockros, M Shiffman, E Schiff, N Afdhal, M Sulkowski, Z Younossi, T Wright, D Dieterich, J Jenkins, G Leitz, P Bowers Long-Term Treatment with Epoetin Alfa Maintains Ribavirin Dose and Hemoglobin Levels in Anemic HCV-Infected Patients Receiving Interferon/Ribavirin Therapy. 19th Annual Conference. American Academy of Nurse Practitioners. 2004.
197. Z Younossi, J Chan, K Schlauch, R Collantes, J Assmann, C Santini, J Ong, J Martin, L Mc Allister, SY Chang. Gene Expression Profiles of Patients with Chronic Hepatitis C Developing Treatment-Related Anemia. Association for Study of Liver Disease. Boston, MA. October 2004.
198. D Farmer, R Collantes, S Makay, JP Ong, H Gujral, L Farquhar, ML Carniello, R Sjogren, ZM Younossi. Filgrastim for the Neutropenia Associated with Combination Therapy in Chronic Hepatitis C. Digestive Disease Week 2005.
199. T Schiano, M Charlton, Z Younossi, E Galun, Timothy Pruett, Ran Tur-Kasa, Rachel Eren, S Dagn. N Graham, and J Andrew. A Phase I/II Study of Monoclonal Antibody HCV-ABXTL-68 in Patients Requiring Liver Transplant for HCV. Association for Study of Liver Disease, San Francisco 2005.
200. L Ramsey, F Nader, CH Bai, , H Gujral, K Terra, S McKay, R Collantes, JP Ong, R Sjogren, ZM. Younossi. Darbepoetin Alfa (DA) and Filgrastim (FL) for the Management of Anemia and Neutropenia of Antiviral Therapy for Chronic Hepatitis C. IDSA Meeting, Toronto, Canada 2006

201. F Nader, CH Bai, K Terra, C Gurung, M Srishord, R Collantes, JP Ong, R Sjogren, ZM Younossi. The Use of Growth Factors (GF) in the Re-treatment of Patients with Chronic Hepatitis C (CHC) Who Are Previous Non Responders to Combination Therapy. EASL, Barcelona. 2007.
202. F Nader, CH Bai, K Terra, C Gurung, M Srishord, R Collantes, J Ong, M Sjogren, R Sjogren, ZM Younossi Darbepoetin Alfa (DA) and Filgrastim (FA) for the Management of Anemia and Neutropenia in Chronic Hepatitis C (CH-C) Digestive Disease Week.Washington, D.C. 2007.
203. ZM Younossi, R Collantes, A Baranova, A Kim, G Manyam, M Stepanova, C Santini, C Sigua, J Chan, A Iverson, SY Chang. Gene Expression Biomarkers Predicting Response to Pegylated Interferon alpha (PEG-IFN) and Ribavirin (RBV) in the Preipheral Blood of Patients with Chronic Hepatitis C (CH-C), Non-responder (NR) to Previous Treatment. American Association for Study of Liver Disease. Boston, MA, 2007.
204. Z Younossi, R Collantes, A Baranova, A Bakshi, M Stepanova, G Manyam, C Santini, C Sigua, J Chan, A Iverson, SY Chang. Gene Expression Biomarkers Predicting Response to Pegylated Interferon Alpha (PEG-IFN) and Rivavirin (RBV) in Treatment-Naive Patients with Chronic Hepatitis C (CH-C). American Association for Study of Liver Disease, Boston, MA, 2007.
205. Z Younossi, A Baranova, R Collantes, M Stepanova, M Garone Jr., A Arsalla, SAhmad, C Santini, C Sigua, J Chan, BS, A Iverson, SP. Chang. Gene Expression Biomarkers Can Predict Sustained Virologic Response (SVR) Early After Initiation of Pegylated Interferon Alfa (PEG-IFN) And Ribavirin (RBV) In Patients With Genotype 1 Chronic Hepatitis C (Oral Presentation, Plenary Session). American College of Gastroenterology, Philadelphia, PA, 2007
206. Z Younossi, A Baranova, M Stepanova, A Afendy, A Wheeler, N Hossain, A Bakshi, C Santini, C Sigua, J Chan, A Iverson, S Chang. A Panel of Gene Expression Biomarkers Predicting Sustained Virologic Response (SVR) in Chronic Hepatitis C Patients (CH-C) Treated with Pegylated Interferon Alpha and Ribavirin. European Association for the Study of Liver, Milan, Italy 2008.
207. Z Younossi, A Baranova, A Afendy, M Stepanova, S Schmidt, I Younossi, F Nader, C Santini, J Chan, SY Chang. Gene Expression Associated with Advanced Fibrosis in Patients with Chronic Hepatitis C (CH-C). European Association for the Study of Liver, Milan, Italy 2008.
208. A Afendy, M Stepanova, A Baranova, N Hossain, I Younossi, A Wheeler, ZM Younossi. Differential Gene Expression between Caucasian and African American Patients With Chronic Hepatitis C. American Association For Study Of Liver Disease. San Francisco, CA 2008
209. E. Lawitz, Z.M. Younossi, M. Shiffman, S. Gordon, R. Ghalib, W. Long, A. Muir, J. McHutchison. Randomized Trial Comparing Systemic And Local Reactions To Controlled-Release Interferon Alpha2b And Pegylated-Interferon Alpha2b In Hepatitis C Patients Who Failed Prior Treatment. European Association for the Study of Liver, Copenhagen, Denmark 2009
210. A Birerdinc, A Afendy, M Stepanova, I Younossi, G Manyam, A Baranova, ZM. Younossi. Functional Pathway Analysis of Genes Associated with Response to Treatment in Chronic Hepatitis C (CH-C). American Association for the Study of Liver Diseases' (AASLD) The Henry M. and Lillian Stratton Basic Research Single Topic Conference 2009, Atlanta, GA
211. E. Lawitz, Z.M. Younossi, P. Mehri, A. Rigney, Z. Krastev, K. Tchernev, D. Takov, W. A. Long. Early Viral Response Of Controlled-Release Interferon Alpha2b And Ribavirin Vs. Pegylated-Interferon Alpha2b And Ribavirin In Treatment-Naïve Genotype1 Hepatitis C: 12 Week Results (Select-2 Trial). European Association for the Study of Liver Disease Meeting 45<sup>th</sup> Annual Meeting 2010, Vienna, Austria
212. W.A. Long, D. Takov, K. Tchernev, I. Kotzev, A. Rigney, Z. Krastev, S. Stoynov, R. Balabanska, E. Lawitz, Z. Younossi, R. Ghalib, E. Zuckerman, R. Safadi, R. Tur-Kaspa, N. Assy, Y. Lurie. Q2week Controlled-Release-Interferon-Alpha2b+Ribavirin Reduces Flu-Like Symptoms >50% And Provides Equivalent Efficacy In Comparison To Weekly Pegylated-Interferon-Alpha2b+Ribavirin In Treatment-Naïve-Genotype-1-Chronic-Hepatitis-C: Results From Empower, A Randomized-Open-Label-12-Week-Comparison In 133 Patients. (Late Breaker). European Association for the Study of Liver Disease Meeting 45<sup>th</sup> Annual Meeting 2010, Vienna, Austria

213. Z. Younossi, D Limongi, M Stepanova, M Pierobon, A Afendy, L. Liotta, E. Petricoin. Protein Pathway Biomarkers Predicting Sustained Virologic Response (SVR) to Pegylated Interferon (PEG-IFN) and Ribavirin (RBV) in Patients with Chronic Hepatitis C (CH-C). European Association for the Study of Liver Disease, 45<sup>th</sup> Annual Meeting 2010, Vienna, Austria.
214. G Manyam, I Younossi, T Gramlich, A Baranova, Z Younossi, A Birerdinc, M Stepanova, A Afendy. Up-regulation of Matrix Metalloproteinase 9 (MMP-9) and Interleukin-8 (IL-8) in African-American Patients with Chronic Hepatitis C. Digestive Disease Week, Annual Meeting 2010, New Orleans, Louisiana
215. D Limongi, M Stepanova, A Afendy, M Pierobon, R Agrawal, L Liotta, E Petricoin, ZM Younossi. Protein Pathway Biomarkers Predicting Sustained Virologic Response (SVR) to Pegylated Interferon (PEG-IFN) and Ribavirin (RBV) in Treatment-Naive Genotype 1 Patients with Chronic Hepatitis C. (Oral Presentation, Plenary Session) Digestive Disease Week, Annual Meeting 2010, New Orleans, Louisiana. D Desai, M Estep, A Birerdinc, H Mir, A Baranova, V Chandhoke, ZM Younossi. Markers of Insulin Resistance in During HCV Treatment: A Relationship to Sustained Virologic Response (SVR). Digestive Disease Week, Annual Meeting 2010, New Orleans, Louisiana
216. A Birerdinc, M Stepanova, A Afendy, G Manyam, I Younossi, T Gramlich, A Baranova, ZM Younossi. Up-Regulation of Matrix Metalloproteinase 9 (MMP-9) and Interleukin-8 (IL-8) in African-Americans Patients with Chronic Hepatitis C. (Poster with Distinction) Digestive Disease Week, Annual Meeting 2010, New Orleans, Louisiana.
217. Aybike Birerdinc, Arian Afendy, Maria Stepanova, Issah Younossi, Ancha Baranova, Zobair M. Younossi. Baseline Gene Expression Profile Associated with Development of Mild and Severe Anemia During Treatment of Chronic Hepatitis C (CH-C) Patients with Pegylated interferon and Ribavirin (PEG-IFN+RBV). American Association for Study of Liver Disease 2010, Boston MA
218. Aybike Birerdinc, Arian Afendy, Maria Stepanova, Issah Younossi, Ancha Baranova, Zobair M. Younossi. Gene Expression Profiles Associated with Depression in Patients with Chronic Hepatitis C (CH-C). American Association for Study of Liver Disease 2010, Boston MA (Oral Presentation)
219. Aybike Birerdinc, Maria Stepanova, Dolores Limongi, Arian Afendy, Mariaelena Pierobon, Issah Younossi, Lance Liotta, Ancha Baranova, Emanuel F. Petricoin, Zobair M. Younossi. AKT Activation is Associated with Sustained Virologic Response (SVR) After Treatment with Pegylated Interferon-alfa and Ribavirin (PEG-IFN+RBV) in Patients with Chronic Hepatitis C (CH-C). American Association for Study of Liver Disease 2010, Boston MA
220. Walker A. Long, Eric Lawitz, Yoav Lurie, Zahary Krastev, Dimitar Takov, Konstantin G. Tchernev, Amy Rigney, Nimer Assy, Zobair M. Younossi. Adverse Event Reporting During HCV Treatment Via Weekly Clinic Visits Substantially Underestimates Flu Frequency & Severity Compared To Daily ePRO: Results From 133 Patients In EMPOWER. American Association for Study of Liver Disease 2010, Boston MA (Late Breaker). American Association for Study of Liver Disease 2010, Boston MA
221. Graham R Foster, Stefan Zeuzem, Pietro Andreone, Stanislas Pol, Eric Lawitz, Moises Diago, Stuart Roberts, Roberto Focaccia, Zobair Younossi, Andrzej Horban, Rolf Van Heeswijk, Sandra de Meyer, Don Luo, Gaston Picchio, Maria Beumont. Efficacy and safety of telaprevir-based therapy in genotype 1 hepatitis C virus-infected patients with prior null response, partial response or viral relapse to peginterferon alfa-2a and ribavirin therapy: final results of the REALIZE phase III trial. Asian Pacific Study for Liver 2010, Bangkok, Thailand, Oral Presentation
222. A. Birerdinc, A. Afendy, M. Stepanova, I. Younossi, G. Manyam, A. Baranova, Z. Younossi. Antigen Processing And Proteasome Degradation Pathways Are Involved In Patients With Chronic Hepatitis C With Negative Predictors Of Response To Pegylated Interferon And Ribavirin. The International Liver Congress 2011 - 46th annual meeting of the European Association for the Study of the Liver (EASL) 2011, Berlin, Germany
223. Z.M. Younossi, J.M. Estep, A. Birerdinc1,2, M. Stepanova, A. Baranova, I. Younossi1, A. Afendy. IL28B-CC Genotype-Related Gene Expression During Treatment Of Chronic Hepatitis C With Pegylated Interferon-Alfa And Ribavirin: Potential Mechanisms For Sustained Virologic Response.

- The International Liver Congress 2011 - 46th annual meeting of the European Association for the Study of the Liver (EASL) 2011, Berlin, Germany
224. Maria Stepanova, Brian Lam, Youssef Younossi, Manirath Srishord, Zobair M. Younossi The Impact of Hepatitis C and Obesity on the Prevalence of Type 2 Diabetes in the U.S. General Population. Digestive Disease Week 2011, Chicago, IL (Submitted)
  225. W.A. Long, Z. Younossi, E. Lawitz, I. Kostev, D. Takov, K. Tchernev, A. Rigney, R. Ghalib, S. Stoinov, R. Balabanska, P. Mehra, Z. Krastev. Onset Times And Rates Of Depression Reported During Hcv Treatment As Adverse Events At Clinic Visits Are Similar To Those Detected By Beck's Depression Index: Results From Select-2, A Randomized-Open-Label-72-Week-Comparison Of Two IFNa's In 116 Patients With Genotype-1 Treatment-Naïve HCV. The International Liver Congress 2011 - 46th annual meeting of the European Association for the Study of the Liver (EASL) 2011, Berlin, Germany
  226. Stefan Zeuzem, Pietro Andreone, Stanislas Pol, Eric Lawitz, Moises Diago, Stuart Roberts, Roberto Focaccia, Zobair Younossi, Graham Foster, Andrzej Horban, Rolf Van Heeswijk, Sandra de Meyer, Don Luo, Gaston Picchio, Maria Beumont. Telaprevir-based regimen in genotype 1 hepatitis C virus-infected patients with prior null response, partial response or relapse to peginterferon/ribavirin: REALIZE trial final results. The International Liver Congress 2011 - 46th annual meeting of the European Association for the Study of the Liver (EASL) 2011, Berlin, Germany, Oral Presentation
  227. Stanislas Pol, Jeroen Aerssens, Stefan Zeuzem, Pietro Andreone, Eric Lawitz, Stuart Roberts, Zobair Younossi, Graham Foster, Rolf Van Heeswijk, Sandra de Meyer, Don Luo, Martin Boytfield, Maria Beumont, Gaston Picchio. Similar SVR Rates In IL28B CC, CT or TT Prior Relapser, Partial- Or Null-Responder Patients Treated With Telaprevir/Peginterferon/Ribavirin: Retrospective Analysis Of The Realize Study. The International Liver Congress 2011 - 46th annual meeting of the European Association for the Study of the Liver (EASL) 2011, Berlin, Germany, Oral Presentation
  228. Graham Foster, Stefan Zeuzem, Pietro Andreone, Stanislas Pol, Eric Lawitz, Moises Diago, Stuart Roberts, Paul Pockros, Zobair Younossi, Roberto Focaccia, Andrzej Horban, Isabelle Lonjon-Domanec, Rolf Van Heeswijk, Sandra de Meyer, Don Luo, Maria Beumont, Gaston Picchio. Subanalyses Of The Telaprevir Lead-In Arm In The Realize Study: Response At Week 4 Is Not A Substitute For Prior Null Response Categorization. The International Liver Congress 2011 - 46th annual meeting of the European Association for the Study of the Liver (EASL) 2011, Berlin, Germany, Oral Presentation
  229. Paul Pockros, Stefan Zeuzem ,Eric J. Lawitz, Zobair M. Younossi, Pietro Andreone, Stanislas Pol, Moises Diago,Stuart Roberts, Roberto Focaccia, Graham Foster, Andrzej Horban, Rolf Van Heeswijk, Sandra de Meyer, Don Luo, Gaston Picchio, Maria Beumont. Telaprevir-based Regimen in Genotype 1 Hepatitis C Virus-infected Patients with Prior Null Response, Partial Response or Relapse to Peginterferon/Ribavirin: REALIZE Trial Final Results. Digestive Disease Week 2011, Chicago, IL (Submitted)
  230. Zobair M. Younossi, Jeroen Aerssens, Stanislas Pol ,Paul Pockros, Eric J. Lawitz, Stefan Zeuzem, Pietro Andreone, Stuart Roberts, Roberto Focaccia, Graham Foster, Andrzej Horban Rolf Van Heeswijk, Sandra de Meyer, Don Luo, Martyn Botfield, Maria Beumont, Gaston Picchio. Similar SVR Rates in IL28B CC, CT OR TT Prior Relapser, Partial- OR Null-Responder Patients Treated with Telaprevir/Peginterferon/Ribavirin: Retrospective Analysis of the REALIZE Study. Digestive Disease Week 2011, Chicago, IL (Submitted)
  231. Eric Lawitz, Graham Foster, Stefan Zeuzem, Paul Pockros,<sup>4</sup> Zobair Younossi, Pietro Andreone, Stanislas Pol, Moises Diago, Stuart Roberts, Roberto Focaccia , Andrzej Horban, Isabelle Lonjon-Domanec, Rolf Van Heeswijk, Sandra de Meyer, Don Luo, Maria Beumont, Gaston Picchio. Subanalyses of the Telaprevir Lead-in Arm in the REALIZE Study: response at Week 4 is not a Substitute for Prior Null Response Categorization. Digestive Disease Week 2011, Chicago, IL (Submitted)
  232. E. Lawitz, Z. Younossi, P. Mehra, A. Rigney, Z. Krastev, K. Tchernev, D. Takov, W.A. Long. Sustained viral response rate of controlled-release interferon alpha 2b (CR2b) and ribavirin

- compared to pegylated interferon alpha 2b (PEG2b) and ribavirin in treatment-naïve genotype 1 (G1) hepatitis C: final Results of the SELECT-2 trial. The International Liver Congress 2011 - 46th annual meeting of the European Association for the Study of the Liver (EASL) 2011, Berlin, Germany
233. Z Younossi, E Lawitz, Z Krastev , A Rigney, K Tchernev, D Takov, R Ghalib, W Long. SELECT-2 Clinical Trial Assessing The Efficacy And Safety Of Controlled-Release Interferon Alpha-2b (CR2b)+Ribavirin (RBV) Versus Pegylated Interferon Alpha-2b (PEG2b)+RBV In Treatment-Naïve Genotype-1 (G1) Hepatitis C. Digestive Disease Week 2011, Chicago, IL (Submitted).
  234. L McGarry, G Davis, Z Younossi, V Pawar, J Rubin, Parekh, M Weinstein. The Impact of Birth-Cohort Screening for Hepatitis C Virus (HCV) Compared with Current Risk-Based Screening on Lifetime Incidence of and Mortality from Advanced Liver Disease (AdvLD) in the United States (US). Digestive Disease Week 2011, Chicago, IL (Submitted).
  235. M Stepanova, B Lam, Y Younossi, M Srishord, Z Younossi. The Association of Hepatitis C and Type 2 Diabetes in U.S. General Population: The Impact of the Epidemic of Obesity. Digestive Disease Week 2011, Chicago, IL (Submitted).
  236. E Lawitz, G Foster, S Zeuzem, P Pockros, Z Younossi, P Andreone, S Pol, M Diago, S Roberts, R Focaccia , A Horban, I Lonjon-Domanec, R Van Heeswijk, S de Meyer, D Luo, M Beumont, G Picchio. Subanalyses of the Telaprevir Lead-in Arm in the REALIZE Study: response at Week 4 is not a Substitute for Prior Null Response Categorization. Digestive Disease Week 2011, Chicago, IL (Submitted)
  237. M Stepanova, F Kanwal, H El-Serag, Z Younossi. Low Insurance Coverage Among Hepatitis C (HCV)-positive Individuals in The United States. Digestive Disease Week 2011, Chicago, IL (Submitted)
  238. P Pockros, S Zeuzem ,E J. Lawitz, ZM. Younossi, P Andreone, S Pol, M Diago, S Roberts, R Focaccia, G Foster, AHorban, RVan Heeswijk, S de Meyer, D Luo, G Picchio, M Beumont. Telaprevir-based Regimen in Genotype 1 Hepatitis C Virus-infected Patients with Prior Null Response, Partial Response or Relapse to Peginterferon/Ribavirin: REALIZE Trial Final Results. Digestive Disease Week 2011, Chicago, IL (Submitted)
  239. ZM. Younossi, J Aerssens, S Pol , P Pockros, EJ. Lawitz, S Zeuzem, P Andreone, S Roberts, R Focaccia, G Foster, A Horban, RVan Heeswijk, S de Meyer, D Luo, M Botfield, M Beumont, G Picchio. Similar SVR Rates in IL28B CC, CT OR TT Prior Relapser, Partial- OR Null-Responder Patients Treated with Telaprevir/Peginterferon/Ribavirin: Retrospective Analysis of the REALIZE Study. Digestive Disease Week 2011, Chicago, IL (Submitted)

**Presentations Related to Other Liver Diseases:**

240. S Hitchcock-De Gregory, Z Younossi, W Brown. Serum Albumin Binds to Tropomyosin. Biophys Journal 47:510a, 1985.
241. L Miller, M Kalnoski, Z Younossi, J Buliniski, E Reisler. Antibodies Directed Against the N Terminus of Actin Bind to the Acto-S-1 Complex. Biophys, 151:392a, 1987.
242. M Poleski, Z Younossi, D Cloutier, D Collins. Prevalence of Ulcerative Colitis and Crohn's Disease in Family Members of 254 Inflammatory Bowel Disease. Patients Comparison Between Those Born in High and Low Risk Areas. Trends in Inflammatory Bowel Disease Meeting. Victoria, Canada. April 6-9, 1994.
243. Z Younossi, V Rodgers, E Beutler, A Johnson. 2-Chlorodeoxyadenosine (Cladribine) Treatment of Refractory Crohn's Disease: A Pilot Study. 10th World Congresses of Gastroenterology. Los Angeles, CA. October 1994.
244. Z Younossi, D Collins, D Cloutier, M Poleski. Inflammatory Bowel Disease in Migrants from Low-Risk Area to Montreal, Canada: A Comparison between Age of Onset of Ulcerative Colitis and Crohn 's Disease. 10th World Congresses of Gastroenterology. Los Angeles, CA. 1994.

245. Z Younossi, D Collins, D Cloutier, M Poleski. Inflammatory Bowel Disease in Montreal, Canada: Comparison between High-Risk and Low-Risk Area. 10th World Congresses of Gastroenterology. Los Angeles, CA. 1994.
246. Z Younossi, W Strum, P Teirstein, R Schatz. Upper GI Bleeding in Postcoronary Stent Patients Following Aspirin and Anticoagulant Treatment. Oral Presentation at Digestive Disease Week Meeting. San Diego, CA. May 14-17, 1995.
247. Z Younossi, JG McHutchison, A Sedghi-Vaziri, CN Broussard. Changes in the Serum-Ascites Albumin Gradient Following Transjugular Intrahepatic Porto-Systemic Shunt. American Association for Study of Liver Disease Meeting. Chicago, IL. 1996). *Hepatology*, Vol. 24 (No.4), 446A, 1996.
248. P Pockros, Z Younossi, A Saven. An Open-Label Pilot Study of 2-Chlorodeoxyadenosine (CdA) in the Treatment of Early Stage Primary Sclerosing Cholangitis (PSC). 47th Annual American Association for Study of Liver Disease Meeting. Chicago, IL. 1996). *Hepatology*, Vol. 24 (No.4), 170A, 1996.
249. J Dumot, D Barnes, Z Younossi, J Henderson, W Carey. Efficacy of Hepatitis A Vaccine in Patients with End-Stage Liver Disease and After Liver Transplantation. *Digestive Disease Week*. Washington, DC. Vol.III(No.4), 1997.
250. R Gacad, Z Younossi, N Boparai, J Hale, WD Carey. Learning Ultrasound-Guided Liver Biopsy. *American College of Gastroenterology*, 1997.
251. M Hang, M Ishitani, W Carey, D Barnes, Z Younossi, J Mayes, D Vogt, M Henderson. Two Compartmental HBIG Pharmacokinetics Allows for Prolonged Outpatient Dose Intervals Following OLT for Chronic HBV. *American Society of Transplant Physicians*. Chicago 1998.
252. M Haug, M Ishitani, S Wimberley, W Carey, D Barnes, Z Younossi, J Mayes, JM Henderson, D Vogt. Hepatitis B Immune Globulin (HBIG) Disposition after Liver Transplant. *American Hepato-Pancreato-Biliary Congress*. 1999.
253. A Aggarwal, J Ong, D Nelson, J Schafle, L. Hoffman Hogg, Z Younossi, A Arroliga. Predictors of Mortality in Patients with Liver Disease Admitted to the Medical Intensive Care Unit. Oral Presentation. *American College of Chest Physicians*. 1999.
254. B Parker, P Potter, V Sabharwal, Z Younossi, D Vogt, J Mayes, JM Henderson. Intraoperative Leukocyte Reduction and The Incidence of Acute Cellular Rejection after Orthotopic Liver Transplantation. *International Liver Transplant Society (ILTS) Meeting*. 2000.
255. Z Younossi, S Sarbah, A Di Bisceglie, T Gramlich, P Osmack, A Younoszai, L Grosso, J Cooper, D Duncan, R Seneca. Determination of HFE Mutations in the Paraffin-Embedded Liver Biopsy Blocks of Patients with Hepatocellular Carcinoma. *American Associate for the Study of Liver Diseases*. Dallas, TX 2001. *Hepatology*, Vol. 34 (No.4) Pt 2. 2001.
256. E Galun, Z Younossi, et al. A Phase 2 Clinical Study Evaluating Safety and Efficacy of Hepex-B, A Mixture of Two Human Monoclonal Antibodies to HBsAg in Combination with Lamivudine in Chronic HBV Patients. *Association for Study of Liver Disease*. Boston, MA. October 2003.
257. S Srivastava, M Duncan, A Joseph, J Ong, D Duncan, Z Younossi. Budd-Chiari Syndrome (BCS) with Mesenteric Vein Thrombosis (MVT) Treated by Direct Intrahepatic Portocaval Shunt (DIPS) and Mechanical Thrombectomy. 68th Annual Scientific Meeting. *American College of Gastroenterology*, Baltimore, MD. 2003.
258. J Estep, L O' Reilly, G Grant, K Schlauch, J Ong, J Piper, J Jonsson, V Chandhoke, K Smith, Z Younossi. Gene Expression Profile Associated With Activated Hepatic Stellate Cells: Implications for Hepatic Fibrosis. *Digestive Disease Week*. 2004.
259. J Michael Estep, G Grant, L O' Reilly, J Piper, J Jonsson, M Gupta, JP Ong, V Chandhoke, ZM Younossi. Expression Of Genes Associated With Apoptosis Of The Hepatic Stellate Cells Obtained From The Explanted Livers. *American Transplant Congress/American Society of Transplantation*, Seattle, WA. 2005.
260. Z Younossi. New Techniques Redefine Assessment of Liver Disease. *Digestive Disease Week*. Washington, DC, 2007.

261. Z Younossi, Y. Benhamou, E. Gane, S. Zeuzem, J. Heathcote, P. Marcellin, J. Sorbel, K. Borroto-Esoda, F. Rousseau and A. Snow-Lampart. Lack of Influence of Baseline Genotype on Antiviral Response In Subjects With Chronic Hepatitis B Infection Receiving Tenofovir DF 300 MG QD For 1 Year. Digestive Disease Week. San Diego, CA, 2008.
262. SS Lee, EJ Heathcote, W Sievert, H Trinh, K Kaita, ZM Younossi, J George, M Shiffman, P Marcellin, J Sorbel, J Anderson, E Mondou, J Quinn, Franck Rousseau. Tenofovir Disoproxil Fumarate (TDF) Versus Adefovir Dipivoxil (ADV) In Asians With HBeAg-Positive And HBeAb-Negative Chronic Hepatitis B Participating In Studies 102 And 103. American Association For Study Of Liver Disease. San Francisco, CA 2008
263. SS Lee, EJ Heathcote, W Sievert, H Trinh, K Kaita, ZM Younossi, J George, M Shiffman, P Marcellin, J Sorbel, J Anderson, E Mondou, J Quinn, Franck Rousseau. Tenofovir Disoproxil Fumarate (TDF) Versus Adefovir Dipivoxil (ADV) In Asians With HBeAg-Positive And HBeAb-Negative Chronic Hepatitis B Participating In Studies 102 And 103. The 13th International Symposium on Viral Hepatitis and Liver Disease (ISVHLD) 2009
264. Rubin Aquino, Maria Stepanova, Abdullellah Alsheddi, Ravindra Gupta, Fang Yun, Zobair M. Younossi. Independent Predictors of Fibrosis in Patients with Chronic Liver Disease. American Association For Study Of Liver Disease 2009, Boston MA
265. S Lee, Jacobs, Z Younossi, E Mandoux. Three Years Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in Asians with HBeAg-positive and HBeAg-negative Chronic Hepatitis B, Preliminary Analysis. American Association for Study of Liver Disease 2009, Boston MA.
266. Ed Gane, S. Lee, J Heathcote, W Sievert, H Trinh, K Kaita, Z Younossi, J George, P Marcellin, D Coombs, Jane Anderson, Elsa Mondou. Four Years Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in Asians with HBeAg-positive and HBeAg-negative Chronic Hepatitis B (CHB), Preliminary Analysis. American Association for Study of Liver Disease 2010, Boston MA.
267. Mitchell L Shiffman, Gadi Lalazar, Adrian Reuben, Stuart Gordon, Arthur McCullough, Rajender Reddy, Fred Poordad, Zobair Younossi, John Vierling, Alexander Fich, Elimelech Zuckerman, Scott Friedman, Rifaat Safadi, Yaron Ilan, Arun Sanyal. Assessment Of Cirrhosis By A Non-Invasive <sup>13</sup>c-Methacetin Breath Test: Results of A Phase 3 Multicenter Trial. American Association for Study of Liver Disease 2010, Boston MA
268. Ed Gane, Samuel S. Lee, E. Jenny Heathcote, William Sievert, Huy Trinh, Kelly Kaita, Zobair Younossi, Jacob George, Patrick Marcellin, Derek Coombs, Jane Anderson, Elsa Mondou. Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in Asians with HBeAg-positive and HBeAg-negative Chronic Hepatitis B (CHB), Four Year Preliminary Analysis. The Asian Pacific Study of Liver Disease (APASL 2011), Bangkok Thailand (Oral Presentation).
269. Z Younossi, A. Sanyal, N. Bass, K. Mullen, F. Poordad, A. Shaw, K. Merchant, E. Bortey, W.P. Forbes, S. Huang. The Impact Of Rifaximin On Health-Related Quality of Life Of Cirrhotic Patients With Hepatic Encephalopathy. Digestive Disease Week 2011, Chicago, IL (Submitted)
270. JK Price. T Leslie, L Pawloski, M Soni, N Hossain, Z Younossi. Association of Chronic Liver Diseases (CLD) and Cirrhosis with Sociogeographic Factors. Digestive Disease Week 2011, Chicago, IL (Submitted)
271. Z Younossi, M Stepanova, B Lam, F Nader. Rate Vaccination Against Hepatitis A and B in Patients with Chronic Liver Diseases and Patients with Type 2 Diabetes: A Population-Based Study. Digestive Disease Week 2011, Chicago, IL (Submitted)

## **LECTURES AND FACULTY PRESENTATIONS**

### **Lectures Related to Non-Alcoholic Fatty Liver Disease and Obesity:**

1. Non-Alcoholic Fatty Liver Disease. Grand Round. Cleveland Clinic. Ft Lauderdale, FL. June 1999.

2. Non-Alcoholic Fatty Liver Disease. Cleveland Clinic Medical Grand Round. Cleveland, OH. June 1999.
3. The Spectrum of Fatty Liver Disease. 36th Annual Cleveland Clinic Gastroenterology Update. Cleveland, OH. September 1999.
4. Non-Alcoholic Fatty Liver Disease: A Review. Department of Endocrinology Grand Round. The Cleveland Clinic Foundation. Cleveland, OH. October 1999.
5. Non-Alcoholic Fatty Liver Disease. American Association for the Study of Liver Disease Regional Course. Chicago, IL. March 2000.
6. Hepatitis B, Non-alcoholic Steatohepatitis and Hemochromatosis. South Point Hospital. Cleveland, OH. May 2000.
7. Non-Alcoholic Steatohepatitis. Frontiers in Gastroenterology. Case Western Reserve University. Cleveland, OH. May 2000.
8. Non-Alcoholic Steatohepatitis. American College of Gastroenterology Post-Graduate Course. New York, NY. October 2000.
9. Pathogenesis of Non-alcoholic Steatohepatitis. American College of Gastroenterology. Early Breakfast Symposium on Non-alcoholic Steatohepatitis. New York, NY. October 2000.
10. Clinical Trial on Non-alcoholic Steatohepatitis. American Association for the Study of Liver Disease. Early Morning Breakfast Session. Dallas, TX. October 2000.
11. Basic Research in Non-alcoholic Steatohepatitis. American Association for the Study of Liver Disease. Early Morning Breakfast Session. Dallas, TX. October 2000.
12. Non-Alcoholic Steatohepatitis. SHINE Investigator Meeting. Orlando, FL. February 2001.
13. Hepatitis C and Steatosis. SHINE Investigator Meeting. Orlando, FL. February 2001.
14. Non-Alcoholic Steatohepatitis. American Association for the Study of Liver Disease. Clinical Update in Hepatology. March 2001.
15. Non-Alcoholic Steatohepatitis Update. Clark Society. Washington, DC. February 2001
16. Non-alcoholic Steatohepatitis Update. Walter Reed Army Medical Center. Gastroenterology Grand Rounds. April 2001.
17. Clinical Aspects of Non-Alcoholic Fatty Liver Disease. Symposium on Obesity and Liver Disease. Digestive Disease Week. May 2001.
18. The Epidemiologic and Economic Impacts of Non-Alcoholic Fatty Liver Disease in the United States. American Association for the Study of Liver Disease Workshop. Digestive Disease Week. May 2001.
19. Non-alcoholic Steatohepatitis Oral Presentations: Co-Moderator. Digestive Disease Week. May 2001.
20. Non-alcoholic Steatohepatitis Update. Georgetown University. Washington, DC. June 6, 2001.
21. Update on Non-alcoholic Steatohepatitis: Maryland GI Society. October 2001.
22. An Update on Non-alcoholic Steatohepatitis. Medical Grand Rounds. Inova Fairfax Hospital. January 2002.
23. Non-alcoholic Steatohepatitis and Hepatitis C: Cornell University. January 2002.
24. HCV & Steatosis: SHINE Investigator Meeting. February 2002.
25. An Update on Fatty Liver Disease: CMD Dinner Program. Cleveland, OH. April 2002.
26. Non-alcoholic Steatohepatitis: CME Dinner Program. Columbus, OH. April 2002.
27. Natural History of Non-alcoholic Steatohepatitis. Digestive Diseases Week. San Francisco, CA. May 2002.
28. Non-Alcoholic Fatty Liver Disease. Rochester. NY 2002.
29. Spectrum of Fatty Liver Disease. Non-alcoholic Steatohepatitis Non-Alcoholic Steatohepatitis. American Association for the Study of Liver Diseases. Single Topic Conference. September 2002.
30. Non-Alcoholic Steatohepatitis. Non-alcoholic Steatohepatitis Medical Grand Rounds. Arlington Hospital. October 2002.
31. Obesity-Related Fatty Liver. Meet the Experts Conference. Inova Fairfax Hospital. December 2002.

32. Non-Alcoholic Fatty Liver Disease. Pittsburgh Gastroenterologists. February 2003.
33. Spectrum of Non-Alcoholic Fatty Liver Disease. SHINE Investigator Meeting. Los Angeles, CA. February 2003.
34. Non-Alcoholic Steatohepatitis. Maryland GI Society. Bethesda, MD. March 2003.
35. Non-Alcoholic Steatohepatitis. Baltimore Gastroenterologists. Baltimore, MD. June 2003.
36. The Spectrum of Non-Alcoholic Fatty Liver Disease. Medical Grand Round. The George Washington University. April 2004.
37. Non-Alcoholic Fatty Liver Disease and the Epidemic of Obesity. Transplant Grand Round. Inova Fairfax Round. June 2004.
38. Non-Alcoholic Fatty Liver Disease. Axcan National Meeting. Washington DC. July 2004.
39. Non-Alcoholic Fatty Liver Disease: Management American Association for Study of Liver Diseases. Post Graduate Course. Boston, MA. 2004.
40. Non-Alcoholic Fatty Liver Disease: What to Do with Your Fatty Liver Patients. American College of Gastroenterology. Orlando, FL. 2004.
41. Management of Non-Alcoholic Fatty Liver Disease: Medical Grand Rounds at Salem Veterans Affairs, Roanok, VA, 2004.
42. Non-Alcoholic Fatty Liver Disease. Rochester, NY. 2004.
43. Interaction between Non-alcoholic Fatty Liver Disease and Hepatitis C. Asian Pacific Association for the Study of the Liver. New Delhi, India. 2004.
44. Insulin Resistance and Non-alcoholic Fatty Liver Disease. Asian Pacific Association for the Study of the Liver. New Delhi, India. 2004.
45. The Spectrum of Non-alcoholic Fatty Liver Disease. Post Graduate Institute, Chandigarh, India, 2004.
46. Obesity-related Non-alcoholic Fatty Liver Disease. Thomas Jefferson University, GI Grand Round. 2005
47. Non-alcoholic Steatohepatitis. Washington VA Hospital, GI Conference, 2005
48. Management of Non-alcoholic Fatty Liver Diseases. Walter Reed and American College of Gastroenterology Bi-annual GI course, McLean, VA. 2005.
49. Epidemiology of Non-alcoholic Fatty Liver Disease in Bariatric Surgery Patients. Digestive Disease Week, Chicago, IL. 2005.
50. Adipokines in Non-alcoholic Fatty Liver Diseases. 7th International Conference on Cytokines and Chemokines. Montreal, CA. 2005.
51. Translational Research, Mid-Atlantic Biotechnology Conference, Washington D.C. Translational Research 2005.
52. Natural History of Non-alcoholic Steatohepatitis. American College of Gastroenterology. Honolulu, HI. 2005.
53. Non-alcoholic Steatohepatitis. American College of Physicians Meeting Washington DC 2005
54. Non-alcoholic Fatty Liver Disease Grand Round, University of California, Sacramento, CA. 2005.
55. Epidemiology and Natural History of Non-alcoholic Steatohepatitis. University of Pittsburgh GI/Hepatology Course, Pittsburgh, PA. 2005.
56. Obesity and Liver Disease 16<sup>th</sup> Annual AMOAA Meeting, Reston, VA. 2005.
57. HCV, Steatosis and Metabolic Syndrome. Postgraduate Institute of Medicine, Scottsdale, AZ. 2006.
58. Epidemiology, Natural History and Progression of Non-alcoholic Fatty Liver Disease. Non-alcoholic Steatohepatitis Expert Panel Meeting. Vienna, Austria. 2006
59. Translational Research Using Genomics and Proteomics to Study Human Diseases. Inaugural Speaker, The President's Series, Inova Health System 2006.
60. Non-alcoholic Steatohepatitis, Basic Science Oral Presentation (Co-Chair). American Association for the Study of Liver Disease, Boston, MA. 2006
61. Proteomics. Early Morning Session (Faculty). American Association for the Study of Liver Disease, Boston, MA. 2006.

62. The Role of Hepatic Steatosis in other Liver Diseases. Post graduate course of American Association for the Study of Liver Disease. Boston, MA. 2007.
63. From Bench to Bedside in Liver Disease. American College of Physicians, Virginia Chapter, Tyson's Corner, VA. 2007
64. Metabolic Syndrome and Liver Disease: Pre & Post Liver Transplantation. American Transplant Congress. San Francisco, CA. 2007.
65. Hepatic Steatosis as a Risk Factor in the Progression of Viral Hepatitis. Canadian Laboratory Medicine Congress. Toronto, Canada. 2007.
66. Non-alcoholic Fatty Liver Disease. Annual Hepatology Roundup. Baylor University Medical Center. Huston, Texas. 2007.
67. Fatty Liver Disease. American Liver Foundation. Chicago, Il. 2007.
68. Proteomics. Meet the Professor Session. American Association for the Study of Liver Disease. Boston, MA, 2007.
69. Epidemiology of Non-Alcoholic Fatty Liver Disease. Early Breakfast Session, American Association for the Study of Liver Diseases, Boston, MA, 2007.
70. The impact of Steatosis, Insulin Resistance and Metabolic Syndrome on HCV Treatment. Hepatitis C Metabolic Advisory Board. New York, December 2007
71. The Evaluation and Management of Non-alcoholic Fatty Liver Disease. Medical Grand Round, Inova Fairfax Hospital, December 2007
72. Non-alcoholic Steatohepatitis Advisory Board, Chair. Boston, MA February 2008
73. Metabolic Syndrome. Chronic Liver Disease Foundation, CME Program, Las Vegas, NV. March 2008
74. Non-alcoholic Fatty Liver Disease: From Clinical Management to Liver Transplantation"? Piedmont Hospital's Updates on Liver and Kidney Disease and Transplantation Course. Atlanta, GA, April 2008
75. Non-alcoholic Steatohepatitis and Fatty Liver. Scripps Clinic's 23<sup>rd</sup> Annual New Treatments in Chronic Liver Disease, La Jolla, CA, April 2008.
76. Epidemiology of NAFLD. NAFLD Advisory Board, Milan, Italy, April 2008
77. Drugs should be used for Non-alcoholic Steatohepatitis. AASLD Clinical Symposium on "Drug Therapy for Non-alcoholic Fatty Liver Disease". Digestive Disease Week 2008, San Diego, California, May 2008
78. State-of-the-Art lecture for Digestive Disease Week Annual Meeting 2008. "Non-alcoholic Fatty Liver Disease - Does it need to be Treated?" San Diego California, May 2008.
79. Non-alcoholic Fatty Liver Disease. Middlesex Hospital Symposium. Middletown, Connecticut, May 2008
80. Dermatology and Metabolic Syndrome. Multidisciplinary-Multispecialty Round Table of Experts During International Psoriasis Council Meeting, Dallas, Texas September 2008
81. Fatty Liver Disease. "Sixth Annual Duke Liver Disease Update and Symposium", Durham, North Carolina, September 2008
82. Recent Advances and Emerging Therapies in Chronic Liver Disease: Fatty Liver Disease. "9<sup>th</sup> Annual International Hot Topics in Liver Conference". Saint Luke's Hospital. Houston, Texas. October 2008
83. Current Treatment of Non-alcoholic Fatty Liver Disease. Symposium on NAFLD. Medica Sur Clinic and Foundation. Mexico City, Mexico. October 2008
84. Prognosis and Treatment of NASH in the Liver and Beyond: Lifestyle or Pharmacology? Post-graduate Course, Meet-the Professor Session, American Association for the Study of Liver Disease. San Francisco, California 2008
85. Obesity-related Liver Disease: Non-alcoholic Fatty Liver Disease (Grand Round): Albert Einstein College of Medicine-Montefiore Medical Center. New York, NY. November 2008
86. Non-alcoholic Fatty Liver Research. Mount Sinai School of Medicine Liver Research Seminar. January 2009

87. Natural history and clinical evaluation of NAFLD and NASH. “8<sup>th</sup> International Meeting on Therapy in Liver Diseases”, Barcelona, Spain September 2009
88. Update in the Treatment for Non-alcoholic Fatty Liver Disease (NAFLD). General Hepatology Update Course, American Association for the Study of Liver Disease, Boston, MA, November 2009
89. Diagnosing NAFLD/NASH: Who to Screen and How to Confirm the Diagnosis? UEGW/WCOG GASTRO 2009, London, United Kingdom, November 2009
90. Non-alcoholic Fatty Liver Disease. Carolinas Medical Center-CME Liver Course, Charlotte, NC, December 2009.
91. NAFLD and NASH. Scripps Clinic 25<sup>th</sup> Annual Treatment in Chronic Liver Disease March 2010
92. Controversy: Results from PIVENS Trial (IR is not Important). Scripps Clinic 25<sup>th</sup> Annual Treatment in Chronic Liver Disease, March 2010
93. NASH: Noninvasive Markers – Emerging Alternatives to Biopsy: Measuring steatosis, fibrosis and cell death. Symposium: What’s New and Hot in Clinical Hepatology. Digestive Disease Week 2010, New Orleans, LA, May 2010
94. Non-Alcoholic Fatty Liver Disease: When should I biopsy? How should I treat? American College of Gastroenterology Annual Meeting, Post Graduate Course 2010, San Antonio, Texas, October 2010.
95. “Non-alcoholic Fatty Liver Disease: Does Differentiating NAFL from NASH Really Matter When There is no Specific Treatment?” ACG Annual Meeting. San Antonio, Texas 2010
96. Obesity-related Non-alcoholic Fatty Liver Disease. Medical Grand Round, Inova Fairfax Hospital, November 2010
97. Non-alcoholic Fatty Liver Disease: Non-invasive Fibrosis Biomarkers and Treatment Strategies. State of the Art Lecture, “The 3<sup>rd</sup> Hepatology and Gastroenterology Post Graduate Course and the 12<sup>th</sup> International Workshop on Therapeutic Endoscopy”, Cairo, Egypt, December 2010
98. Long Term Mortality, Morbidity and Hepatocellular Carcinoma in patients with NASH and Related Cirrhosis. State of the Art Lecture, “The 3<sup>rd</sup> Hepatology and Gastroenterology Post Graduate Course and the 12<sup>th</sup> International Workshop on Therapeutic Endoscopy”, Cairo, Egypt, December 2010
99. Treatment of metabolic syndrome and liver fibrosis. The Fourth Scientific Meeting on Liver Fibrosis, May, 2011, Bordeaux, France.
100. Will bariatric surgery change the natural history of NASH? Bariatric Surgery, Obesity and NAFLD Session. Digestive Disease Week, Chicago II, May 7, 2011
101. The Impact of Alcoholic and Non-alcoholic Fatty Liver Disease on Hepatitis C. 2011 Pittsburgh Liver Update Symposium, University of Pittsburgh, June 2011

**Lectures Related to Quality of Life Research:**

102. Health-Related Quality of Life and Chronic Liver Diseases. Case Western Reserve University. Cleveland, Ohio. March 1999.
103. Health-Related Quality of Life in Clinical Research of Encephalopathy. 10th International Symposium on Hepatic Encephalopathy. Istanbul Turkey. May 1999.
104. Health Policy and Research. Co-Moderator Oral Presentation. American Association for the Study of Liver Disease Meeting. Dallas, TX. November 1999.
105. Economic and Quality of Life Outcomes for Viral Hepatitis. Bluegrass Symposium on Chronic Viral Hepatitis. University of Kentucky. Lexington, KY. October 1999.
106. Quality of Life and Symptom Assessment in Hepatitis C. Lunch Breakout Session American Association for the Study of Liver Disease, Post-Graduate Course. Dallas, TX. October 2000.
107. Health-Related Quality of Life and Liver Transplantation. Transplant Grand Rounds UCLA. December 2001.
108. Quality of Life in Chronic Liver Disease: The Impact of Treatment and Liver Transplantation. The 8<sup>th</sup> Annual Virginia Liver Symposium. VCU, Richmond, VA. March 2004.

109. Makes a Difference: Improving Outcomes and Quality of Life in Patients With Hepatitis C. Orlando, FL. 2004.
110. Health-related Quality of Life and Liver Transplantation. American Transplant Congress Meeting, Seattle, WA. 2005
111. Health-related Quality of Life in Hepatitis C. Indenix Presentation. Cambridge, MA. 2005
112. Health Related Quality of Life in Hepatitis C: Expert Panel Meeting on Extra Hepatic Burden of HCV Infection. New York, NY, December 2007
113. Quality of Life Assessment in HCV, Merck Headquarters. December 2007
114. Quality of Life in Chronic Liver Disease, Chairperson for the Session. UEGW/WCOG GASTRO 2009, London, United Kingdom, November 2009
115. "Quality of Life in Cirrhosis". Post Graduate Course. American Association for the Study of Liver Disease Annual Meeting, San Francisco, CA 2011

**Lectures Related to Outcomes and Health Services Research:**

116. A Cost Effective Evaluation of Patients with Elevated Liver Enzymes. 33rd Annual Cleveland Clinic Foundation, Gastroenterology Update. Cleveland, Ohio. November 1996.
117. Understanding Evidence-Based Medicine. Course Director. The Clinic Foundation. Cleveland, Ohio. March 1999.
118. Methodologies in Healthcare Outcomes in Gastroenterology: AGAGRC San Diego, CA. December 1999.
119. Outcomes Research and Chronic Liver Disease. Transplant Grand Round. Inova Fairfax Hospital. April 2000.
120. How to Assess Evidence? The Evidence Based Approach. 6<sup>th</sup> World Congress of International Hepatobiliary Association. Washington D.C. June 2004.

**Lectures Related to Hepatitis C:**

112. A Clinical Overview of Chronic Hepatitis C: The Cleveland Clinic Foundation. Medical Grand Round. Cleveland, Ohio. March 1996.
113. Epidemiology of Hepatitis A, B and C. Hepatitis Foundation International. Cleveland, Ohio. May 1996.
114. Extrahepatic Complications of HCV Infection. The Cleveland Clinic Foundation. Medical Grand Round. Cleveland, Ohio. January 1998.
115. The Challenges of Hepatitis C for Generalists. The Cleveland Clinic Foundation, Department of CME. Cleveland, Ohio. April 1998.
116. Interferon and Ribavirin for Treatment of Chronic Hepatitis C. Cleveland, Ohio. September 1998.
117. Hepatitis C: An update. Akron Gastroenterologists. Akron, Ohio. October 1998.
118. Chronic Hepatitis C: A Review for Primary Care Physicians. Ashtabula County Medical Center. Ashtabula, Ohio. October 1998.
119. Update on Chronic Hepatitis C. 35th Annual Cleveland Clinic Gastroenterology Update. The Cleveland Clinic Foundation. Cleveland, Ohio. November 1998.
120. An Update on Hepatitis C: The Virus and the Disease. Buffalo NY. February 1999.
121. Beyond the 90's: A Healthier Focus for the New Millennium: An Update on Cleveland Hepatitis C. The Cleveland Clinic Foundation. Cleveland, Ohio. April 1999.
122. Treating Hepatitis C: Solutions for a Critical Need. Cleveland, OH. July 1999.
123. Treating Hepatitis C: Solutions for a Critical Need. Farmington, PA. July 1999.
124. Treating Hepatitis C: Solutions for a Critical Need. Hershey, PA. October 1999.
125. Panelist in the State Capitol for Hepatitis C Coalition. Columbus, OH. October 1999.
126. Hepatitis C: A Silent Epidemic. Medical Grand Round. The Cleveland Clinic Foundation. Cleveland, OH. February 2000.
127. Treating Hepatitis C: Solutions for a Critical Need. Cleveland, OH. April 2000.

128. Treating Hepatitis C: Solutions for a Critical Need. Seattle, WA. May 2000.
129. Hepatitis C, Interferon and Depression. Talk for Local Gastroenterologists. Cleveland OH. June 2000.
130. Treating Hepatitis C: Solutions for a Critical Need. Mount Carmel, CA. July 2000.
131. Treating Hepatitis C: Solutions for a Critical Need. Boston, MA. July 2000.
132. Treating Hepatitis C: Solutions for a Critical Need. New York. August 2000.
133. The Impact of Hepatitis C. Inova Fairfax Hospital Medical Grand Round. Fairfax, VA. September 2000.
134. Hepatitis C and Liver Transplantation. Transplant Grand Round. Inova Fairfax Hospital. 2001
135. Hepatitis C: An Update on New Therapies. Medical Grand Rounds. Shady Grove Hospital. January 2001.
136. Hepatitis C: New Therapies. Beachwood Marriott. Beachwood, OH. February 2001
137. An Update in HCV: New Therapies. Tyson's Corner, VA. March 2001.
138. HCV Update. Inova Fairfax Hospital. Trauma Grand Rounds. April 2001.
139. Achieving Optimum Outcomes: Customizing Treatment for Patients with HCV infection. Greenwich, CT. May 5, 2001.
140. American Liver Foundation Support Group. Update on HCV. Oakton, VA. May 6, 2001.
141. American Liver Foundation Support Group. Update on HCV. Woodbridge, VA. May 7, 2001.
142. Northern Virginia/ALF HCV Support Group: An Update on HCV. October 2001.
143. Current Treatment and Research Protocols in the Treatment of Hepatitis C: UNOS Region 2 Clinical Forum. Bethesda. March 2002.
144. Hepatitis C: An Updated for 2002. Medical Grand Rounds. Inova Fairfax Hospital. December 2002.
145. Extrahepatic Manifestation of HCV. Dermatology Section Meeting. Inova Fairfax Hospital. April 2003.
146. The Role of Adherence on the Efficacy of Antiviral Therapy for HCV. Santa Monica CA. December 2003.
147. The Role of Growth Factors in the Management of Hepatitis C. Chicago IL. March 2004.
148. The Role of Growth Factors in the Management of Hepatitis C. South Beach FL. April 2004.
149. Effective Side Effect Management in Anti-HCV Therapy. New Orleans, LA. May 2004.
150. In Depth Side Effect Management Strategies for HCV Treatment. Miami FL. June 2004.
151. Management of Hepatitis C: 2004 Update. Guest Lecturer. Amgen, Inc. Thousand Oaks, CA.
152. HCV Therapy: Shortfalls in Management. La Jolla, CA. July 2004.
153. Maximizing HCV Therapy. Atlanta, GA. July 2004.
154. Maximizing HCV Therapy: In Depth Side Effect Management Strategies. Boston, MA. July 2004.
155. Maximizing HCV Therapy: Side Effect Management Strategies. Washington DC. July 2004.
156. Management of Hepatitis C Roundtable. Cleveland Clinic. 2004.
157. Helping Patients Stay the Course on Treatment for Hepatitis C. Bethesda, MD. 2004.
158. Striving to Achieve Improved Outcomes: An Integrated Approach to HCV Treatment. Boston, MA. 2004.
159. Anemia Management for Hepatitis C Therapy. Univ. of Michigan Program. Ann Arbor, MI. 2004.
160. Issues in the Management of Adverse Effect of HCV Therapy. Indian Association for Study of Liver Disease, New Delhi, India. 2004.
161. Hepatitis C and its Implications for Rheumatologists. American College of Rheumatology Meeting, Santa Barbara, CA. 2005.
162. An Update on hepatitis C and HIV/HCV Co-infection. Tyson's Corner, VA. 2005
163. Emerging Data in the Management of Hepatitis C. Woodbridge, VA. 2005.
164. Hepatitis C. Scripps Consortium Seminar, Washington D.C. 2005.
165. Hepatitis C Oral Presentations (Co-chair), Digestive Disease Week, Los Angeles CA 2006
165. Managing Hepatitis C. Hot Topic 2007 (CME Program), Norfolk, VA. 2007.
166. Managing Hepatitis C. Hot Topic 2007 (CME Program), Tyson's Corner, VA. 2007

167. Case challenges in HCV: Overcoming Boundaries to Hepatitis C Treatment (CME Program). Miami, FL. 2007
168. Case challenges in HCV: Overcoming Boundaries to Hepatitis C Treatment (CME Program). Chicago, IL. 2007
169. Case challenges in HCV: Overcoming Boundaries to Hepatitis C Treatment (CME Program). Washington DC. 2007
170. Case challenges in HCV: Overcoming Boundaries to Hepatitis C Treatment (CME Program). New York, New York. 2007
171. Why Is Standard of Care for HCV Treatment Falling Short? American Association for the Study of Liver Disease, Projects in Knowledge CME Program, San Francisco, CA 2008
172. An Update on Chronic Hepatitis C. Second Annual Hepatology Congress. East Palo Alto, CA. December 2008
173. Hepatitis B and Hepatitis C Content Development Meeting. Chronic Liver Disease Foundation, Dallas, TX 2009
174. The Past, Present, and Future of Hepatitis C: A Discussion With the Experts. AGA Institute and Medscape, Chicago 2009
175. Hepatitis C and Metabolic Syndrome. CMETV, Chronic Liver Disease Foundation, Chicago 2009
176. STAT-C Therapy for Chronic Hepatitis C Round Table (Chair), New York, NY November 2009
177. Management of Nonresponders to Previous HCV Therapy: What Lessons Have We Learned? Medscape-AGA CME Program. New Orleans, LA 2010
178. Treatment advances in Chronic Hepatitis C. Medscape Gastroenterology. Boston, MA 2010

**Lectures Related to Other Liver Diseases:**

177. Timing of Liver Transplantation. 32<sup>nd</sup> Annual Cleveland Clinic Foundation. Gastroenterology Update. Cleveland, Ohio. November 1995.
178. Portal Hypertensive Bleeding. 34th Annual Cleveland Clinic GI Update. Cleveland, Ohio. 1997.
179. Management of Variceal Bleeding. Metro Health Medical Center. Cleveland, Ohio. Dec 1997.
180. First Update from American Association for the Study of Liver Disease. Course Director. Cleveland, Ohio. December 1997.
181. Current Concepts in the Management of Acute Variceal Hemorrhage. Teleconference. Cleveland, Ohio. January-March 1998.
182. Hepatic Manifestations of Inflammatory Bowel Disease. The Cleveland Clinic IBD Course. 1998.
183. Portal Hypertensive Bleeding: The Role of the Endoscopist. 35th Annual Gastroenterology Update. The Cleveland Clinic Foundation. Cleveland, Ohio. November 1998.
184. Second Update from American Association for the Study of Liver Disease. Course Director. Cleveland, Ohio. December 1998.
185. The Cleveland Clinic Intensive Review of Internal Medicine. Cleveland, OH. June 1999
186. An Update on Viral Hepatitis. Ob Gyn Grand Rounds. Cleveland Clinic Foundation. Cleveland, OH. August 1999.
187. Ascites. Inova Fairfax Hospital. Housestaff Lecture. January 2001.
188. Fulminant Hepatic Failure. Inova Fairfax Hospital. House staff Lecture. January 2001.
189. Liver Disease in Women. Meet the Professor Session. American Association for the Study of Liver Disease Workshop. Digestive Disease Week. May 2001.
190. Associates Course: American Association for the Study of Liver Disease. October 2001.
191. Women's Health Issues 2001: Evaluation of Abnormal Liver Enzymes. November 2001.
192. Management of Variceal Bleeding: Critical Care Forum. Inova Fairfax Hospital. December 2001
193. Viral Hepatitis: University of Michigan. GI/Liver Wrap-Up Course. February 2002.
194. Hepatitis B: To Treat or Not to Treat. ACG/Walter Reed Annual GI Course. Tyson's Corner, VA. March 2003.
195. Update on Hepatitis B, Medical Grand Rounds. Inova Fairfax Hospital. July 2003.

196. Role of Hematopoetic Growth Factors in Management of Ribavirin-Induced Anemia. Dallas TX. September 2003.
197. Epoetin Alfa and Darbepoetin Alfa for Management of Ribavirin-Induced Anemia. Miami, FL. November 2003.
198. Hematopoetic Growth Factors for Management of Ribavirin-Induced Anemia. New York, NY. December 2003.
199. New Data on Treatment for Hematologic Side Effects. Tarrytown, NY. June 2004.
200. Hepatitis B Update for Korean Physician Workshop. Tyson Corner, VA. 2004
201. Implication of Hepatitis B. McLean, VA. 2004.
202. Management of Hepatic Encephalopathy. Tyson's Corner, VA 2004
203. Hepatitis B: Fighting the Invisible Enemy. Seven Corners, VA. 2005.
204. Case Presentations by Staff. Visiting Professor, Post Graduate Institutes, Chandigarh, India. 2004.
205. Hepatitis B Update. Taiwanese Medical Association, Fairfax, VA. 2005.
206. Hepatitis B: Management of Difficult Cases. Fairfax, VA. 2005.
207. Integrating Clinical Research into a Business Plan of Hepatology Practice. American Association for the Study of Liver Disease Annual Meeting, San Francisco, CA. 2005.
208. Chronic Hepatitis B Treatment. Fairfax, VA. 2005.
209. American Liver Foundation's Post-AASLD Review (Chair), Alexandria, VA. 2005.
210. Autoimmune and Metabolic Liver Disease. Hepatology SEP Course. Digestive Disease Week, Washington, D.C. 2007.
211. Research Training Day for Inova Health System: Course Director December 2007
212. Hepatitis B Update. Middlesex Hospital Symposium. Middletown, Connecticut, May 2008
213. Hepatic Encephalopathy CME Meeting. Chronic Liver Disease Foundation Dallas 2009
214. Management of Overt Hepatic Encephalopathy CME Teleconference, Chronic Liver Disease Foundation 2009.
215. Hepatic Encephalopathy Content Development Meeting. Chronic Liver Disease Foundation, Chicago, IL 2009.
216. Hepatic Encephalopathy-CME, Chronic Liver Disease Foundation, Las Vegas, NV January 2010
217. Hepatocellular Carcinoma. CLDF CME Program. New Orleans, LA 2010
218. 2010 National Hepatitis B and C Training Program and Treatment Update. Crystal City, VA 2010
219. The Clinical Implications of Managing Cirrhotics. Chronic Liver Disease Foundation, Tysons Corner, VA 2010
220. The Clinical Implications of Managing Cirrhotics. Chronic Liver Disease Foundation, McLean VA 2010
221. Hepatic Encephalopathy Teleweb Presentation. Chronic Liver Disease Foundation 2010